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Abstract 
Nutrition is a major concern in paediatric cancer, increasing the risk of co-
morbidities, affecting tolerance of therapies and influencing survival. Despite this, 
very few studies have aimed to identify the nutritional risks of children treated for 
cancer in the western world. 
A unique retrospective study was therefore proposed to assess the degree of 
nutritional risk in paediatric cancer using the need for nutrition support (NS) as a 
proxy for high nutritional risk. Of 168 patients, seventy four (44%) required NS of 
whom 50 (67%) and 24 (33%) had solid and haematological malignancies. These 
findings underline the common need for NS in this childhood cancer cohort. 
A prospective study was consequently designed to assess the effect of cancer and its 
treatment on nutritional status, using commonly used assessment techniques. 
Measurements were taken regularly at six time points over a period of up to 18 
months. 26 patients, 18 (69%) male and 8 (31%) female (median age 5.1; IQR 2.3, 
7.9) volunteered for the study. At recruitment and during the first three months of 
treatment, those with solid tumour demonstrated nutritional deprivation, low BMI 
(median 25.5, IQR 5.5-60.5; median 18.0, IQR 7.5-54.2 respectively), low fat mass 
%(median 76.3, IQR 48.5-99.1; median 70.8, IQR 62.6-124.8 respectively), low 
energy intake (median kcal/d 1200, IQR 866-1970; median 1305 kcal/d, IQR 901-
1488) and a high need for NS. In contrast, those with haematological cancer 
demonstrated an excess BMI (median 66.0, IQR 41.5-82.2; median 79.5; IQR 70- 
94.2 respectively), high fat mass % (median 102.0, IQR 78.6- 153.0; median 129.4, 
IQR 96.5-202.6,respectively) and excessive energy intake (median kcal/d 2076; IQR 
1453-2525, median kcal/d 1078, IQR 919-1206 respectively) 
These results suggest that children undergoing cancer therapy are at high risk of both 
undernutrition and obesity and they indicate apparent differences in nutritional risk 
according to diagnosis and treatment. 
Key words: Children, cancer, nutritional status, nutrition screening, malnutrition
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1 CHAPTER ONE 
REVIEW OF THE LITERATURE 
1.1 INTRODUCTION 
 
During the critical period of growth and development in the life of a child, optimal 
nutrition is essential. A diagnosis of cancer during childhood modifies the body’s 
nutritional needs and therefore it can affect the ability of the child to achieve optimal 
growth and development. Cancer treatments can also independently affect a child’s 
nutritional status at certain stages of the disease (Murphy et al. 2009). Whilst 
children are treated for cancer, these factors can be very significant as their growth 
and development must be sustained. Furthermore, undernutrition during cancer can 
increase morbidity and mortality (Mejia-Arangure et al. 1999; Reilly et al. 1994) 
which, in turn, causes decreased quality of life (QoL) and increased health care costs 
(Agostoni et al. 2005). It is becoming increasingly apparent that appropriate 
nutritional care (comprising nutritional assessment and nutrition support) is vital to 
ensure optimal growth from the stage of birth to the end of puberty during cancer 
therapy (Agostoni et al. 2005). Despite these facts, the evidence base on nutritional 
care in children and young people with cancer is scarce and fragmented. 
The prevalence of undernutrition has been described at different stages and in 
specific diagnoses (Garofolo et al. 2005; Mejia-Arangure et al. 1997; Reilly et al. 
1999; Yaris et al. 2002). However, a limited amount of evidence exists to determine 
the overall risk factors for the development of undernutrition such as age at 
diagnosis, gender, type of tumour, stage of tumour, treatment modalities and 
protocols in children treated for cancer. Therefore defining the risk factors for 
undernutrition in cancer patients is now pivotal. 
Overnutrition also has detrimental effects during cancer therapy. It has been 
suggested that obesity during cancer therapy can increase the risk of mortality, 
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morbidity and chemotherapy induced toxicity (Butturini et al. 2007; Lange et al. 
2005). Additionally, survivors of childhood Acute Lymphoblastic Leukaemia (ALL) 
seem to gain weight excessively during and after therapy and become overweight 
and obese (Ventham and Reilly 1999). With the increased number of people who 
survive childhood cancer, long term nutritional consequences are becoming a new 
concern for this particular cohort. Hence, the maintenance of growth and 
development, the monitoring of nutritional status, as well as the prevention of 
chronic issues such as obesity, are now essential goals for oncology practice. This 
introduction will provide an overview of childhood cancer and its treatments and it 
will focus on the nutritional issues, nutritional risks and nutritional management of 
children treated for cancer. 
1.2 Childhood Cancer 
Cancer or neoplasm is a life threatening illness characterised by an unregulated cell 
growth (Kumar et al. 2006). A neoplasm can be classified as benign or malignant 
according to their ability to metastasise to other organs. Malignant tumours grow 
uncontrollably and spread to other parts of the body whereas benign tumours do not 
(Kumar et al. 2006). 
Cancer is the most common cause of disease related deaths in children in the western 
world (Cancer Research UK 2012) with the majority of childhood cancers being 
malignant (93%). The non-malignant brain tumours are included in the classification 
of childhood cancer because they are generally treated the same as malignancies and 
they can also be life threatening (Information Service Division Scotland 2012). 
Figures from the 2006-2008 period show that around 1550 children in the UK were 
diagnosed each year and of those around 260 children died each year including non-
malignant brain tumour (Cancer Research UK 2012). Considerable improvement in 
treatments during the past few decades has dramatically increased the survival rate at 
five years from around 28% in the sixties to around 80% currently. At the end of 
year 2000 in the UK there were more than 26000 people who had in the past been 
diagnosed with some type of childhood cancer. The survival rate at ten years does 
not differ from those at five years with the leading cause of death among childhood 
cancer survivors being the recurrence of the original cancer followed by cardiac and 
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pulmonary treatment related complications (Mertens 2007). Hence, with the 
increased number of people who survive childhood cancer, the long term 
consequences of the disease and its treatments need to be prevented whenever 
possible. 
For treatment and research purposes childhood cancer is classified according to the 
International Classification of Childhood Cancer (ICCC-3) (Steliarova-Foucher et al. 
2005). This classification is based on morphology and consists of 12 main diagnostic 
groups. Each of the broad 12 diagnostic groups has numerous subgroups. The 
Leukaemia group includes all the haematological malignancies which are defined as 
those cancers affecting the haematopoietic tissue causing an abnormal increase of 
immature blood cells (Brooker 1994). Leukaemia is the most common diagnosis of 
childhood cancer (Cancer Research UK 2012) and it can be classified in three sub-
types: Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML) 
and Chronic Myeloid Leukaemia (CML) (Steliarova-Foucher et al. 2005). ALL 
includes patients with high risk disease (high risk ALL) and low risk disease (low 
risk ALL). Survival rates are much lower for patients with high risk disease 
compared to the low risk. 
The most common childhood solid tumours are those of the brain and central 
nervous system (CNS) (both malignant and non-malignant), which account for 22% 
of all childhood cancers overall, followed by Lymphoma, accounting for around 
19% of the total cancers (Boon et al. 2006; Cancer Research UK 2012; Information 
Service Division Scotland 2012). Even though benign tumours do not metastasize, 
they are life threatening because they grow on a limited space causing obstruction 
and pressure on the brain which leads to increased intracranial pressure, seizure and 
eventually death (Boon et al. 2006). Figure 1.1 shows the incidence and mortality 
rate expressed as percentage of total childhood cancers in the UK (Cancer Research 
UK 2012). The incidence and mortality data for the Scottish population reflects the 
national data (Information Service Division Scotland 2012).  
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Figure 1.1 Incidence and mortality percentage rate in the UK according to 
diagnosis using the ICCC-3 classification (Cancer Research group 2004). 
The management of childhood cancer is very complex and it aims to achieve a cure 
whilst minimising pain and adverse effects of treatments. The main treatments for 
cancer are chemotherapy, radiotherapy and surgery; they can be used singly or in any 
combination. Chemotherapy targets dividing cells, both healthy and cancerous (Pui 
and Jeha 2007). Radiotherapy consists of the use of radiation to destroy multiplying 
cells and surgery removes the cancer from the body (Chan 2007). Children with 
cancer are generally treated in clinical trials or standard regimens and the treatments 
are often combined. However, the most recent practice is to avoid radiotherapy 
whenever possible in this cohort as children are more prone to long term effects 
which include learning disabilities, stunting bone growth, and lung and heart damage 
depending on the irradiated area; therefore it should be used in children only when 
there no other options are available (Oeffinger and Hudson 2004). In particular, 
cranial irradiation therapy (CRT) was used in the past to prevent central nervous 
system (CNS) relapse in ALL. However, in the more recent treatments prophylactic 
CRT has been omitted (Chan 2007) to avoid the detrimental effect. 
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Specificity of treatments in children is necessary because childhood cancers differ 
from adult cancers in many aspects including type, pathology, treatments and 
survival rate. Adults cancers are mainly carcinomas of different tissues, whereas 
most of the common childhood cancers are embryonal in origin, their cells are 
undifferentiated and still capable of differentiating in different type of mature tissue, 
which makes them more responsive to treatments. Furthermore, children tend to 
have acute forms of lymphomas and leukaemia compared to adults who tend to have 
the chronic form (Chan 2007). All of these aspects, in addition to the fact that 
children are developing and growing individuals, hopefully with many years of life 
ahead, make this patient group unique and very complex. This is especially relevant 
when considering this disease in relation to nutritional risk. However most of the 
research published in this area, especially in cancer cachexia and energy metabolism 
and has been carried out in adults (Falconer et al. 1994; Hyltander et al. 1991b; 
Moses et al. 2004; Nixon et al. 1988). This is largely due to the methodological 
limitations of measuring children and to the smaller incidence of cancer in children 
compared to adults. Because of this lack of evidence, in writing this document it has 
often been necessary to refer to the adult literature available. However, it is not 
always clear whether such findings can be directly applied to the paediatric cohort 
and therefore the interpretation of the results must be done with caution. Furthermore 
the paucity of paediatric research underlines the necessity for studies designed to 
explore the nutritional risks related to cancer in this specific cohort. 
1.3 Malnutrition in children with cancer 
Malnutrition occurs when there is a deficiency (undernutrition) or excess 
(overnutrition) of energy, protein and other macronutrients and micronutrients which 
causes adverse effects on the body’s functions and results on a poorer outcome 
(Joosten and Hulst 2013). However the term malnutrition is often wrongly used as 
synonymous to that of undernutrition. In this thesis, the term malnutrition will only 
be used when it refers to both undernutrition and overnutrition.  
The extent to which nutrients are available to meet metabolic needs is referred to as 
nutritional status. Nutritional status is determined by the availability of nutrients in 
the body and their utilisation to maintain health and growth (Shaw and Lawson 
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2007). Body weight homeostasis is regulated by the energy balance equation. Total 
energy expenditure (TEE) is composed of resting energy expenditure (REE) 
accounting for 60-70% of energy output, physical activity (PA) (15-30%) and diet 
induced thermogenesis (7%-13%). The fat free mass (FFM) or lean tissue is the 
metabolic active component of the body and intrinsically relates to REE (Elia 
1992a). When energy balance is disrupted and energy intake does not meet the 
energy expenditure over a long period of time, the body energy stores are utilised to 
meet the energy requirement leading to weight loss. This negative energy balance 
weight can lead to undernutrition. However, when energy intake exceeds the energy 
expenditure over a long period of time the body is in positive energy balance and the 
excess energy is converted into fat stores, causing increased body weight which can 
eventually lead to obesity (Macdonald 2007). Childhood malignant disease and its 
treatments can dramatically disrupt energy balance causing both undernutrition 
(Carter et al. 1983a; Donaldson et al. 1981; Garofolo et al. 2005) and obesity (Reilly 
et al. 1998; Reilly 2009; Ventham and Reilly 1999) with detrimental consequences 
to growth, development, morbidity and mortality (Donaldson 1982; Lange et al. 
2005). 
1.4 Undernutrition in childhood cancer 
Energy requirements vary throughout life stages. From conception to adulthood, 
cells turnover very fast and many essential nutrients and energy are required to 
support cell division, growth and development. Therefore, during this period energy 
balance should be positive and energy intake must meet the energy requirement to 
support this anabolic state. Children’s growth is characterised by alternating phases 
in which the body accumulates nutrient stores followed by a phase of growth. As a 
result, if the demand for nutrients to support continuous growth cannot be met solely 
by the nutrient intake there is a reliance on the nutrient stores previously 
accumulated (Whitney et al. 1987). An inadequate supply of nutrition at any time 
during childhood cancer can therefore impact on optimal growth and development. 
Undernutrition can be classified as acute and chronic, depending on the length of the 
energy deprivation. In children, when nutritional deprivation begins, the first 
measurable body change is a decrease in body weight (acute undernutrition) 
7 
 
whereas, when the nutritional deprivation persists and the energy intake is 
insufficient to sustain growth and development, growth impairment will occur 
resulting in a deficit in length and height (chronic undernutrition) (Waterlow 1972). 
Furthermore, a poor or absent weight gain and the failure to maintain a growth 
trajectory can also indicate acute undernutrition. This inadequate growth in 
childhood is defined as failure to thrive (Waterlow 1972). In children treated for 
cancer, the disease and the therapy can cause both acute and chronic undernutrition 
(Brennan 1998). It is therefore pivotal that during childhood cancer treatments, acute 
undernutrition is promptly detected and nutritional intervention quickly initiated to 
avoid chronic undernutrition with consequent growth and development impairment.  
The pathophysiology and consequences of undernutrition in disease are more 
complex and multifactorial than in health. Undernutrition in disease can be 
associated with disease severity and can be a consequence not just of decreased 
intake but also of altered nutritional requirement, decreased absorption, 
inflammation and difficulties in feeding (Macdonald 2007). A further distinction is 
essential when the disease in question is cancer. Contrary to other diseases, where 
there is the involvement of a single organ or system, (e.g. kidney, GI tract) cancer 
and its treatment can affect nearly every organ thereby having more widespread 
significant nutritional consequences (Bozzetti et al. 2000). In addition, the scenario 
becomes even more complex when we consider that, compared with adults; children 
treated for cancer have additional needs to support continuous growth and 
development.  
Undernutrition is common among hospitalised children, however it is often 
unrecognised and therefore not treated (Agostoni et al. 2005). Many paediatric 
oncology patients become undernourished at some stage of the disease (Murphy et 
al. 2009) and the manifestation of undernutrition in paediatric cancer is often 
insidious and may be not identified. This is because the presence of oedema fluid 
retention and the weight of the tumour itself may mask undernutrition especially 
when assessed by weight related techniques (Pietsch and Ford 2000; Smith et al. 
1991).  
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The exact prevalence of undernutrition in childhood cancer patients is unknown. 
Prevalence figures vary considerably from around 10% to 50% (Carter et al. 1983a; 
Carter et al. 1983b; Pietsch and Ford 2000; Smith et al. 1991; Uderzo et al. 1996). 
The heterogeneity of diagnosis, different stage of treatment, treatment protocol, 
definition of undernutrition used, and methodology used to assess nutritional status 
make an accurate estimate very difficult. Moreover the rate of undernutrition for the 
general population varies dramatically between countries and, with many studies 
carried out in developing countries, the undernutrition rate reported in some studies 
must be interpreted in relation to the regional prevalence of undernutrition, making 
the quantification of prevalence of undernutrition even more difficult. The 
assessment of prevalence of undernutrition is important to identify and target 
causative factors. The difficulty of estimating the prevalence of undernutrition is a 
major limiting factor in research in this area. 
Cancer associated undernutrition is a complex and multi-factorial phenomena. 
Factors implicated in the development of undernutrition in childhood cancer are: 
reduced dietary intake, malabsorption and altered metabolism (Figure 1.2). These 
factors can results from the host response to the cancer itself, the anti cancer therapy 
or the effects of the cancer itself on metabolism (Balducci and Hardy 1985). These 
detrimental factors can act as single cause or combined leading to a greater risk of 
undernutrition.  
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Figure 1.2 Multifactorial causes of cancer undernutrition. Cancer related 
undernutrition results from the combinations of multiple factors caused by the 
cancer it self, the treatments, and the host response to cancer and treatments. 
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1.4.1 Direct effects of tumour on undernutrition 
Metabolic disturbances, caused by the tumour and the host response to treatments 
involving many organs causing a catabolic state and eventually leading to cachexia, 
are commonly reported contributors to the nutritional deterioration of cancer 
patients. The catabolic state or pre-cachexia is characterised by a breakdown of 
tissue and compounds caused by a body’s response to stress, trauma, starvation and 
infection and it is define as weight loss >5%, anorexia and metabolic changes 
(Radbruch et al. 2010). Cachexia is a more advanced catabolic state characterised by 
wasting of lean tissue, muscle atrophy, inflammation and fatigue associated with 
significant changes in macronutrient metabolism for a prolonged time, often 
occurring in patients with advanced disease (Fearon et al. 2011).  
Cancer cachexia causes the host production of catabolic mediators and inflammatory 
markers. However, the inflammatory response is not exclusively related to cachexia 
but can also be induced by infections (Prat et al. 2008; Stryjewski et al. 2005) and 
chemotherapy (Ek et al. 2001). The acute phase- protein response (APR) aims to 
prevent further tissue damage by initiating the repair process and isolating and 
removing the pathogen. In response to the pro- inflammatory cytokines (interleukin-
1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor (TNFα), the synthesis of 
APPs is stimulated in the liver (C- reactive proteins and mannose binding proteins) 
(Baumann and Gauldie 1994). This causes increased metabolism and weight loss 
(Falconer et al. 1994; Staal-van den et al. 1995) and is associated with poor 
prognosis in cancer patients with advanced disease (Blay et al. 1992). Cachexia is 
also mediated by circulating tumour-derived factors synthesised by the cancer itself 
which can cause breakdown of the host tissue (Norton et al. 1985). Examples of this 
include the proteolysis-inducing factor (PIF), which induces muscle wasting, (Cariuk 
et al. 1997) and the lipid mobilising factor (LMF), which induces mobilisation of 
adipose tissue (Bing et al. 2002). 
There is strong evidence of cancer causing hyper-metabolism, increased protein 
turnover and gluconeogenesis in adults (Heber et al. 1992; Hyltander et al. 1991a). In 
a healthy and fed subject, the preferred substrate for energy metabolism is glucose. 
During the fasting state, visceral protein and muscle amino acids can be utilised as 
precursors of gluconeogenesis. When the body is in a fed state, protein catabolism 
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decreases and functional tissue is preserved. This preservation mechanism is altered 
in cachectic patients where the protein turnover is very rapid and amino acids are 
preferentially transported to the tumour to be used as source of energy. Furthermore, 
compared with a healthy subject, postprandial inhibition of amino acid uptake does 
not take place leading to the amino acids being used to produce ATP even in a fed 
state (Norton et al. 1980). Even though the energy requirement is met by glycolysis 
(Weber 1982; Weinhouse 1982), the cancer increases the hepatic production of 
glucose, lactate and amino acids from protein and fat tissue (Lundholm et al. 1981; 
Stein 1982). Glucose however is not taken up and metabolised from peripheral 
tissues due to the increased glucose intolerance and insulin resistance (Rofe et al. 
1994). The utilisation of lipid and protein then leads to weight loss (McAndrew 
1986). Furthermore, the rate of gluconeogenesis causes an increased requirement for 
gluconeogenetic enzymes which require the utilisation of amino acids in the liver for 
synthesis (Stein 1982).  
The cachectic patient usually presents with oedema, anorexia, early satiety, anaemia 
and with severe weight loss (Fearon and Preston 1990). Cancer cachexia occurs in 
30% to 80 % (DeWys et al. 1980; Kosacka et al. 2008) of total adult cancer patients, 
whereas the prevalence of cancer cachexia in paediatric cancer patients has not been 
precisely assessed. The complexity of cachexia and its definition make the diagnosis 
very difficult. The diagnosis of cachexia is generally based on both >5% weight loss 
and metabolic changes that are present. However, there is no specific definition of 
cachexia in children. Poor weight gain, or a shift of growth from expected 
trajectories, is also an important sign of nutrition inadequacy in children. Therefore, 
a weight loss of > 5% in children is more indicative of nutritional depletion in 
children than in adults and the definition of cachexia in childhood cancer patients 
should be made upon poor weight gain as well as weight loss >5%. However, only a 
few studies (Delbecque-Boussard et al. 1997; Schmid et al. 2005; Siimes et al. 1991; 
Siimes et al. 1991; Yu et al. 1994) have studied nutritional status in relation to 
inflammation in children with cancer. 
A study by Siimes at al. (1999) measured the relation between TNFα concentration 
in relation to nutritional status (measured as muscle mass) in 12 children treated for 
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ALL during the first 16 weeks of treatments. They observed a high TNFα 
concentration at diagnosis followed by a gradual decrease to normal reference values 
at 16 weeks. A similar pattern of TNFα was observed in children with solid cancer 
undergoing chemotherapy but without the use of steroids, which excludes the 
normalising effect of steroids alone on TNFα release. The study did not show any 
correlation between nutritional status and TNFα. Elevated levels of inflammatory 
markers at diagnosis have also been reported elsewhere (Yu et al. 1994). Cytokine 
antagonists (soluble tumor necrosis factor receptor II and interleukin-1 receptor 
antagonist) have been studied in relation to nutritional status to investigate whether 
they had protective effects against undernutrition and hyper-metabolism. Their level 
was observed to be higher in children with high risk leukaemia (high white cell 
count) but did not relate to nutritional status (Schmid et al. 2005). In contrast, 
inflammatory markers were observed to be very low in paediatric ALL patients 
during the first ten weeks of treatments (Delbecque-Boussard et al. 1997).  
From these findings inflammation seems a common feature at diagnosis and it 
decreases during treatments. However, the only study that investigated inflammation 
in relation to nutritional status failed to show any correlation (Siimes et al. 1991). 
Most of the studies had the limitation of investigating the relationship between 
inflammation and nutritional status in patients treated for ALL, which includes high 
doses of dexamethasone and prednisolone as part of their protocol. Steroids are 
known to reduce immune response and decrease cellular turnover (Pui and Jeha 
2007) which are likely to have caused the decreased inflammatory markers during 
the first phase of treatments observed in the studies (Delbecque-Boussard et al. 
1997). It is therefore very important to study the role of inflammation in order to 
assess the prevalence of cachexia in the development of undernutrition during cancer 
therapy. 
The acute phase responses just described, (in both cachexia and catabolic state) 
causes raised REE which can contribute to weight loss and undernutrition. Several 
investigators (Bosaeus et al. 2001; Falconer et al. 1994; Hyltander et al. 1991a; 
Hyltander et al. 1991b; Moses et al. 2004; Nixon et al. 1988) have suggested that 
cancer is a hyper-metabolic disease causing elevated resting and non resting energy 
13 
 
expenditure in most adult patients affected by cancer. This continued negative 
energy balance leads to the development of undernutrition in cancer patients. 
However, even though there is unequivocal evidence to support the role of hyper-
metabolism in adults, the evidence of increased REE in paediatric cancer patients is 
very limited.  
Only few studies have investigated REE in paediatric cancer patients (Bond et al. 
1992; den Broeder et al. 2001; Stallings et al. 1989), probably due to the 
methodological issues that this type of measurement implies. Measuring REE in 
children is very difficult. The most suitable method of measuring REE in a clinical 
setting is the computerised open circuit calorimeter, which has the advantage of 
being transported easily compared to the other techniques, such as the direct 
calorimetry. This technique is generally well accepted by the adult subjects, 
however, its use in sick children is challenging as children treated for a disease tend 
to be frightened by the use of the mask and they do not tolerate this measurement 
very well (Picton 1998). Furthermore, REE is intrinsically related to FFM therefore, 
measuring REE in this particularly cohort, must be done taking into consideration 
the possible lean body mass loss due to weight loss an the host response to cancer 
treatments. 
The limited number of studies published suggests REE is related to tumour burden 
with a greater tumour load causing hyper-metabolism and a normalising effect of 
cancer therapy causing the REE to go back to expected values during cancer therapy 
(den Broeder et al. 2001; Schmid et al. 2005; Stallings et al. 1989; Vaisman et al. 
1993). Increased REE was observed in a small cohort of nine newly diagnosed ALL 
patients compared to estimated REE for age gender and size. Remarkably, the 
observed increase in REE was found only in children with higher white cell count 
and organomegaly (high risk ALL) compared to the low risk ALL (Stallings et al. 
1989). However, this study measured REE in relation to body weight without taking 
into account actual body composition. Since REE is intrinsically related to FFM, and 
body composition in this particularly cohort is affected by treatments, this 
methodology may have caused some error on the REE estimate. Similar results were 
also reported by den Broeder et al. (den Broeder et al. 2001) in 13 children with solid 
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tumours. They studied changes in REE corrected for differences (kcal/kg FFM) in 
body composition at three stages: diagnosis, during treatments and after two cycles 
of therapy. REE in relation to FFM was increased in 44% of patients at diagnosis, 
and then decreased by a mean of 12.6 % in all the patients during cancer treatment. 
After the two cycles of chemotherapy the REE for the treated group was no longer 
different to the expected REE.  
Although all these studies suggest increased REE depending on tumour burden, the 
evidence to support hyper-metabolism in children remains inconclusive. A study 
(Green et al. 2008) conducted in a small cohort of ten children newly diagnosed with 
stage IV Neuroblastoma failed to observe any increased REE. The study recorded 
the REE at three points in time (diagnosis, after two courses of treatments and after 
surgery). Even though 50% of children where undernourished, the REE was not 
higher than the healthy matched control group during any of the three phases. 
Therefore, this study failed to show any increased REE at any stage of the disease in 
contrast to the other studies (den Broeder et al. 2001; Schmid et al. 2005; Stallings et 
al. 1989; Vaisman et al. 1993). However, this study did not measure FFM, and REE 
was compared against prediction values for healthy control matched for age, gender 
and weight. Therefore, similar to the Stallings et al. (1989), the methodology may 
have caused some error on the measurement of REE. More lack of evidence on 
increased REE in childhood cancer comes from Delbeque-Boussard and co-workers 
(1997) which assessed REE corrected for FFM at diagnosis, and during treatments. 
Although inflammation and increased REE has been observed by some authors at 
diagnosis (den Broeder et al. 2001; Schmid et al. 2005; Stallings et al. 1989; 
Vaisman et al. 1993), there is no evidence on the prolonged presence of hyper-
metabolism and the occurrence of cachexia in children treated for cancer.  
A possible confounder when assessing REE in cancer patients is the pro-
inflammatory genotype. It has been shown that patient genetic makeup plays an 
essential role on response to inflammation which may contribute to the differences in 
the host response to cancer and cancer treatments. The risk of inflammation and 
consequent increased REE and cachexia is higher in genetically predisposed patients 
(Howell et al. 2002). Many studies in adult cancer patients, have shown that genetic 
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polymorphism for many pro-inflammatory cytokines such as IL1, IL6, IL8, TNFα 
(Broekhuizen et al. 2005; Jatoi et al. 2010; Tan and Fearon 2010; Zhang et al. 2007), 
can increase the susceptibility to cachexia. Nevertheless, genotypes that result in a 
decreased susceptibility to inflammation may have the reduced risk of developing 
cachexia (Tan and Fearon 2010). Therefore, the risk of increased REE is higher in 
specific cancer and in patients whose the genetic makeup predisposes them to an 
inflammatory status. This genetic predisposition may explain some of the 
contradictory results on the effect of cancer on REE previously discussed. 
The literature is lacking to show evidence of raised REE during treatment for 
childhood cancer with the evidence of raised REE at diagnosis being limited. 
Comparison and interpretation of the studies reported (Bond et al. 1992; den Broeder 
et al. 2001; Green et al. 2008; Stallings et al. 1989), may be limited due to the 
heterogeneity of diagnoses studied (solid and ALL patients) even though all the 
studies used the same assessment method for measuring REE. In order to gain 
further knowledge on the energy metabolism in children treated for cancer, more 
research with large cohorts is now required, especially in children treated with 
protocols which do not include steroids. That would permit the stratification of 
patients by diagnosis and treatment protocols to specifically identify those groups of 
paediatric cancer patients at higher risk of hyper-metabolism REE and presumably at 
risk of poor nutritional status.  
In addition to producing metabolic disturbances, the tumour mass may have direct 
detrimental effects on the host’s food intake and absorption. Increased local pressure 
may occur in brain tumours and brain metastasis which lead to nausea and vomiting 
(Balducci and Hardy 1985). When the tumour mass is located in the head or neck, or 
in the GI tract, such as oesophageal, stomach and intestinal cancers, it may cause 
partial or total gut obstruction. This may lead to delayed digestion, nausea, vomiting, 
early satiety, intestinal atrophy, pain and difficulty in swallowing (Nitenberg and 
Raynard 2000). The delayed digestion may also cause longer transit and 
accumulation of gastrointestinal contents with excessive GI distension leading to 
early satiety and malabsorption (Nitenberg and Raynard 2000). Hence, physical 
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effects of solid may tumours exacerbate metabolic effects of cancer and cancer 
treatments. 
1.4.2 Effects of treatment modality on undernutrition 
Cancer treatments aim to cure the disease or slow down the tumour growth when a 
cure is not possible, while minimising symptoms and reducing the risk of recurrence. 
Each type of treatment modality and the host response to treatment may have 
specific effects on the development of undernutrition which have been described in 
this section. It is also important to consider that protocols which combine more 
treatment modalities e.g. chemo plus radiotherapy, may have a synergetic impact on 
side effects which ultimately result in greater effects on nutritional status. 
1.4.2.1 Chemotherapy 
Chemotherapy is a combination of drugs aiming to destroy fast dividing cells. 
Therefore, chemotherapy kills both rapidly dividing cancer cells and healthy cells 
which normally divide fast including haematopoietic cell, mucosal cells and hair 
follicles. As a consequence of this unselective cell damaging effect, chemotherapy 
has a range of side effects that depends on the type of drug used and may result in 
depression of the immune system , fatigue, gastrointestinal distress and hair loss (Pui 
and Jeha 2007).  
Because of its damaging effects on the GI tract, chemotherapy can negatively affect 
the patient’s nutritional status. Even though antiemetic drugs available are becoming 
more efficient, chemotherapy induced nausea and vomiting are still reported as 
causes of decreased food intake in children treated for cancer (Skolin et al. 2006). 
Furthermore, other drugs widely used in cancer patients, such as narcotic and 
antibiotics, can also cause nausea and vomiting (Grant and Kravits 2000) and 
quickly lead to dehydration and undernutrition.  
Moreover, it has been widely described that chemotherapy causes changes in smell 
and taste perception in both adults and children which may further decrease food 
intake (DeWys 1974; DeWys and Walters 1975; Grant and Kravits 2000; Greene et 
al. 1994; Skolin et al. 2006). Learned food aversion is also often reported as a cause 
of decreased intake in children (Skolin et al. 2006) and adults (Grant and Kravits 
2000). It develops in relation to foods that have become tasteless due to the changes 
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in taste perception, or towards food that were consumed close to chemotherapy 
followed by an unpleasant event such as nausea and/or vomiting (Skolin et al. 2006).  
During the early years of life, a child develops eating behaviours which set the 
foundations for future eating habits and weight status (Savage et al. 2007). 
Therefore, as well as the direct detrimental effect on the nutrient intake during cancer 
therapy, it may negatively influence food choice and eating behaviours as adults. 
Hence, the learned food aversion has an even greater negative effect in children than 
in adults.  
Furthermore, systemic chemotherapy causes mucositis, an inflammatory response on 
the epithelial cells of the gastrointestinal tract which causes lesions in various part of 
the GI tract. The dysfunctional mucosa causes pain with consequent decreased 
dietary intake and decreased nutrient absorption. Any of the gastrointestinal side 
effects of chemotherapy can therefore lead to acute or chronic loss and 
malabsorption of fluid as well as malabsorption of macronutrients and 
micronutrients and electrolytes. This exacerbates undernutrition and may cause 
dehydration (Donaldson 1982). A prolonged treatment with chemotherapy is likely 
to aggravate the side effects and it is likely to cause a greater risk of undernutrition 
(Grant and Kravits 2000). 
Although the side effects of chemotherapy causing nutritional decline as described 
above are shared among many chemotherapeutic agents, this class of drugs is very 
vast and some treatments may have specific negative effects on nutritional status. 
For example vomiting, nausea and anorexia are common to most chemotherapy 
agents whereas taste and smell alteration have been reported in patients treated with 
carboplatin, doxorubicin, 5-fluorouracil or methotrexate, and mucositis in the 
treatment with antimetabolites (Grant and Kravits 2000). Therefore, those patients 
with treatment regimens which include a broad variety of chemotherapy drugs, are 
likely to experience a multiplicity of side effects, which place them at a higher risk 
of undernutrition.  
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1.4.2.2 Radiotherapy 
Radiotherapy uses ionizing radiation to kill cancer cells. Radiotherapy side effects 
are usually limited to the area that is treated (Chan 2007). The detrimental effects on 
patients nutritional status varies depending on the length and dose of irradiation as 
well as the location of the irradiated area and the extent of body area treated. For 
example, radiotherapy in the abdominal pelvic
 
(Donaldson 1977) and cervical area
 
increase the risk of nutritional consequences (Piquet et al. 2002). Radiotherapy of the 
pelvic and abdomen area also damages the gastrointestinal mucosa causing mucositis 
leading to secretory and mixed diarrhoea. These gastrointestinal side effects, may 
lead to excess fluid loss, and electrolyte imbalance leading to dehydration. 
Furthermore, the damage to the intestinal lining causes impairment of carrier 
proteins responsible for the active transport of nutrient, decreased absorption of 
micro- and macronutrients leading to undernutrition (Donaldson 1982). A small 
percentage of patients treated with abdominal radiotherapy, develop chronic 
radiation enteropathy, a condition characterised by fistulas and gastrointestinal 
strictures leading to severe undernutrition. Irradiation of the head and neck also 
causes severe mucositis and pain resulting in decreased dietary intake and decreased 
nutrient absorption. This exacerbates dehydration and undernutrition (Piquet et al. 
2002). 
All the gastrointestinal and neural complications related to radiotherapy can lead to 
nutritional deficits and dehydration. In addition, cranial radiotherapy (CRT) can 
cause damage to the pituitary and hypothalamus (Borgstrom and Bolme 1988; 
Cicognani et al. 1988; Pomarede et al. 1984) been linked to the late onset of obesity 
in children treated for ALL. This topic will be discussed in more detail later (Section 
1.5). 
1.4.2.3 Surgery 
It is well known that patients undergoing major surgery are at greater risk of 
undernutrition (Emery et al. 1999). Surgical trauma increases REE as a consequence 
of hyper-metabolism. This host response is activated to support inflammation and 
healing mechanisms to promote recovery. Furthermore it has been observed 
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(Dempsey et al. 1988) that after any type of major surgery, not just in cancer surgery, 
dietary intake is often remarkably reduced.  
These features are generally short-term and they improve as recovery progresses. 
However it has been reported (Rivadeneira et al. 1998) in cancer patients who have 
undergone surgery of the gastrointestinal tract that they may have a prolonged 
decreased food intake and malabsorption. When the tumour mass is removed from 
the GI tract, food digestion and nutrient absorption can be impaired leading to those 
problems persistently. Fat absorption had been largely described to be inadequate 
after GI surgery (Lawrence et al. 1960; Walther et al. 1989) with consequent 
limitation in caloric intake and the absorption of fat soluble vitamins (Bozzetti et al. 
2000). Furthermore, many other micronutrients with limited area for absorption in 
the GI tract, such as vitamin B12, folic acid, iron and calcium are at risk of deficiency 
depending on the location of the resected area (Bozzetti et al. 2000).  
The most common bowel malignancy in children is the non-Hodgkin lymphomas, 
however it only accounts for around 5% of total childhood cancers (Cancer Research 
UK 2012; Information Service Division Scotland 2012), with other gastro-intestinal 
malignancies even less common in children (Kliegman 2007) and therefore, the 
nutritional consequences of GI resection surgery are rarely observed in children 
compared to the adult population. Therefore, paediatric cancer patients treated with 
surgery as part of their treatment modality are likely to be hyper-metabolic short 
term after the surgical procedures, but less likely to be at risk of long term 
consequences. For this reason there is not any study focusing on the role of surgery 
alone in undernutrition during treatment for childhood cancer.  
1.4.3 Meeting the energy requirements 
The previous section explored the mechanisms by which cancer and its treatments 
can potentially disrupt the energy balance causing undernutrition. This section will 
review the evidence for changes in nutrient intake and the issues related to 
measuring dietary intake in children with cancer. 
The association of poor dietary intake with undernutrition in children treated for 
cancer has not been extensively researched (Bond et al. 1992; Carter et al. 1983b; 
Delbecque-Boussard et al. 1997; Smith et al. 1991) and the few studies available in 
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the literature have used different methods to assess energy intake and determine the 
adequacy. Some studies (Bond et al. 1992; Carter et al. 1983b; Delbecque-Boussard 
et al. 1997; Smith et al. 1991) used healthy controls as a reference, whereas some 
others used the 80% of the recommended daily allowance (RDA) for healthy 
children as the cut off point for energy intake adequacy (Carter et al. 1983a; Smith et 
al. 1991) which make the interpretation of the results problematic.  
The results from the studies conducted with a matched healthy control have shown a 
decreased energy intake especially at diagnosis. Delbecque-Boussard et al. (1997) 
compared dietary intake in 15 newly diagnosed children with ALL with a control 
group, by 24 h diet recall at diagnosis and at day 22, 36 and 71. They observed a 
significant lower energy intake at diagnosis compared to the control group; however 
this difference disappeared at day 36. This positive change in intake may be 
explained by steroid therapy, which is known to increase appetite (Loprinzi 1995). 
Similarly, Smith et al. (1991) observed that 27% of the total cohort treated for 
various types of cancer (n=62) at diagnosis consumed <80% of the energy 
requirements, compared to 1% of the matched control group. 
In marked contrast Carter and co-workers (Carter et al. 1983b) reported the energy 
intake being around 80% of RDA and comparable to the healthy general population 
in 277 paediatric patients with several cancer types at diagnosis. The energy intake 
did not change after six months. This contrasting evidence may be caused by the 
methodological limitation of using 80% of RDA as criterion for adequacy. Bond et 
al. (1992) showed no evidence of decreased energy intake. Furthermore, they 
reported no differences in energy intake between both ALL and solid tumour patients 
to the control group during maintenance chemotherapy. However, the Bond et al. 
study (1992) was conducted in children in the maintenance phase, which is the last 
phase of treatment and involves different types of chemotherapy which may have 
accounted for the normal energy intake observed in the study. 
Very interestingly, protein intake was found to be adequate when energy intake was 
found inadequate, which suggests that protein energy undernutrition in this cohort is 
not common (Carter et al. 1983, Delbecque-Boussard et al. 1997, Garcia et al. 1989). 
However, the protein intake was compared to the DRV (Dietary Reference Value) 
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for the healthy and this criterion to assess adequacy may be questioned since the 
specific protein requirement for children treated for cancer is unknown.  
Assessing the energy status of a child treated for cancer is very challenging. Dietary 
assessment can be an extra burden for the family, and under-reporting is very 
common (Bandini et al. 1990). Furthermore, quantification of intake when a child is 
very sick after chemotherapy is very difficult. Additionally, there is no specific RDA 
or EAR (Estimated Average Requirements) for children treated for cancer and those 
for the healthy population are likely to be inappropriate. This is because the 
metabolic demand of cancer is unknown but is undoubtedly different to healthy 
children. Furthermore, DRV are generally based on an average level of physical 
activity for healthy children and it is likely that children treated for cancer are less 
active (Aznar et al. 2006; Sanford et al. 2008).  
Due to the contrasting evidence in the literature and the major role that energy intake 
plays on the maintenance of energy balance, it is essential to understand how it is 
affected by cancer and its treatments. Furthermore, because cancer treatments vary 
during the course of the disease, longitudinal research is needed to assess what are 
the treatment phases at higher risk of undernutrition. 
1.4.4 Consequences of paediatric cancer- related undernutrition 
The consequences of undernutrition, during the treatments and the course of the 
disease are varied and some are shared with any child experiencing undernutrition 
such as growth and development impairment (Waterlow 1972), whereas some others 
are specific for the paediatric cancer patients. Undernutrition during cancer therapy 
has been shown to increase mortality (Lobato-Mendizabal et al. 1989; Sala et al. 
2012), increase risk of morbidity (van Eys 1979; van Eys et al. 1980) and increase 
the risk of early relapse (Reilly et al. 1994). Although increased mortality has been 
extensively reported in relation to poor nutritional status in paediatric cancer in 
developing countries, (Lobato-Mendizabal et al. 1989; Mejia-Arangure et al. 1999; 
Viana et al. 1994; Sala et al. 2012)  there is very limited evidence to support the 
increased mortality as a consequence of undernutrition in children with cancer in the 
western world (Donaldson et al. 1981; Lange et al. 2005).  
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A case control study (Mejia-Arangure et al. 1997) has reported increased mortality 
(2.6 times) in 17 ALL patients during the initial phase of treatment in 
undernourished patients compared with those well nourished. They also reported a 
significant increased risk of mortality with increased severity of undernutrition. 
Similarly, a prospective (five years) study, (Lobato-Mendizabal, Ruiz-Arguelles, and 
Marin-Lopez 1989) conducted in 43 paediatric patients newly diagnosed with ALL, 
reported that undernourished children had a worse outcome than well nourished 
children. Undernutrition at diagnosis was associated with shorter survival and lower 
tolerance to therapy. The survival after five years was 26% in undernourished 
children compared to 83% in well nourished children.  
Although these studies showed a relationship between undernutrition and mortality, 
it is very hard to isolate nutritional status as an independent marker of clinical 
outcome. This is because none of the above studies accounted for the disease 
severity. Poor nutritional status may be a consequence of the severity of the disease 
hence the increased mortality and decreased event free survival, could be an effect of 
disease severity rather than undernutrition per se.  
A retrospective study, (Lange et al. 2005) evaluated the association between the 
survival rate and being underweight (Body Mass Index (BMI) ≥ 10th centile) in 768 
American children affected by Acute Myeloid Leukaemia against outcome. This 
study is the only one which stratified the patients according to disease severity 
(blood cell count, cytogenetics). Treatment-related mortality (TRM) was 
significantly higher in undernourished patients. Therefore, this study has provided 
the first and only evidence on the poor prognosis as a result of undernutrition 
independent of disease severity. 
Conversely, other studies showed that nutritional status at diagnosis was not 
associated with survival (Weir et al. 1998; Yaris et al. 2002). Weir et al. (1998) 
conducted a retrospective study based on the clinical notes of 1025 patients treated 
for ALL where nutritional status was measured by BMI SDS. The study failed to 
show any association between undernutrition and mortality. However, this study had 
the limitation of using weight related measurements, which are known to be affected 
by steroids and may have masked undernutrition. However, many other authors have 
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failed to show any prognostic effect of nutritional status (Pedrosa et al. 2000; Yaris 
et al. 2002) in paediatric cancer patients affected by both solid and haematological 
tumour. These contradictory findings for the increased risk of mortality in 
undernourished children are very hard to clarify. One possible explanation is the 
difficulty in isolating nutritional status as a cause of mortality independently of 
disease severity. Furthermore, nutritional status is very hard to assess in children 
treated for cancer because during cancer treatments weight can be affected by 
hydration status and tumour mass, masking weight loss (Pietsch and Ford 2000; 
Smith et al. 1991).  
Although, the evidence for the detrimental effects of poor nutritional status on 
mortality in children treated for cancer is limited, its detrimental effect on time of 
relapse is well established (Donaldson et al. 1981; Reilly et al. 1994; Viana et al. 
1994). Donaldson et al. (1981) conducted a retrospective analysis of the clinical 
records of 455 Australian paediatric oncology patients to investigate the role of 
nutritional status on relapse and survival. Nutritional status was assessed by 
comparing weight for height (W/H) to the median of the population for the same age 
and gender. They found a significant relationship between nutritional status at 
diagnosis and freedom from relapse in both localised and non localised solid 
tumours. Analogous results were reported by Reilly and co-workers (Reilly et al. 
1994; Reilly et al. 1994) in a retrospective study in 78 children treated for ALL with 
poor nutritional status measured as W/H. Due to the retrospective nature of the 
study, it was not possible to establish the mechanisms responsible for the 
unfavourable outcome of the undernourished children. Similarly, a more recent 
prospective study (Sala et al. 2012) (n=2954) assessed the effect of undernutrition at 
diagnosis (measured by albumin, BMI, triceps skin fold (TSF) and mid upper arm 
circumference (MUAC)) on clinical outcome. After two years of treatments the 
malnourished children were more likely to stop cancer therapy and have a shorter 
event free survival. 
There are several mechanisms believed to play a role in the increased mortality and 
morbidity risk caused by undernutrition in cancer. It has been observed that 
malnourished patients do not tolerate chemotherapy as well as well nourished 
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patients (Lobato-Mendizabal et al. 1989; Lobato-Mendizabal et al. 2003) and often 
have a shorter duration of chemotherapy with increased incidence of treatment 
toxicity (Andreyev et al. 1998). A study in 1555 adult GI cancer patients showed that 
undernourished patients (nutritional status measured as weight and weight loss) 
experienced more frequent and more severe chemotherapy toxicity and treatment 
delays than patients without weight loss. Furthermore, a multivariate analysis 
showed that those patients who had a significant weight loss had a 43% increased 
risk of death, and showed a better survival rate in association with better nutritional 
status. The authors concluded that the treatment delays and the reduced 
chemotherapy received as a consequence of undernutrition are the reasons for the 
increased mortality. However, similar to other studies (Lobato-Mendizabal et al. 
1989; Mejia-Arangure et al. 1999; Viana et al. 1994) it is not clear if the weight loss 
was caused by disease severity hence the undernourished patients were simply more 
ill.  
Undernutrition negatively affects haematopoiesis and immune function  (Daly et al. 
1979; DeWys et al. 1980) which causes increased incidence of infection and poor 
wound healing, therefore increasing the morbidity risk. A higher infection rate has 
also been reported in undernourished children treated for cancer compared to well 
nourished controls (van Eys 1979). 
Although the negative effect of undernutrition in mortality from cancer in the 
industrialised word is still under debate, poor nutrition negatively impact outcome, 
increases morbidity and causes impairment of growth and development. Therefore, 
this review of the literature highlights the importance of early detection of poor 
nutritional status and the role of nutritional management in preventing detrimental 
consequences. 
1.5 Obesity in paediatric cancer survivors 
In the previous section, the pathophysiology of cancer-related undernutrition and its 
consequences has been widely described. This section will focus on the 
pathophysiology of obesity as a long term consequence of childhood cancer therapy. 
It is well documented that childhood cancer patients can become obese in later life 
(Dalton et al. 2003; Meacham et al. 2005; Oeffinger et al. 2003; Warner et al. 1995) 
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which is subsequently a recognised risk factor for diabetes, metabolic syndrome and 
cardio vascular disease (CVD) (Sinaiko et al. 1999). With the increased survival rate 
of childhood and adolescent oncology patients (Cancer Research UK 2012; 
Information Service Division Scotland 2012) the long term consequences of the 
disease and its treatments have become a serious consideration for cancer treatment 
and care, and it is now essential to address and identify risk factors for those 
modifiable outcomes.  
Several studies have attempted to investigate the increased risk for obesity and its 
aetiology in cancer survivors (Dalton et al. 2003; Meacham et al. 2005; Oeffinger et 
al. 2003; Warner et al. 1995). The association between childhood cancer and later 
obesity has been mainly observed among ALL survivors (Nysom et al. 1999; 
Oeffinger et al. 2003; Razzouk et al. 2007; Schell et al. 1992) with little evidence for 
other types of childhood malignancies (Muller et al. 1998; Nysom et al. 1999). Since 
the increased risk of obesity has been primarily observed in ALL patients, the unique 
features of the treatments for this group have been a particular focus of research. 
Treatments for ALL differ from the other childhood cancers, mainly due the 
prophylactic use of CRT (which has been stopped in the more recent protocols), the 
use of high doses of steroids (dexamethasone and prednisolone) and for the longer 
course of chemotherapeutic treatments (three years for boys and two years for girls) 
compared to an average of the nine -twelve months for solid tumours. 
A full understanding of the aetiology of obesity in ALL survivors would provide 
evidence for preventative clinical practice in this specific cohort. Many studies 
(Dalton et al. 2003; Meacham et al. 2005; Oeffinger et al. 2003; Warner et al. 1995) 
have investigated the relationship between treatments and characteristics of patients 
which lead to the late onset of obesity. Those studies identified non-modifiable 
characteristics such as age at diagnosis (Dalton et al. 2003; Reilly et al. 2000), and 
gender (Meacham et al. 2005; Oeffinger et al. 2003; Warner et al. 1995) , low BMI 
SDS (standard deviation score) at diagnosis (Reilly et al. 2000) and modifiable risk 
factors such as CRT and chemotherapy (Odame et al. 1994; Zee and Chen 1986). 
Conversely, some other authors (Mayer et al. 2000; Reilly et al. 2001; Warner et al. 
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1997b; Warner et al. 1998) have focused on the cause of energy imbalance which 
results in excess body weight following childhood cancer. 
Targeting those high risk groups of patients is essential in order to prioritise 
intervention aiming to prevent obesity from the early stages. This section will focus 
on the evidence regarding the pathophysiology and the factors implicated for the 
increased risk of obesity in childhood cancer survivors. 
1.5.1 Steroids therapy and the risk of obesity  
Several investigators have focused on the role prednisolone and dexamethasone used 
in the treatment of ALL and their contribution to the increased risk of obesity in 
ALL patients. Steroids negatively impact growth and body composition (Ahmed et 
al. 2002; Groot-Loonen et al. 1996; Wallace et al. 2003) by impeding linear growth 
and stimulating weight gain (Ahmed et al. 2002). Further, prednisolone and 
dexamethasone are known to transiently increase appetite (Loprinzi 1995) and that 
altered appetite regulation would influence nutrient intake and lead to a positive 
energy balance. However, it is not clear whether this increase in body weight caused 
by steroids is a short term consequence or whether it persists after treatment. Hence, 
although steroid administration is known to potentially lead to excess body weight 
gain, the evidence to support this as the only cause of the late onset of obesity in 
ALL patients is still inconclusive. 
Evidence to support the increased risk of obesity as a consequence of steroid therapy 
comes from a follow up study (Groot-Loonen et al. 1996) carried out in 92 ALL 
patients five to twelve years after treatments. The study reported a significantly 
greater long term increase in weight for height with dexamethasone treatment 
compared to those treated with equivalent dose of prednisolone (Groot-Loonen et al. 
1996). Steroids inhibit growth by up-regulating somatostatin production from the 
hypothalamus, hence the authors argued that the inhibitory effect of steroids on 
growth hormone secretion (Giustina and Wehrenberg 1992) may be responsible for 
the observed long term weight gain after treatments, however the study did not test 
this hypothesis. 
Further work which examined the late effects of treatment regimens on weight gain 
came from Van Dongen-Melman and co-workers (Van Dongen-Melman et al. 1995) 
27 
 
in a retrospective study after up to ten years of treatments. All the patients (n= 113 
ALL survivors) were stratified according to treatments received (steroids vs. steroids 
+CRT). The study showed an increased prevalence of overweight that persisted over 
time. The prevalence of overweight after four years of treatment was comparable 
between the two groups (27% steroids only, 29% steroids + CRT, p=0.54). Therefore 
steroid therapy might be implicated in the increased prevalence of obesity in ALL 
survivors observed. The study also observed that dexamethasone caused the most 
significant weight gain immediately after therapy cessation. However, after four 
years, the differences between the two types of steroids disappeared and the highest 
prevalence of obesity (44%) was observed in those patients treated with a 
combination of the two steroids. Therefore, although the patients treated with 
dexamethasone may experience an immediate weight gain after treatments, the 
patients treated with prednisolone had the same risk of gaining weight long term. 
The Van Dongen-Melman and co-workers study (1995) had the advantage of a 
sample size that allowed comparison of irradiated vs. non irradiated patients which 
has not been possible in other studies (Odame et al. 1994; Zee and Chen 1986). 
However, the study (Van Dongen-Melman et al. 1995) did not explain the reason for 
the continuous weight gain after treatment cessation. 
Only one study (Lustig et al. 2003) investigated the independent effects of steroid 
therapy on BMI in survivors of childhood cancers other than ALL. This study did 
not find any increased risk of developing obesity associated with steroid therapy on 
childhood brain tumour survivors. However, the study excluded patients on steroid 
treatment for longer than six months which may have influenced the results. 
Furthermore, the dose of steroids used in brain tumour is lower than in ALL, 
therefore comparison of data relating to ALL studies, where steroid therapy is also 
much longer, may not be appropriate. 
In summary, the evidence suggests a detrimental effect of steroid therapy in 
childhood ALL on body composition and BMI. However, the mechanisms by which 
they cause long term weight gain are still not fully understood and there is no 
convincing evidence to support the solely role of those two chemotherapeutic drugs 
on the late onset of obesity in childhood ALL survivors. Therefore, the underlying 
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mechanisms for the late development of obesity in survivors of childhood cancer are 
still unclear and the increased risk of obesity observed in this patient group is likely 
to be multifactorial. This area of investigation needs to be explored further since 
steroids are widely used to treat ALL and to decrease intracranial pressure in brain 
tumour. 
1.5.2 Energy balance 
Several studies have focused on the disturbances of energy balance in childhood 
ALL as a risk factor for the late onset of obesity rather than treatments (Mayer et al. 
2000; Reilly et al. 2001; Warner et al. 1997b; Warner et al. 1998). There is strong 
evidence to support the idea that children treated for ALL are in positive energy 
balance as consequence of increased dietary intake (Reilly et al. 2001), reduced 
energy expenditure (Reilly et al. 1998; Warner et al. 1995; Warner et al. 1997b; 
Warner et al. 1998) and reduced physical activity (PA) (Aznar et al. 2006; Jacob et 
al. 2007; Jansen et al. 2009; Sanford et al. 2008). 
For example Reilly et al. (Reilly et al. 2001) investigated energy intake associated 
with steroid therapy. The maintenance phase thus was associated with a 20% 
increased in energy intake during the five day period on steroids compared to the off 
period, although there was a significant difference between dexamethasone and 
prednisolone. They also observed a significant increase in BMI SDS in the ALL 
group treated with steroids in maintenance, compared to reference data. The study 
did not find a significant difference between the two types of steroids used, however 
the study was only carried out up to two years post diagnosis and it is not possible to 
draw a conclusion on longer term effects of the drugs beyond this. 
These findings are in contrast with the Wallace study (Wallace et al. 2003), where 
dexamethasone therapy was found to be more potent in causing weight gain than 
prednisolone at similar doses. Being important contributors to the weight gain 
observed in ALL patients, the different effects of those two steroids in energy 
balance are very important and must be explored further. 
Similarly, another study (Jansen et al. 2009) reported increased energy intake in ALL 
patients (n=16). However, Jansten and co workers (2008) also compared the energy 
intake during the period on dexamethasone and off dexamethasone. Interestingly 
29 
 
they found a significant increased energy intake during dexamethasone compared to 
control (2,125.9 ± 476.0 kcal/d vs. 1,775.1 ± 426.1 Kcal/d respectively) and a 
significant lower energy intake during the phase off dexamethasone compared to 
control (1,305.0 ± 249.4 Kcal/d vs. 1,775.1 ± 426.1 Kcal/d respectively). The 
increased energy intake during the period on dexamethasone observed in those 
studies may contribute to the weight gain observed in ALL patients. However, other 
studies did not show any increased energy intake associated with ALL treatments in 
the remission phase (Bond et al. 1992; Mayer et al. 2000). Those contradictory 
findings are difficult to reconcile but it may be that different treatment phases for 
ALL cause differences in energy intake.  
Some studies (Reilly et al. 1998; Warner et al. 1998) offer convincing evidence to 
support a decreased level of TEE in this cohort. For example, Warner and co-
workers (Warner et al. 1998) measured total daily energy expenditure by indirect 
calorimetry in 88 long term survivors of ALL at least 1.5 years from cessation of 
treatments and compared this cohort to 21 children previously treated for other 
malignancies and to healthy siblings as controls. The study reported a significant 
lower total energy expenditure (TEE) in all ALL survivors (TEE= 150 Kj∙Kg∙d) 
compared to other malignancies (TEE= 207 Kj∙Kg∙d) and control (TEE=185 
Kj∙Kg∙d). The presence of decreased energy expenditure is also supported by the 
work of Reilly and colleagues (Reilly et al. 1998) who studied 20 patients treated for 
ALL without CRT and control subjects at mean 4.5 years after diagnosis. Energy 
expenditure was calculated using the doubly labelled water method and, when 
compared to the control they found a much lower total energy expenditure and 
energy intake (mean differences of 286 Kcal/d for TEE, 76 Kcal/d for REE and 238 
Kcal/d for energy intake). The decreased energy expenditure considered in relation 
to the length of ALL treatments (two years for girls and three years for boy) would 
suggests that the energy excess experienced by these patients could indeed result in 
the consequent onset of obesity.  
Evidence suggests that the positive energy balance observed in ALL cancer patients 
survivors may be also accounted for by reduced physical activity. The accurate 
assessment of PA however is very difficult because of its methodological limitation. 
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There are two types of methods to assess physical activity, the subjective, which 
includes questionnaires and interviews, and the objective, which involves 
measurements of physiological or biomedical parameters by instruments such as a 
pedometer or an accelerometer (Corder et al. 2008). The subjective methods rely on 
the ability to accurately recall physical activity which may also be influenced by the 
judgment of the reporter or interviewer (Sallis 1991). Furthermore, the estimation of 
energy expenditure from the subjective methods rely on equations based on adults 
and may do not apply to the children (Sallis 1991). Consequently questionnaires are 
not very accurate and do not provide a good measurement of PA in children. 
However, the accelerometer has been indicated as one of the best methods for 
assessing free-living physical activity and strong validity has been observed in 
laboratory conditions (Freedson et al. 1998; Nichols et al. 1999; Trost et al. 1998; 
Trost et al. 2000; Welk et al. 2003). Nevertheless, this method is only able to record 
physical activity on a vertical axis and physical activities on a horizontal axis such as 
cycling are likely to be under recorded (Cooper et al. 2005). Furthermore the 
accuracy is strictly dependent on the length of measurement with four to five days 
being suggested as the minimum required to guarantee accuracy (Trost et al. 2000) 
and this would require a high level of subject cooperation. The high participant 
cooperation and the time length required to carry out the measurements may account 
for the limited sample size and limited numbers of studies aiming to assess PA in 
children treated for cancer. 
The studies available in the literature on the level of physical activity as a component 
of TEE during treatments for childhood cancer, were conducted using both the 
accelerometer (Aznar et al. 2006; Jacob et al. 2007; Jansen et al. 2009; Sanford et al. 
2008) and numeric rating scale (Jacob et al. 2007). The unequivocal evidence from 
these studies supports reduced PA during treatment for childhood cancer (Aznar et 
al. 2006; Jacob et al. 2007; Jansen et al. 2009; Sanford et al. 2008). 
For example, a study (Aznar et al. 2006) showed a significantly lower PA assessed 
by accelerometer in children (n=7) undergoing maintenance therapy for ALL 
(320±107 min/ week) compared to control (506±175 min/ week). The presence of 
reduced PA in ALL patients was also observed by Jansen and co-workers (2009) 
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who studied 16 ALL patients in maintenance treatment and 17 matched controls. 
When compared to control they noted a significantly reduced physical activity 
related with the treatment phase. PA was observed to be lower than control (30.0 ± 
3.9 vs. 40.0 ± 6.0 kcal/kg/day) during the days on dexamethasone compared to the 
days off the drug, when, PA did not differ from the control group. The difference in 
PA depending on the therapy phase has also been observed elsewhere (Sanford et al. 
2008). This finding would suggest a particularly increased risk for sedentary 
behaviour during dexamethasone; hence this phase of treatment should be a potential 
target for intervention aiming to increase PA during cancer therapy. 
A similarly reduced PA was also observed in paediatric patients treated for other 
types of malignancies (Jacob et al. 2007, Winter et al. 2009). For example, Winter 
and co-workers (2009) showed a decreased level of PA in 80 children treated for 
cancer compared to 45 healthy controls using the accelerometer method. 
Furthermore, they showed differences in PA during hospital stays compared to the 
days at home. Children treated for cancer had 77% lower physical activity compared 
to the healthy control during the hospital stay, whereas, the physical activity was 
higher during the days at home, but was still lower compared to the control by 60%. 
Those findings suggest that children treated for cancer are at risk of reduced PA and, 
remarkably, those children with longer hospital stays are at even higher risk of 
reduced physical activity. PA affects various aspects of development and it must be 
considered as an essential part of a child's life. Therefore the reduced PA observed in 
this patient group must be regarded not only in relation to the energy balance 
homeostasis but also to the achievement of normal growth and development. 
In summary, the evidence suggests increased energy intake (Reilly et al. 2001) , 
reduced physical activity during treatments (Jansen et al. 2009, Jacob et al. 2007, 
Jacob et al. 2007, Aznar et al. 2006) and reduced energy expenditure implicated on 
the late onset of obesity. However, it does not explain the underlying causes for the 
reduced physical activity in ALL survivors. The differences in energy expenditure 
among patients treated with steroids suggest the implication of this class of drug 
however the exact mechanism are still unknown. Moreover, some authors (Reilly 
2009) have suggested the reduction of physical activity and increased sedentary 
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behaviour as a psychosocial response to ALL treatment. However, the discussion of 
the psychological aspects of cancer treatments goes beyond the purpose of this 
paper. 
1.5.3 Early Adiposity Rebound 
A possible factor that may play an important physiological role for the onset of 
obesity following childhood cancer therapy is the early adiposity rebound (AR). The 
adiposity rebound is a phenomenon that generally occurs between the age of five and 
six where, after having reached the minimum body fatness (nadir) the BMI and fat 
mass (FM) increase again into adulthood (Rolland-Cachera et al. 1984). The 
occurrence of AR before the age of four is very rare and it has been widely reported 
that children undergoing an early adiposity rebound are at higher risk of developing 
obesity in later life (Gasser et al. 1995; Rolland-Cachera et al. 1984; Rolland-
Cachera et al. 1987; Williams et al. 1999). Since the average age at diagnosis for 
ALL is around three years of age, it has been hypothesised that the start of childhood 
ALL treatments causes AR to start early. This would cause a shift in the adiposity 
rebound trajectories and lead to the excess fat gain observed in this cohort (Reilly et 
al. 2001b). To date, only one study (Reilly et al. 2001b) was performed on children 
treated for ALL to investigate whether they experience early AR. The authors 
studied the timing of AR in 35 boys and 35 girls who survived ALL with a mean age 
at diagnosis of 30 months. The study showed that 42.6 % of ALL survivors had AR 
at the age of three and 80.9 % at the age of four in contrast to 4.5% at age of three 
and 21.2 at age of four in the control group. Interestingly, these findings confirm that 
AR occurred significantly earlier in patients treated for ALL compared to the 
matched healthy group and that the degree of positive energy balance was enough to 
cause early AR. Therefore, these findings show that timing of treatments of ALL can 
be an independent risk factor for the late onset of obesity. 
Early AR may be a possible explanation for the increased risk of obesity in children 
diagnosed before four years of age. However, the underlying mechanism causing 
early AR in children treated for ALL is still poorly understood. Disrupted appetite 
regulation could be an important contributor to early adiposity rebound in ALL 
survivors. Subjects who experience large FM losses tend to have a consequent 
energy compensation mechanism (hyperphagia) with a consequent excess body 
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weight regain (weight over-shooting) (Dulloo et al. 2012). This phenomenon is 
illustrated in Figure 1.3 and may be applied to children treated for ALL in 
maintenance where steroids are taken in pulses. During maintenance therapy, they 
experience alternate phases of low energy intake when off steroids and high energy 
intake when on steroids (Jansen et al. 2009). This may cause the FM losses during 
the off steroids period as a consequence of chemotherapy, followed by hyperphagia 
during the steroid period, which possibly causes fat overshooting and might lead to 
excess body weight gain observed in ALL survivors. 
 
Figure 1.3 Pattern of changes in energy intake, body fat (FM) and fat free mass 
(FFM) (Dulloo et al. 2012). 
However, to date, there is no data to suggest that this model (Dulloo et al. 2012) can 
be applied to ALL patients. Therefore in the future prospective studies should aim to 
investigate adiposity rebound in children treated with chemotherapy and CRT before 
the expected age of AR and in relation to appetite regulation and FM overshooting as 
a consequence of starvation and hyperphagia.  
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1.5.4 Cranial irradiation  
Evidence suggests a detrimental role of CRT on BMI and excess weight gain in 
survivors of ALL with an increased risk at higher radiation doses (Groot-Loonen et 
al. 1996; Odame et al. 1994; Oeffinger et al. 2003) and according to gender, with 
females being at higher risk (Oeffinger et al. 2003). A large (n= 1765) retrospective 
study (Oeffinger et al. 2003) compared a cohort of childhood ALL to a sibling 
control group (n=2565). They investigated whether excess weight gain was 
associated with different doses of cranial radiotherapy or a chemotherapeutic agent. 
Furthermore, they assessed if age at diagnosis and gender affected the risk of 
obesity. They observed a significantly increased prevalence of excess body weight 
and obesity among ALL survivors group who received higher doses of CRT (≥20 
Gy) when compared with siblings. However, the study did not find any association 
of obesity with any chemotherapeutic agent alone or for those patients who received 
chemotherapy and CRT of 10 to 19.9 Gy. Females treated with chemotherapy and 
CRT ≥ 20 Gy were found to be a greater risk of being overweight or obese when 
compared to the male cohort (OR 2.59, 1.86 respectively). Furthermore this risk was 
further increased by age at diagnosis with the greater risk for those female diagnosed 
at age of zero to four (OR 3.81) (Oeffinger et al. 2003). 
Further work to support the relationship between CRT and the late onset of obesity 
comes from a retrospective analysis (Odame et al. 1994) of the frequency and trend 
of weight gain in 40 survivors of childhood ALL in relation to CRT at a dose of 
1800 Gy against matched oncology patients who received chemotherapy but not 
radiotherapy. A significant weight gain was observed at four years with 57% of girls 
(mean BMI SDS 2.36 ; SD 1.2) and 21% of boys (mean BMI SDS 1.13 ;SD 1.2) 
being obese (classified as SDS >2). 
More recent studies used the DEXA method (Dual Energy X-ray absorptiometry) to 
evaluate body composition as a gold standard for evaluating adiposity in ALL 
survivors (Jarfelt et al. 2005; Nysom et al. 1999; van Beek et al. 2006; Warner et al. 
2002). These studies showed an increased percentage of body fat in ALL survivors 
who were treated with CRT compared with those not receiving CRT, even when the 
BMI values were similar between the two groups (Jarfelt et al. 2005; Nysom et al. 
1999; Warner et al. 2002). These finding suggests a detrimental effect of CRT on 
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body composition and would advocate that the increased risk of obesity reported by 
the previous study may be even higher. However, other studies did not observe any 
increased risk of obesity in ALL in relation to CRT and failed to report an increased 
risk according to age at diagnosis and gender (Dalton et al. 2003; Razzouk et al. 
2007; Van Dongen-Melman et al. 1995). The reasons for this inconsistency are not 
clear. Although, the use of BMI is common in clinical practice, its ability to measure 
body fatness in children with cancer may be questioned. 
Only one study (Gurney et al. 2003) evaluated the BMI changes in response to CRT 
in survivors of brain tumours. They did not identify any effect of treatments on 
having BMI >30 or more in the 921 patients analysed in remission when compared 
to control. The female group with an early age at diagnosis (<4 years) however was 
associated with the risk of obesity. Furthermore, the risk of obesity among the entire 
female cohort was increased two to three fold when they were treated with CRT, 
which seems to indicate an effect of gender.  
There appears to be a consensus on the detrimental role of cranial radiotherapy on 
the development of obesity in ALL survivors. Analysis of body composition in ALL 
survivors showed that patients treated with protocols which included CRT have 
increased body FM compared to the non CRT groups even at similar BMI values. 
Female ALL survivors are especially at increased risk of excessive FM in later life. 
However, the majority of the studies above aiming to research changes in body 
composition as a consequence of CRT have the limitation of a small sample size. 
Furthermore, the prevalence of obesity in ALL survivors has been reported to 
increase significantly even in patients that have been not been treated with CRT 
(Dalton et al. 2003; Razzouk et al. 2007; Van Dongen-Melman et al. 1995). This 
evidence suggests the involvement of other factors on the development of obesity. 
This is significant when considering that most recent protocols no longer include 
prophylactic CRT.  
One possible reason for the observed weight gain following extensive cranial 
irradiation and tumour excision is hypothalamic-pituitary axis damage. The 
hypothalamus and hypothalamus-pituitary axis regulates many physiological 
processes including food intake. When the hypothalamus is structurally damaged a 
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condition defined as hypotalamic obesity can occur. Muller et al. (Muller et al. 2004) 
showed an increased risk of obesity in cranyopharyngioma (benign brain tumour) 
survivors in a longitudinal retrospective study from birth to median 6.2 years post 
diagnosis. They reported a significantly higher BMI at diagnosis and during follow 
up in the craniopharyngioma group with hypothalamic involvement (n=49). One of 
the possible consequences of hypothalamic-pituitary axis damage responsible for the 
increased risk of obesity, is the growth hormone deficiency (GHD), with increased 
risk observed with higher and longer doses of CRT (Borgstrom and Bolme 1988; 
Cicognani et al. 1988; Pomarede et al. 1984). However, some studies did not show 
any relation between CRT and GHD (Birkebaek et al. 1998; Gurney et al. 2006)) and 
reported an increased risk also in ALL survivors who were treated with 
chemotherapy alone. This evidence suggests a possible implication of other factors 
such as chemotherapy, other than hypothalamic- pituitary axis damage alone on the 
development of GHD and obesity in childhood survivors. 
Another possible consequence of CRT implicated in weight gain, is the damage of 
mechanisms that control body weight. The body controls weight homeostasis by an 
intricate series of pathways which regulate food intake, energy expenditure and fat 
deposition (Hochberg and Hochberg 2010). Damage to key anorexogenic (e.g pro-
opiomelanincortin (POMC)), orexigenic signalling neurones (eg. Agouti Related 
Peptide (AgRP) and Neuropetide Y (NPY) and/or Leptin insensitivity, as 
consequence of head cancer and CRT, has been reported as the possible cause of 
obesity in this cohort (Hochberg and Hochberg 2010). For example, Brennan and co-
workers (1999) described that CRT causes damage to the Leptin receptor in the 
hypothalamus which disrupts the Leptin signal and ultimately results in obesity. In 
this study they assessed BMI and Leptin concentration in 32 survivors of ALL 
previously treated with CRT in comparison to 35 matched healthy controls. BMI and 
FM were not significantly different between the two groups, however, lean body 
mass was significantly decreased and Leptin was significantly increased in the ALL 
survivors, which may have occurred as a consequence of hypothalamic damage or 
GH deficiency. The Brennan et al. (1999) study has provided the first evidence to 
suggest the presence of damage involving other pathways implicated in food intake 
regulation rather than GHD alone following CRT.  
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Further evidence to support the potential damage to the Leptin pathway as a 
consequence of CRT in ALL survivors, comes from a later study (Ross et al. 2004). 
Because the development of obesity after CRT in ALL patients has been shown to be 
inconsistent, the authors suggested a polymorphism in the LEPR gene as contributor 
of this discrepancy. The study showed that LEPR polymorphism influenced the 
predisposition to obesity in female ALL but not in males at similar genotype 
distribution. These findings would explain the increase risk for later obesity in the 
female population treated for ALL previously described (Odame et al. 1994; 
Oeffinger et al. 2003). However, those findings are still preliminary and further 
research is needed on LEPR polymorphism to clarify the presence of a gender 
predisposition. In conclusion, GHD and Leptin insensitivity are believed to be the 
possible causes for the late development of obesity in this cohort and the reasons for 
GHD in non irradiated patients are still unknown.  
In summary, obesity as a long term consequence in children treated for cancer is well 
documented and, with the increased survival rate, prevention of this should be a 
consideration during and after treatment. It is evident from this review that a number 
of mechanisms lead to a positive energy balances in this cohort. Reduced PA, 
increased appetite and the damage to the nervous system regulating appetite and 
growth are now well identified mechanisms to contribute to this imbalance. It is well 
known that prevention of obesity is more achievable than treatments and it is feasible 
in children (Dietz 1998). Therefore, during the clinical management of the disease, 
excess weight gain should be monitored closely and raise concern as there should be 
an attempt to treat and prevent excess body weight during ALL treatment. For 
example, it might be prudent to encourage PA whenever possible. However, even 
though the mechanisms leading to excess body weight have been identified, the 
literature lacks intervention studies, aiming to modify patients’ behaviour or 
treatment regimens in order to prevent the late onset of obesity. Therefore future 
research should focus on intervention studies preferably multicentre, randomised 
controlled trials to understand how to prevent this childhood ALL sequela. 
Considering the limited number of new referrals for childhood cancer to each 
hospital per year, a multicentre study would be essential to ensure an appropriate 
sample size. Furthermore, random allocation to the intervention and non intervention 
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groups would ensure the exclusion of differences between the two groups and would 
reduce the bias (Sibbald and Roland 1998) 
1.5.5 Consequences of paediatric cancer- related obesity 
Only two studies have investigated the prognostic effects of excess body weight and 
obesity in paediatric oncology patients (Butturini et al. 2007; Lange et al. 2005) and 
they reported an increased mortality rate and an increased risk of relapse among 
obese children.  
The first retrospective study (Lange et al. 2005) evaluated the association between 
survival rate and obesity (BMI ≥ 95% percentile) in 768 American children affected 
by Acute Myeloid Leukaemia against outcome. Treatment-related mortality (TRM) 
after the second course of chemotherapy was significantly higher in the overweight 
compared to the normal weight group (Hazard Ratio 3.49). The authors hypothesised 
that obese patients were receiving too much chemotherapy leading to chemotherapy 
toxicity and death. However, the analyses of data concerning neutrophil recovery 
and course duration, which are an index of chemotherapy toxicity, suggested that 
obese patients were receiving the right amount of chemotherapy. This study has 
provided the first evidence to suggest that obesity during cancer therapy is associated 
with increased mortality.  
The second study (Butturini et al. 2007) retrospectively analysed data from 4260 
patients diagnosed with ALL. The cohort consisted of 342 (8%) obese patients (BMI 
≥ 95th percentile) and 3.971 non obese patients (92%). They reported an independent 
negative effect of obesity on outcome when compared to normal weight patients. 
The five years event free survival (EFS) rate was significantly lower for the obese 
group (72% ± 2%) compared to the non obese group (77%± 0.6%). This study 
showed an increased risk of relapse but they did not assess the risk of increased 
mortality. Contrary to the Lange et al. study (2005), they believed obese patients 
where at higher risk of relapse compared to the normal weight patients because of an 
inadequate chemotherapy dose since it is calculated based on body surface area. 
However, the outcome was independent of the chemotherapy dose.  
This limited data is also mirrored by adult studies. The obesity-related increased risk 
of relapse has also been reported in adults affected by ALL, (Butturini, Vignetti and 
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Gibbotti 2005), colorectal cancer (Meyerhardt et al. 2004) and breast cancer 
(Colleoni et al. 2005) and the obesity-related increased risk of treatment induced 
mortality has been reported in adult patients affected by acute myelogenous 
leukaemia (Meloni et al. 2001) 
These two studies (Butturini et al. 2007; Lange et al. 2005) have the limitation of 
assessing obesity based on BMI centile which may not be the best method to assess 
adiposity in children with chronic disease since it tends to underestimate FM 
(Warner et al. 1997a). Moreover, it is not possible to conclude what the causes of the 
observed increased mortality are, and it is not known whether those detrimental 
effects are caused by obesity per se, or if they are a consequence of factors 
associated with obesity, such as unhealthy diet and lack of exercise. 
The mechanisms causing increased mortality and morbidity in obese cancer patients 
are still poorly understood. Some authors suggested that obese patients receive less 
chemotherapy than needed (Bastarrachea et al. 1994; Georgiadis et al. 1995; 
Meyerhardt et al. 2004) which are in contrast with the Butturini et al. (2007) and the 
Lange et al. (2005) results. This inconsistency is hard to explain but possibly due to 
different diagnostic groups analysed and the different type of chemotherapeutic 
drugs used. Some authors propose a more complex interaction between obesity and 
chemotherapy (Brakenhielm et al. 2004; Fukuhara et al. 2005). Adypokines, growth 
factors and lymphokines produced by the adipose tissue or in response to the 
metabolic syndrome may alter cancer therapy effects and increase toxicity 
(Brakenhielm et al. 2004; Fukuhara et al. 2005; Onuma et al. 2003). Leptin and 
growth factor increase cancer growth (Onuma et al. 2003) and tumour necrosis factor 
(TNF) and IL-8 and IL6 increase inflammation, oxidation and increase angiogenesis 
and tumour growth  (Brakenhielm et al. 2004; Fukuhara et al. 2005) 
In this chapter the consequences of obesity during cancer treatments and after 
recovery were extensively discussed. However, evidence for the detrimental effects 
of obesity is very limited. The published studies suggest an increased risk of 
mortality and morbidity which has also been reported in adults patients. 
Furthermore, the long term consequences of obesity, such as increased risk of CVD 
later in life cannot be ignored. Therefore, issues relating to over and undernutrion 
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paediatric cancer patients needs effective management to reduce possible nutritional 
consequences 
1.6 Nutritional management in paediatric oncology patients 
As previously discussed, for many childhood cancer patients, the progression of the 
disease and the start of cancer treatments can bias the nutritional status towards 
malnourishment (under or overnutrition) with many detrimental consequences 
(Donaldson et al. 1981; Mejia-Arangure et al. 1999; Rickard et al. 1983; Viana et al. 
1994). Hence, identification of patients at nutritional risk from diagnosis and 
throughout treatment is essential. 
Early identification of high risk or undernourished patients would allow close 
nutritional monitoring and prompt nutritional therapy. This would help to prevent the 
decline of nutritional status, support growth and development. Additionally, a rapid 
identification of those patients at high risk of becoming overweight and obese would 
allow a preventative intervention targeting potentially modifiable risk factors, such 
as diet and sedentary life-style to be initiated. 
Nutritional management should therefore be an essential part of paediatric cancer 
treatment. The ESPGHAN committee on nutrition has highlighted substantial 
deficits in nutritional management in paediatric hospitals across Europe (Agostoni et 
al. 2005). The implementation of nutrition support teams in paediatric units has 
therefore been suggested. Amongst the various recommendations from the 
ESPGHAN meeting, of relevance to the current research study, is the urgent need for 
screening of nutritional risks, the identification of patients who requires nutrition 
support (NS) and the provision of adequate nutritional management. 
From an audit conducted in 2003 within the ‘Royal Hospital of Sick Children, 
Edinburgh’ (RHSC) (Holt 2003), it emerged that oncology patients were not having 
their height and weight monitored and consequently were not being referred 
appropriately for dietetic intervention. Only 30% of the patients in the audit had 
growth chart completed and patients had a weight loss greater than 5% before NS 
initiation. It was apparent that it was unclear whose role it was to conduct the 
nutritional screening. This evidence underlines the urgent need for a proper way of 
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assessing nutritional risk in children undergoing cancer treatments. An appropriate 
nutritional screening tool should be able to predict outcome due to factors relating to 
nutrition and to estimate the likelihood of adequate nutritional intervention on 
affecting the nutritional outcome in this particular group of patients.  
A general nutritional management pathway is adopted in the adult health care setting 
is shown in Figure 1.4 (Elia 2005). Its applicability in the paediatric scenario 
however, is difficult for many reasons. The main difficulties identified are the lack of 
a specifically designed screening tool for paediatric cancer patients and the 
limitations of the nutritional assessments available for assessing nutritional status in 
this cohort. These issues will be explored in this chapter.  
 
Figure 1.4 General nutritional management pathways (Elia 2005) 
 
1.6.1 Nutritional screening 
The first step for the management of undernutrition is the identification of 
undernourished patients or those at risk of developing undernutrition. Nutritional 
screening should aim to detect those patients who are malnourished or at risk of 
undernutrition so that an appropriate course of action can be taken. Nutritional 
screening is generally carried out by those members of nursing or medical staff at 
first contact with the patient. Any tool used for screening should be quick and easy to 
complete in order to allow for immediate action and subsequent monitoring. 
The European Society of Enteral and Parenteral Nutrition (ESPEN) recommend the 
Malnutrition Universal Screening Tool (MUST) for the screening of adults, in both 
community and health care setting (Kondrup et al. 2003a). However, to date , there 
are few screening tools for assessing the risk of undernutrition in general paediatrics; 
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the Subjective Global Nutritional Assessment (SGNA)(Secker and Jeejeebhoy 
2007), the Screening Tool for Assessment of Malnutrition in Paediatrics (STAMP) 
(McCarthy et al. 2008) and the Paediatric Yorkhill Malnutrition Score 
(PYMS)(Gerasimidis et al. 2010). Nevertheless, a validated screening tool for 
paediatric oncology patients is not yet available and the lack of a specific nutritional 
screening tool is a well recognised limiting factor for improving nutritional care in 
hospitalised children, including childhood cancer patients (Kondrup et al. 2003a). 
The Subjective Global Nutritional Assessment (SGNA) (Secker and Jeejeebhoy 
2007), is an adaptation of a previously designed adult nutritional assessment tool 
(Subjective Global Assessment) (Baker et al. 1982). It was validated (Secker and 
Jeejeebhoy 2007) in a prospective study that followed children having thoracic and 
abdominal surgery. The SGNA includes the child’s height, weight history, the family 
weight and height, dietary intake, type, frequency and duration of gastrointestinal 
symptoms, functional capacity muscle and FM wasting, oedema as well as metabolic 
demands of the disease. Its use was shown to correlate with the markers of 
nutritional status examined in the study (height (H), weight (W), TSF, MUAC, % of 
ideal body weight, handgrip strength, albumin transferrin, haemoglobin and white 
cells). The authors therefore concluded that this new tool was a valid means to assess 
those at higher risk of later undernutrition. However, this tool was not designed or 
validated for childhood cancer patients. Moreover, it has not been introduced in 
routine clinical practice because it is too complicated to be performed and is time-
consuming (Joosten and Hulst 2013). 
The STAMP tool (McCarthy et al. 2008) is a much easier screening tool for use in 
paediatric care and its use has been validated in hospitalised children aged two to 16. 
The STAMP consists of five steps (likelihood of the diagnosis to cause 
undernutrition; child’s current nutrient intake; height and weight centile; calculation 
of the risk score for undernutrition based on the previous steps and the care plan). 
Children are classified at high medium and low risk of undernutrition. The high risk 
patients are referred to the dietitian, nutrition support team or consultant; the medium 
risk patients are monitored and reassessed after three days and the low risk patients 
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are reassessed weekly. However, similarly to the SGNA, this tool has not been 
validated for its use in paediatric oncology. 
The most recent undernutrition screening tool developed for the general paediatric is 
the PYMS (Gerasimidis et al. 2010) . This tool is based on the current guidelines for 
nutritional screening published by the ESPEN (Kondrup et al. 2003). It is a four 
stage assessment tool based on BMI cut off points; recent weight loss; decreased 
dietary intake from previous the week; whether the child‘s diet will be affected by 
admission / condition in the next week. 
Gerasimidis et al. (2010) assessed the validity of the PYMS conducted by a nurse by 
comparing the outcome against a full dietetic assessment as golden standard in 247 
children admitted to hospital with several diagnoses. The study also compared the 
PYMS to the STAMP tool completed by a dietitian. The prevalence of patients 
identified at risk of undernutrition varied significantly between the screening tool 
and the full dietetic assessment. For example, the nurse assessments identified fewer 
high risk patients than the PYMS and STAMP completed by a dietitian, but more 
that the full dietetic assessment. However, the study showed a high specificity and 
sensitivity of the PYMS when completed by a dietitian compared to the full dietetic 
assessment. These findings highlight the issue of misclassifying well nourished 
patients and how the prevalence of nutritional risk can vary depending on the 
assessor. The misclassification of nutritional risk would cause an increased workload 
for the dietetic staff and increased costs for the health service. However, the authors 
believed that further training and continual use would increase diagnostic accuracy 
in non dietetic staff which is further supported by a previous study carried out by the 
same authors (Gerasimidis et al. 2001). The study (Gerasimidis et al. 2001) 
demonstrated that the PYMS does not produce large numbers of false cases when 
carried out by trained staff.  
To date there is not a study that focused on validating any of the above 
undernutrition screening tools in the paediatric oncology cohort. At present, the 
nutritional screening of children with malignancies at the Royal Hospital of Sick 
Children in Edinburgh is carried out by using PYMS completed by the nursing staff. 
As previously discussed the PYMS and the STAMP are simple methods based on 
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weight and height measurements expressed as BMI, nutrient intake and nutritional 
implications of the disease. However, the use of those tools may be misleading when 
used to screen paediatric oncology patients for nutritional risks.  
The use of weight and height related measurements are thought to be deceptive in 
paediatric oncology practice. This is because they do not assess body composition 
and the weight of tumour mass (Smith et al. 1991), oedema, the increased body fat 
caused by steroid therapy (Ahmed et al. 2002) and the rapid change of fluid in 
response to chemotherapy, are likely to affect body weight and mask 
undernourishment. Furthermore, the initiation of nutritional intervention based on 
the false classification of high risk patients (Gerasimidis et al. 2010), their decreased 
nutrient intake, or the classification of cancer as a high risk of nutritional 
implications alone, can lead to unnecessary nutritional intervention. This may lead to 
an increased risk of developing obesity after recovery plus an unnecessary work load 
for the dietitian and extra cost for the health service. Therefore, there is evidence to 
indicate the inappropriate use of the STAMP and PYMS tools in paediatric oncology 
practice. 
To date, there has been only one screening tool devised to look specifically at 
nutritional risk in this specific population group (Attard-Montalto et al. 1998). This 
screening tool is based on symptoms that alter nutrient intake and food absorption 
rather than anthropometrical indices; however it has not yet been validated. Attard-
Montalto and co-workers (1998) conducted a prospective study to compare the 
ability of their Symptom Score (SS) to assess the nutritional status of children treated 
with chemotherapy in comparison to anthropometric indices (weight, height, BMI, 
MUAC , TSF, and bioelectrical impedance analysis (BIA) serum albumin, insulin 
like growth factor-1 (IGF-1) IGF binding protein 3 (IGFBP-3) and whole protein 
turnover (WBPT). They recorded 511 symptom scores over 24 months in 30 patients 
(mean and median 17 per patient) aged between 0.7 and 17.5 years. They found no 
correlation with anthropometric measurements or IGF1 and IGFBP-3 but they 
reported a correlation of the SS with protein breakdown. From these results they 
suggested that the SS is better than the other parameters taken into consideration in 
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the study for assessing nutritional status during therapy. However, this SS has not 
been validated since its initial description, nor has it been taken up into routine use.  
The lack of a specific and widely accepted screening paediatric tool has been 
reported as the main limiting factor for improving nutritional support in hospitalised 
patients (Kondrup et al. 2003a; Kondrup et al. 2003b). For this reason it is essential 
to design a screening tool based on data from this particular patient’s cohort and to 
validate it with respect to clinical outcome. The first stage in the design of such a 
tool is to identify the risk factors for the development of undernutrition and evaluate 
the usefulness of commonly used anthropometric measurements in this unique 
population group. Furthermore, with the robust evidence of the increased risk of 
obesity for certain type of childhood malignancies and the evidence of a worse 
outcome for obese patients (Butturini et al. 2007) the nutrition screening tool for this 
population should also take into account the likelihood of developing over-nutrition 
as a consequence of childhood malignancy. Patients at high risk of obesity should 
also be classified as at risk of undernutrition and nutritional management should be 
as important as for those at risk of under-nutrition. 
1.6.2 Nutritional status assessment  
Several ways have been suggested as a means of assessing nutritional status for both 
research and clinical purposes; subjective global assessments (SGA), anthropometry 
and blood biochemistry are an example (Zunft 1992; Zunft 1992). However, none of 
these single methods gives an overall picture of nutritional status for all the nutrients. 
Furthermore, many issues have been identified in the assessment and interpretation 
of nutritional status in children with cancer.  
During cancer treatments actual weight can be affected by hydration status and 
tumour mass, masking body weight loss (Pietsch and Ford 2000; Smith et al. 1991). 
Additionally, it has been shown that children treated for cancer experience a change 
in the distribution of body compartments , with decreased FFM and FM (Murphy et 
al. 2010). For this reason, many authors argued (Murphy et al. 2009; Murphy et al. 
2010; Smith et al. 1991) that the measurement of body compartments (FM and FFM) 
can provide more valuable information about nutritional status than weight related 
measurements alone. Additionally, the assessment methods must be accurate and 
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precise (Atkinson and Nevill 1998; Jamaiyah et al. 2010; Ulijaszek and Kerr 1999). 
These concepts are discussed in depth later in Chapter three. 
The practicality and cost of the measurement in children treated for cancer is also 
crucial and it can be a limiting factor when assessing their nutritional status. For 
example, some techniques to assess body composition such as a Dual-energy X-ray 
absorptiometry (DEXA scan) are very expensive, therefore are not used routinely in 
this cohort. Finally, the interpretation of the measurements relies on the availability 
of reference values which should reflect the population characteristics and the study 
design (Gorstein et al. 1994). However, reference values for the UK population are 
often available for some methods but not for others, making interpretation of the 
results problematic.  
This section will discuss the use of the methods available in clinical practice and in 
research and their capability to assess nutritional status along with the issues 
involved with their use. This list of techniques is not exhaustive but covers the main 
methods relevant to this current study and to the paediatric oncology clinical 
environment.  
1.6.2.1 Subjective Global Assessment  
Currently, at the RHSC Edinburgh, nutrition support is initiated on the basis of a 
subjective global assessment (SGA) performed by the oncology multidisciplinary 
team and the hospital nutrition support team. The global assessment is based on 
weight loss, energy, nutrient and fluid intake, gastrointestinal and other symptoms 
(Detsky et al. 2008). SGA is considered a simple and inexpensive means of 
measuring nutritional status. Its use in general paediatric has been reported to be 
reproducible and precise in assessing hospitalised children (Secker and Jeejeebhoy 
2007). However, it needs to be performed by an experienced practitioner, 
particularly where there are diagnoses in paediatric cancer. Nevertheless its use in 
paediatric cancer patients has not been validated yet and it has been shown (Cooper 
et al. 2002), to be largely subjective, inaccurate and not reproducible in adults. 
Therefore, it is not clear whether this tool is acceptable in paediatric cancer patients. 
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1.6.2.2 Anthropometric measurements 
The word anthropometry comes from the Greek words anthropos "man" and metron 
"measure" therefore it literally means measurements of man (Gore et al. 1996). 
Anthropometrical techniques include height (H) weight (W), body mass index 
(BMI), TSF and MUAC among others, and they have been used extensively to 
assess the nutritional status in both research and clinical settings.  
The most widely used tool to assess nutritional status in general paediatrics, is the 
assessment of BMI centile (Cole, Freeman and Preece 1995). BMI does not require 
any specific expertise, it is cheap and easy to carry out in both clinical and research 
settings. Furthermore, it is a non-invasive technique, which makes this method easily 
acceptable by children and their parents. In adults, BMI correlates with FM 
independently of age and gender, and cut off point are used to identify those 
underweight (BMI < 18.5), normal weight (BMI 18.5-24.9) overweight (BMI ≥ 25) 
and obese (BMI ≥ 30) (WHO 2004). However, in children FM is dependent on age 
and gender. Therefore, the most appropriate way of interpreting BMI is by 
comparison to national reference data according to age and gender as centile (Cole et 
al. 1995; Cole et al. 2007). 
Triceps Skin Fold (TSF) and Mid Upper Arm Circumference (MUAC) are also 
measurements easily available and relatively cheap to obtain in both clinical and 
research setting. However, contrary to BMI, these methods require some level of 
expertise and training (Gore et al. 1996) and are not generally used in oncology 
clinical practice. TSF measurement assesses the amount of subcutaneous fat which 
indicates the energy reserves stored as fat tissue, while MUAC measurement 
assesses the muscle size which reflects protein reserves stored as lean body mass 
(Frisancho 1974; Frisancho 1981). These two measurements are single sited and they 
have been suggested not to be accurate for estimating total body composition in 
adults because of the uneven distribution of fat. However, they have been reported to 
reflect body composition in children, where fat deposits are more evenly distributed 
(Roche et al. 1981). Furthermore, MUAC and TSF are believed to be accurate for 
measuring changes in nutritional status over time which is the intent of this current 
study (Kyle et al. 2004b). Accuracy of TSF and MUAC depends on the observer’s 
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skill and training. However, the use of standardised protocols, a single trained 
observer and suitable equipment has been reported to improve accuracy and 
reproducibility (Jebb and Elia 1993). 
Because a child’s body composition depends on age and gender, TSF and MUAC 
are compared to expected frequencies and are converted to centiles. However, there 
are no specific TSF and MUAC charts for the UK population , hence the WHO 
reference value up to a year and the Frisancho for over one year of age (Frisancho 
1974; Frisancho 1981) are generally used. This reference data is from the early 70s 
and is based on US data for white subjects from one year of age. TSF and MUAC 
can be combined to calculate fat mass area and muscle mass area using published 
equation (Frisancho 1974) to assess FFM and FM body stores. Arm muscle mass and 
fat muscle mass have been reported to overcome the underestimation of tissue 
changes in the upper arm observed in TSF and MUAC alone (Frisancho 1981). 
However, the equation does not take into account the subject variation of bone 
diameter when measured by MUAC (Frisancho 1981). 
It has been widely reported that the level of undernutrition among childhood cancer 
patients varies with the method (Murphy et al. 2009; Sala et al. 2004) and the 
definition of undernutrition utilized (Pietsch and Ford 2000). Although height and 
weight related measurements are easy and cheap to measure (Mei et al. 2002) 
(Murphy et al. 2009), their use is believed to be misleading in paediatric oncology 
practice. The reasons for this, are that body weight related measurements do not 
assess body composition and the weight of tumour mass (Smith et al. 1991), oedema 
and increased body fat caused by steroid therapy (Ahmed et al. 2002) can affect 
body weight and mask undernourishment. Therefore, many authors (Garofolo et al. 
2005; Oguz et al. 1999; Smith et al. 1991) have suggested TSF and MUAC as better 
nutritional assessment methods in this particular cohort. 
Several studies have aimed to evaluate the best anthropometric methods to assess 
nutritional status in children treated for cancer (Murphy et al. 2009; Nething et al. 
2007; Oguz et al. 1999; Pietsch and Ford 2000; Smith et al. 1991; Smith et al. 1991). 
There is strong evidence to support the use of arm anthropometry as a better 
assessment method of undernutrition in children treated for cancer (Garofolo et al. 
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2005; Oguz et al. 1999; Smith et al. 1991). A large prospective controlled study 
(Smith et al. 1991) showed that, even though W/H were normal, arm anthropometry 
was significantly lower in a cohort of 100 newly diagnosed British children with 
cancer when compared to control and reference values. Remarkably, the difference 
between W/H and arm anthropometric measurements on assessing undernutrition 
was not observed the control group, further supporting the idea that the tumour and 
cancer treatment may have a masking effect on undernutrition when measured by 
weight related measurements.  
Further work to support TSF and MUAC as better indicators of undernutrition comes 
from a later study (Oguz et al. 1999) which detected a much higher incidence of 
undernutrition (27%) than reported by Smith and co-workers (1991). The reasons for 
the difference in undernutrition incidence between the two studies are not clear. 
Possible explanations are the differences in the cancer type included in the study. 
The first study (Smith et al. 1991) included both haematological and solid cancers, 
whereas the Oguz et al. (1999) included only solid cancers. Furthermore the racial 
and socioeconomic differences between the two groups of patients may also account 
for this difference since the Smith et al. (1991) was carried out in British patients and 
the Oguz et al. (1999) study was carried out in Turkey.  
Further supporting evidence has been reported by a cross sectional study (Garofolo 
et al. 2005) conducted in 127 Brazilian patients during the first phase of treatments. 
A significantly higher percentage of undernutrition was detected by using TSF 
(40.2%) and MUAC (35.4%) compared to W/H (18.9%). Compared to the Smith et 
al. (1991) study the reported incidence of undernutrition was much higher which is 
likely to be a reflection of the socioeconomic status of the country where the study 
was carried out.  
Two later studies (Nething et al. 2007; Pietsch and Ford 2000) aimed to compare the 
use of weight and height related measurements (BMI, weight for height (W/H), 
weight for age (W/A) and height for age (H/A). Pietsch and Ford (Pietsch and Ford 
2000) conducted a retrospective study on 127 American children with several types 
of cancers and they observed a variety in the rate of undernutrition at diagnosis in the 
same cohort ranging between 1% to 46%, depending on the method used for the 
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nutritional status assessment. They concluded that BMI <-1SD was the better 
assessing method since it detected the highest undernutrition rate compared to the 
weight and height related measurements (BMI, weight for height (W/H). However, 
this study used a very loose cut off point (BMI <-1SD) to define undernutrition 
instead of the BMI ≤-2SD (World Health Organisation 2011) generally used to 
define undernutrition. Hence, it is very possible that it resulted in an unverified high 
prevalence of undernutrition, therefore BMI <-1 SD should not be used. 
Furthermore, this study did not use arm anthropometry, so it is not possible to draw 
any conclusion regarding the comparison of height and weight related measurements 
and arm anthropometry. 
Conversely, Nething et al. (2007) failed to show the usefulness of BMI as an 
indicator of undernutrition in children with malignancies and they reported a lack of 
agreement between BMI centile and H/A and W/A. Furthermore they reported that 
BMI for age classified too many patients as being at risk of under-nutrition 
compared to the other measurements. However, those measurements were not 
compared against a gold standard and it is not possible to conclude whether BMI 
causes an overestimation of undernutrition or whether H/A and W/A caused an 
underestimation. 
The evidence strongly suggests that weight related measurements as the only 
measurements of nutritional status in childhood cancer may be not reliable enough. 
However, it may be argued that the higher incidence of undernutrition measured by 
arm anthropometry is not caused by a better measurement but by misclassification 
and the generation of false positives which lead to higher rates of undernutrition. 
However, this is very unlikely because it has been shown that TSF correlates with 
FM% obtained from air displacement plethysmography in children undergoing 
cancer therapy (White et al. 2011), which is a reliable and valid technique to assess 
body composition in children (Fields et al. 2002). Importantly regardless of the 
reliability of each method, these findings imply that many undernourished patients 
are not identified and patients with solid tumour are most likely to be missed by 
weight related measurements. Given the pivotal role of assessing nutritional status in 
this cohort, and the fact that most common clinical practices rely on weight related 
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measure to assess nutritional status, the lack of an appropriate nutritional assessment 
method negatively affects the nutritional management of children treated for cancer. 
1.6.2.3 Bioelectrical Impedance 
Bioelectrical impedance (BIA) has been extensively used to assess the nutritional 
status of healthy adult subjects. This technique does not require any specific 
expertise, it is quick to be performed and it is relatively non invasive. BIA assesses 
body composition by measuring resistance and reactance at a specified electrical 
frequency. The tissue conductivity is determined by the concentration of fluid and 
electrolytes present. Therefore, from those measurements, using a validated 
prediction equation, it is possible to obtain total body water (TBW) which is an 
indication of lean body mass (LBM) and FM (Zunft 1992).  
The use of BIA in healthy adults (Berger et al. 2000; Haas et al. 2012) has been 
shown to be accurate for estimating body composition. However, the use of BIA for 
nutritional assessment in paediatrics is controversial. A satisfactory level of accuracy 
for estimating FM has been reported by some authors (Okasora et al. 1999; Schaefer 
et al. 1994; Wabitsch et al. 1996) but not by others (Hosking et al. 2006). Many 
factors could contribute to the disparity found in the literature, with the main one 
being the lack of a specific paediatric prediction equation (Schaefer et al. 1994).The 
equations available for healthy adults are not applicable in children due to the fact 
that children experience changes in the proportion of fluid compartments during 
growth and development, therefore a specific equation specifically designed for 
children must be used in relation to age (Boileau et al.1984; Deurenberg et al. 1990; 
Houtkooper et al.1989). However, the validation studies needed to design the 
prediction equation in children are challenging for many reasons. For example, the 
estimation of FFM from total body water techniques is based on the assumption that 
FFM is constant, which, as discussed, is not the case in children (Boileau et al. 1984; 
Deurenberg et al. 1990; Houtkooper et al. 1989). Furthermore techniques such as 
densitometric underwater weighting, requires a high level of subject cooperation 
which is unlikely to occur in young children. Although there are some equations 
available for paediatrics (Clasey et al. 2011; Schaefer et al. 1994) there is not a 
validated equation available in the literature for the use in children with cancer. 
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Another factor that can impact on the impedance results is the type of analyser used. 
There are two main methods for bioelectrical analysis, the single frequency BIA (SF-
BIA), generally at 50 KHz and the multi frequency BIA (MF-BIA) using different 
frequencies ranging from 0 to 500 KHz. The SF-BIA measures a sum of extra 
cellular water (ECW) and intra cellular water (ICW) therefore it can estimate total 
body water without distinguishing between the two compartments. In contrast, multi 
frequency BIA (MF-BIA) can evaluate TBW and ICW and ECW distinctly (Kyle et 
al. 2004). For this reason the SF-BIA has been indicated to be more accurate than the 
MF-BIA when assessing patients with normal hydration (Gudivaka et al. 1999) ) 
whereas the MF-BIA has been reported to be more accurate when measuring 
subjects with altered hydration (Patel et al. 1996).  
The value of using the BIA technique in clinical, where the disease and the 
treatments may have cause a fluid shift, is still under debate (Kyle et al. 2004a). Few 
studies (Fredrix et al. 1990; Simons et al. 1995) have shown a correlation between 
BIA and the reference method (deuterium dilution technique) to predict total body 
water in adult cancer patients. The Simons and co-workers study (Simons et al. 
1995) used a single frequency 50Hz BIA among a heterogeneous group of adult 
cancer patients with and without cachexia. FFM was calculated using a prediction 
equation developed from normal weight healthy adults (Lukaski and Bolonchuk 
1988) and it was compared to the deuterium results. In the 41 patient studies, the 
TBW was found to be overestimated by 5% (1.67 l) in underweight patients (n=16), 
whereas it was found to be strongly correlated with the deuterium technique (r
2
= 
0.85) in normal weight patients (n=25). The reason for this inconsistency between 
the normal weight and underweight group is probably due to the shift in fluids 
caused by cachexia, which may have altered the conductivity of body compartments. 
Therefore, BIA may not be able to assess body composition in patients with 
significant shifts in fluid especially if used with a prediction equation developed for 
a healthy group. 
Since paediatric cancer patients are likely to have altered hydration status caused by 
the treatments and the disease (Warner et al. 2004) the regression equation 
developed for healthy children (Clasey et al. 2011; Schaefer et al. 1994) is likely to 
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result in substantial error and should not be used in paediatric cancer patients. The 
only available equation for the paediatric cancer cohort is the Brennan and co-
workers (Brennan and Thomas 1997). The equation was validated against the 
deuterium-oxide technique on a study carried out on 40 children newly diagnosed 
with solid and haematological tumours. However, it is not clear from the article 
published whether they use a SF-BIA or a MF-BIA. The study showed a wide limit 
of agreement (mean 0.9, limit of agreement = -2.46 to 4.06) between deuterium 
technique and BIA. This shows some level of inaccuracy and it suggests that more 
work is needed to increase the BIA precision in assessing this group of patients. 
Only one study used the BIA technique to assess nutritional status in paediatric 
cancer patients and it was published in the same year as the Brennan equation 
(Dubuque et al. 1997). Therefore, the study used an equation (Schaefer et al. 1994) 
for general paediatrics to calculate FFM. However, even though the equation was not 
specific for children with cancer they reported no difference between the FFM 
obtained from TSF and the BIA. The level of accuracy is likely to have been 
increased by the use of a MF-BIA which may be due to it being a better device to 
measure subjects with altered hydration status (Patel et al. 1996). However, these 
results must be interpreted with some caution since the authors did not compare the 
FFM % against a gold standard using arm anthropometry instead. 
Another issue in the use of BIA for the assessment of undernutrition in children with 
cancer is the limited availability of FM reference data for children from birth to 
adulthood. To date there are only three studies that provide FM reference values for 
paediatrics (Fomon et al. 1982; Laurson et al. 2011; Wells et al. 2012), however they 
cover different age groups and were carried out using different validation methods. 
Only one study (Fomon et al. 1982) provides reference values from birth, but it has 
the big limitation of using only one subject. The reference data in this study were 
determined using the deuterium technique and the data is presented as FM%. The 
Laurson et al. study (2011) provides references expressed as FM % as the Fomon et 
al. study (1982) and it covers the age range from five to eighteen years and the 
reference data was obtained using skinfold thickness measurements coming from the 
National Health and Nutrition Examination Survey (NHANES) IV based on 8289 
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subjects. Although this study had the advantage of a big sample size, the FM% was 
not obtained using a gold standard.  
Very recently, reference data for UK children aged five to twenty have been 
published as FM and FFM SDS and centiles (Wells et al. 2012). The study assessed 
body composition by using the air displacement plethysmograpy, in a sample of 535 
British children. Although the study has the great advantage of a big sample size and 
a good study design, it has the limitation of covering only children from five years of 
age.  
Therefore, the lack of comprehensive reference data from zero years of age onwards, 
is a further limiting factor on the assessment of body composition in children. 
However, whilst comparison of FM against reference values may be limited by this 
lack of reference values, it provides a useful measurement to examine changes in 
body composition in response to cancer and its treatments in longitudinal studies. 
1.6.2.4 Energy and nutrient intake assessment methods 
A variety of methods may be employed to estimate energy and nutrient intake with 
the preferred method of choice in the childhood cancer literature being the dietary 
recall (Delbecque-Boussard et al. 1997; Poslusna et al. 2009; Sgarbieri et al. 1999) 
and the dietary diary (Bond et al. 1992; Carter et al. 1983b). These assessment 
methods are self reported and each method is subject to some extent of error (Biro et 
al. 2002). Weighted diet diaries overcome the issue of estimating portion sizes and 
minimize the error resulting from memory lapses (World Health Organisation 1995). 
However, although it has been shown to provide a relative reproducible estimate of 
energy intake and macronutrients (Willett 1998; Willett 1998) , this method has a big 
respondent burden since it requires that all food eaten must be methodically 
weighted and recorded (Pekkarinen 1970). This methodology therefore is very 
demanding for the families and the patients undergoing cancer treatments. Similarly, 
the dietary records using portion sizes instead of the weight still require participant 
involvement and the participant must be very motivated. Moreover, if a meal is not 
recorded as it is eaten, the errors increase (Biro et al. 2002). In contrast, the dietary 
recall method has the great advantage of having a small respondent burden and 
hence it is suitable for a dietary assessment during cancer treatments. Other 
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advantages are that there is no requirement for literacy and this procedure does not 
alter the pattern of food intake because it is done retrospectively. However, this 
approach depends on the respondent’s recall and estimation of portion sizes and only 
provides information on a single day intake but also has an increased error due to 
recall. 
Validation studies in children have shown that both weighted dietary diary and diet 
history tend to underestimate energy intake in children and adolescents (Bandini et 
al. 1990; Bratteby et al. 1998) and are affected by under-reporting (Black et al. 
1991). Moreover, multiple pass 24 h recall has been reported to be accurate on a 
group level but not at an individual level (Johnson et al. 1996). Therefore, there is 
not a perfect method to assess dietary intake and the choice of one method over 
another should consider feasibility and the nutrient to be measured and the 
interpretation of the results should take into consideration the limitations of the 
method used. 
1.6.2.5 Blood biomarkers 
Selected blood biomarkers such as albumin, pre albumin, transferrin and retinol 
binding protein have been extensively used (Forse and Shizgal 1980; Kirby 1997; 
Santos et al. 2003) to assess nutritional status with serum albumin being the most 
frequently used among all the blood parameters. However, the ability of blood 
proteins to assess nutritional status has been subject to much debate (Forse and 
Shizgal 1980; Kirby 1997; Santos et al. 2003). The rationale behind the use of 
albumin as a biomarker of nutritional status is that, during chronic protein 
undernutrition, when the main energy source is carbohydrate, the secretion of insulin 
prevents muscle breakdown to replace albumin thus leading to hypoalbuminemia. 
However too many non nutrition markers contribute to a low plasma concentration 
(Lipman 2005). Among all, albumin is an acute phase reactant and hypoalbuminemia 
is caused by inflammation as sparing mechanisms to sustain the synthesis of 
inflammatory chemicals needed to maintain the inflammatory response (Bistrian 
1986).  
Many studies (Donaldson et al. 1981; Forse and Shizgal 1980; Merritt et al. 1985; 
Santos et al. 2003) have shown a poor specificity and sensitivity of albumin in 
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measuring nutritional status with hypoalbuminemia being caused by inflammation 
and fluid shifts rather than protein undernutrition in hospitalised patients (Forse and 
Shizgal 1980; Santos et al. 2003) and paediatric oncology patients (Donaldson et al. 
1981; Merritt et al. 1985). Furthermore, it is well established that plasma albumin 
recovers when the clinical condition improves (Charney 1995), but not in response to 
artificial feeding (Ireton-Jones and Hasse 1992) which highlights albumin as a 
disease marker more than a nutritional status indicator. 
Retinol binding protein (RBP) and transferrin are also used in the clinical setting to 
assess protein undernutrition. Retinol binding protein is the protein carrier for retinol 
and its serum concentration is believed to reflect retinol serum levels and therefore 
undernutrition (World Health Organization 1996). Serum transferrin is the transport 
protein for iron. However, similarly to albumin, a decreased concentration of serum 
transferrin (Ruggiero and Riccardi 2002) or RBP level (Gamble et al. 2001) could be 
caused by inflammation and infection and be mistaken for undernutrition. 
Furthermore, the use of this parameter in cancer patients may not be appropriate 
since cancer is associated with anaemia. Serum iron is often decreased (Tessmer, 
Hrgovcic, and Wilbur 1973) but levels of ferritin are extremely elevated and 
transferrin saturated. Therefore, albumin RBP and transferrin are believed not to be a 
good measurement of undernutrition in this cohort (Gamble et al. 2001; Merritt et al. 
1985; Ruggiero and Riccardi 2002).  
The role of albumin as an indicator of inflammation more than nutritional status has 
been addressed by Merritt and co-workers (Merritt et al. 1985). The study was 
specifically designed to determine the implication of hypoalbuminemia in 90 
children treated for a combination of malignancies. They observed abnormal serum 
albumin associated with normal anthropometrical nutrition parameters. Furthermore, 
an association of hypoalbuminemia with fever was reported. Therefore, this study 
further supports the role of hypoalbuminemia as an indicator of acute metabolic 
response to infection more that undernutrition in paediatric cancer patients.  
Contrasting evidence comes from other studies (Kibirige et al. 1987; Yu et al. 1994). 
Kibirige and co-workers (1987) reported serum albumin concentration of less than 
32g/l as a useful indicator of poor nutritional status measured as weight loss greater 
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than 5% in newly diagnosed children with ALL. However this study did not measure 
markers of inflammation and it is not possible to establish if the decreased serum 
albumin was caused by inflammation or by undernutrition. Moreover, Yu et al. (Yu 
et al. 1994) investigated the use of the biomarkers previously described, Pre Albumin 
(PA) RBP and transferrin as sensitive indicators of mild and moderate undernutrition 
in 25 leukemic children, either in remission or newly diagnosed. The authors used 
pre-albumin as a better indicator of undernutrition in paediatrics compared to 
albumin because it has higher turnover rate compared to albumin (half -life 1.9 days, 
20 days respectively); therefore a limited substrate supply would cause a much 
quicker drop in plasma concentration of pre-albumin than albumin. In order to 
exclude low levels of blood biomarkers caused by inflammation they measured CRP 
levels. CRP levels were comparable to the healthy children 50% of patients were 
found with lower blood PA concentration than the expected rank for their age and 
gender, whereas only 10-18% has lower blood concentration of albumin, transferrin 
and retinol binding proteins. Therefore, they concluded that PA was a good indicator 
nutritional status when compared to the other blood parameters. However, steroids 
are known to decrease CRP levels (Felson et al. 1995; Mitchell 2006) and the 
patients in the two studies (Kibirige et al. 1987; Yu et al. 1994) were ALL patients 
treated with high doses of steroids as part of their cancer treatments. Furthermore 
hepatic synthesis of albumin has been shown to be increased by steroids 
(Oppenheimer and Werner 1966). Therefore, the treatments are likely to have 
impacted on the inflammation markers and on the synthesis of albumin, causing the 
debatable results. 
This literature review highlights the lack of a convenient, sensitive, specific and 
measurable indicator of undernutrition in paediatric oncology. Comparisons between 
the results available in the literature to determine the best tool to assess nutritional 
status in this specific cohort are difficult because of the difference in sample size, 
type of cancer and assessment methods used. Furthermore, the evidence puts into 
question the accuracy of the current simple nutritional measurements, based on 
weight and height related measurements, in paediatric oncology. Based on this 
evidence, it is very likely that some undernourished children with cancer assessed for 
undernutrition based on weight and high are missed and that body FM stores should 
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also be assessed. It is true that children experiencing evident nutritional problems 
during cancer therapy are globally assessed; however the problem is in identifying 
those who do now show any obvious sign of undernutrition and those at risk. 
Therefore it is now essential to address this issue and it is necessary to evaluate 
nutritional risks on a global scale in conjunction with all the factors believed to play 
a role in the development of undernutrition in this specific population. 
1.6.3 Micronutrients status 
So far, this review explored the malnutrition in paediatric oncology patients as a 
consequence of energy imbalance. However, cancer and its treatments can also result 
in a selective impairment of intake, reduced absorption and net losses of 
micronutrients with a detrimental effect on micronutrients status (Foltz et al. 1996; 
Grant and Kravits 2000; Greene et al. 1994; Van Cutsem and Arends 2005). 
Furthermore, paediatric cancer patients may have an increased metabolic demand for 
micronutrients, for example as a consequence of increased REE and the consequent 
increased demand for co- factors and enzymes. However, the specific micronutrient 
requirements for this cohort are unknown and micronutrient assessment in this group 
can be challenging. Micronutrient assessment in a clinical setting is generally carried 
out using plasma samples; however, many factors affect plasma micronutrient 
concentration such as post prandial status, exercise and, of particular relevance to 
this cohort, inflammation (Tomkins 2003). Furthermore, plasma levels of some 
nutrients (e.g. copper), may not reflect tissue concentration and nutrient status 
Therefore, the altered plasma levels of some nutrients ( e.g. zinc, ferritin, copper) 
may be caused by the use of an inappropriate assessment technique (Aggett and 
Davies 1983) or by inflammation (Galloway et al. 2000; Tomkins 2003) rather than 
undernutrition per se. Thus, this possible interaction must be taken into account 
when interpreting the results. 
Although many studies have aimed to assess plasma vitamins and trace element 
concentration in adults (Durken et al. 1995; Nakagawa 2000), only few studies have 
been carried out in children to assess the nutritional status of vitamin and trace 
elements during childhood cancer therapy. However, all the evidence showed a 
detrimental effect of cancer and its treatments on micronutrient status. 
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1.6.3.1 Vitamin A, C , E. 
Vitamin A, C, and E are dietary factors with antioxidant properties and they have 
protective effects during cancer. For example, vitamin A and E induce cell 
differentiation and growth inhibition in vitro in some types of cancer cell (Prasad and 
Edwards-Prasad 1982; Prasad and kumar 1996; Sporn and Roberts 1983) and In vivo 
studies have shown a decrease in tumour size in response to high doses 
supplementation with vitamin A (Gundimeda et al. 1993; Prasad et al. 1993). 
Similarly, vitamin C has been shown to inhibit cancer growth in cells cancer culture 
in a dose dependent manner (Prasad 1980). However, some other authors observed 
an increase in cancer growth at small doses and different types of cancer (Prasad et 
al. 1994), which may suggest different effects of vitamin C in cancer depending on 
the dose and the type of tumour. Furthermore, these nutrients are essential to 
maintain growth and development, therefore, their adequate status in children during 
cancer therapy is pivotal. 
Alterations in plasma concentration of vitamin A, C and E have been described in 
children undergoing treatment for cancer. A study (Fiore et al. 1997) reported a 
significantly lower level of plasma vitamin A in 54 children with cancer at onset of 
the disease in comparison to a matched healthy control. Since only 33% of the cohort 
had an inadequate dietary intake of the vitamin, this study would suggest an 
increased requirement for the vitamin; however, vitamin A intake was assessed by 
48 h dietary recall which is not a very accurate means of assessing micronutrient 
intake (Poslusna et al. 2009). Unfortunately the study did not measure plasma 
vitamin A after therapy had started therefore, effects of treatments on plasma vitamin 
A is unknown. 
Further work to support the increased risk of vitamin deficiency during childhood 
cancer come from Malvy et al. (1997). They observed a low plasma retinol, β-
carotene, and α-tocopherol in 170 children with several types of cancers at diagnosis 
compared to 632 healthy matched controls. The study did not assess nutrient intake, 
therefore it is not clear what were the causes for the reduced plasma level at baseline 
and whether the improvement observed at six months was caused by nutrient intake 
or by other factors. 
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Data from other studies (Kakar et al. 1975; Neyestani et al. 2007) also suggests a 
poor vitamin C status in this cohort. A study (Kakar et al. 1975) showed a lower 
plasma and leucocytes vitamin C concentration in ten ALL patients compared to 
control even though vitamin C dietary intake was similar. These finding would 
suggests an increased need for vitamin C in patients treated for ALL. However, from 
this study it is not possible to determine the causes for the increased requirement.  
The effect of micronutrients with antioxidant properties supplementation during 
cancer therapy is still unclear. Some oncologists may argue that the supplementation 
of antioxidants may interact with cancer treatments by protecting both healthy cells 
and tumour cells against oxidative species generated by those treatments to destroy 
the tumour. However, some studies have shown that vitamin C, A and E enhanced 
the growth inhibitory effects of many chemotherapeutic agents (Prasad et al. 1979; 
Prasad 1980; Prasad et al. 1999; Ripoll et al. 1986). Moreover, those vitamins play 
an essential role in many other body functions and their nutritional status must be 
adequate to sustain growth and development during childhood cancer. Hence, the 
role of supplementation needs to be elucidated further especially to understand the 
specific requirements for those nutrients during cancer therapy.  
1.6.3.2 Vitamin D 
Vitamin D is currently attracting a great deal of scientific and media attention in the 
UK. Due to the lack of sunlight exposure and with very few foods being fortified 
with vitamin D ,children and adults are at high risk of being deficient or insufficient 
(Holick 2006a; Holick 2006b). Vitamin D deficiency can cause secondary 
hypoparathyroidism. A decreased secretion of the parathyroid hormone (PTH) is a 
secondary response to calcium and vitamin D deficiency. PTH enhances calcium 
release from the bone and the conversion of the inactive form of vitamin D to its 
active form Vitamin D (1,25-dihydroxy vitamin D). Therefore vitamin D deficiency 
can cause bone mass loss (Sahota et al. 1999; Sahota et al. 2001) with detrimental 
effects in bone growth and development, particularly important in children 
(Baradaran et al. 2012; Goshayeshi et al. 2012; Zwart et al. 2011).  
Vitamin D status has been reported to negatively correlate with BMI in adults and 
adolescents. Hence obesity may be a risk factor of vitamin D deficiency per se, and 
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if the secular trend towards an increased prevalence of obesity is considered, it is 
likely that the prevalence of vitamin D deficiency will also increase even at adequate 
sunlight exposure (Baradaran et al. 2012; Goshayeshi et al. 2012; Zwart et al. 2011). 
The role of Vitamin D goes beyond growth and development. Recent studies have 
also shown that vitamin D is protective against cancer (Holick 2006b; Mantell et al. 
2000) by inducing apoptosis and preventing angiogenesis. Therefore, this evidence 
highlights even further the importance of vitamin D during childhood cancer therapy.  
Children treated for cancer have an increased risk of poor vitamin D status since they 
may not rely on the vitamin D3 synthesis on the skin, for the limited time spent 
outdoors or dietary intake to meet their vitamin D requirements. Furthermore, 
patients treated for leukaemia may have a higher risk of deficiency (Skversky et al. 
2011) due to the increased vitamin D catabolism caused the steroids (Zhou et al. 
2006) and for the effect of steroids therapy on increasing FM and BMI (Reilly et al. 
2001; Reilly 2009; Ventham and Reilly 1999).  
Plasma vitamin D has been reported to be insufficient in the paediatric oncology 
population at all stages of treatment (Helou et al. 2008; Sinha et al. 2010; Halton et 
al. 1996). Halton and co-workers (Halton et al. 1996) observed vitamin D plasma 
levels below normal range in 70% of children (n=40) treated for ALL at both 
diagnosis, and after one year of treatments. Lower prevalence of plasma vitamin D 
deficiency has been reported elsewhere (van der Sluis et al. 2002), where only 20% 
and 4.5% of ALL patients (n=61) had decreased plasma vitamin D at diagnosis and 
during therapy respectively. This inconsistency may be explained by the different 
cohort characteristics. The Holton et al.(1996) study contained a higher percentage 
of high risk patients compared to the van der Sluis et al. (2002) study, which are 
treated with higher doses of corticosteroids compared to the low risk patients. 
Vitamin D supplementation has been reported to improve vitamin D status in all 
patients apart from the haematological group (Helou et al. 2008). This difference 
response to vitamin D supplementation observed among the diagnostic groups may 
be explained by the increased vitamin D catabolism in ALL patients consequent to 
steroid therapy (Skversky et al. 2011) or by the increase in BMI caused by steroids. 
However, vitamin D status was not correlated to BMI to investigate any independent 
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risk of obesity in vitamin D status (Baradaran et al. 2012; Goshayeshi et al. 2012; 
Zwart et al. 2011) in any of these studies (Helou et al. 2008; Sinha et al. 2010). 
1.6.3.3 Zinc copper and selenium  
Several studies have described zinc deficiency in paediatric cancer patients 
(Carpentieri et al. 1986; Cavdar et al. 1980; Gupta et al. 1994; Malvy et al. 1997; 
Mocchegiani et al. 1994; Sgarbieri et al. 1999) and it has often been reported with 
increased plasma copper (Delves et al. 1973; Gupta et al. 1994; Sgarbieri et al. 1999; 
Tessmer et al. 1973). However, zinc and copper are acute phase reactants and the 
changes in plasma concentration described in these studies may be caused by 
inflammation rather than undernutrition (Galloway et al. 2000). Nevertheless, none 
of the above studies assessed inflammation and therefore, it is not known if the 
changes in plasma concentration observed in those studies were cause by 
inflammation alone or if there was some other mechanism involved. However, the 
normalisation effect of chemotherapy on plasma zinc and copper may support the 
role of inflammation as the possible leading cause of imbalance.  
Possible other factors playing a role on the observed decreased plasma zinc in cancer 
are the increased urinary excretion caused by steroids (Flynn et al. 1971) which are 
often used in anti-cancer therapy, the depressing effect of copper in zinc and their 
competition for absorption in the intestinal mucosa (Cavdar et al. 1980). 
Furthermore, zinc deficiency decreases thymulin activity and IL2 production (Prasad 
et al. 1988) which are essential in T cell and Natural Killer regulation as well has 
being essential for anti-viral and anti-tumour body response. Interestingly a study 
(Malvy et al. 1997) reported a reduced level of active thymulin compared to the 
control group and an extremely high level of its inactive form in children with 
cancer. When zinc was added in vitro to match the concentration of the healthy 
control group, the thymulin conversion from its inactive form restarted. The authors 
suggested zinc deficiency as cause of reduced thymulin. However, it may be possible 
that decreases plasma level of zinc observed in cancer patients is a consequence of 
an increased activity of this pathway in response to inflammation, rather than the 
cause.  
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Additionally, the decreased concentration of serum zinc may be caused by decreased 
nutrient intake and absorption. However, of all the above studies only one (Sgarbieri 
et al. 1999) measured zinc intake by the 24 h diet recall method and found an intake 
lower than the RDA. Even so, the 24 h diet recall is not an accurate method of 
measuring trace element intake and their estimate may not reflect the actual intake 
(Poslusna et al. 2009) and the low zinc intake could have been attributed to the 
underestimation of the method to measure it, rather than the intake itself. Therefore 
the hypothesis of low plasma zinc being caused by poor intake has not yet been 
tested. 
Even though inflammation may explain the changes in zinc and copper plasma 
concentration during the acute phase response it is not clear if cancer and its 
treatment can further impact the nutritional status of those trace elements. Moreover, 
the literature lacks intervention studies aiming to explore the effect of zinc 
supplementation in this cohort. Since the aetiology of this deficiency is still not clear, 
further research is essential to understand if reduced nutrient intake, reduced 
absorption and metabolic abnormalities can have an impact on the factors and 
whether supplementation may reverse this deficiency. 
Further work on the trace element status in paediatric oncology patients showed a 
detrimental effect of cancer and its treatment on selenium status (Pazirandeh et al. 
1999; Zuo et al. 2006). A study (Pazirandeh et al. 1999) in newly diagnosed 
leukaemia patients and a healthy matched control showed normal level of selenium 
before treatment followed by a drop in serum selenium in the ALL group but not on 
the AML group after induction chemotherapy. Therefore, the study showed a 
different effect among the induction treatments for ALL and AML on selenium 
status. However, it is not clear what the exact mechanisms for the negative effect of 
ALL treatments are. Contrarily, Malvy and co-workers (1997) did not find any 
significant difference in newly diagnosed paediatric oncology patients including 
ALL with a variety of cancer types both at diagnosis and after six months. The 
contradictory findings are difficult to reconcile, but it may be that, since the ALL 
patients were not stratified according to risk levels, they may have been in different 
chemotherapy protocols which may have caused the different plasma concentration. 
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This literature review of studies highlights the detrimental effect of cancer treatments 
on vitamin and trace element status in children treated for cancer. However, the 
specific mechanisms for these changes are still unknown and it is not clear whether 
they are caused by the inflammatory response of the host to the cancer or by other 
factors such as increased metabolism, reduced intake and absorption or a 
combination of those. Furthermore, the specific requirements for this cohort have not 
been established yet and the consequences of those micronutrient imbalances are 
unknown. Considering the pivotal role of those nutrients in development and growth, 
not to mention their potential protective role during cancer treatment, it is now 
fundamental to clarify this topic. 
1.7 Nutrition support in paediatric cancer therapy 
When a patient is found to be undernourished by the nutritional status assessment, 
nutritional therapy may be initiated. However, there are no universally agreed 
criteria for the nutrition support (NS) duration, timing and type composition of feeds 
in paediatric oncology probably because of the broad spectrum of the disease and the 
complexity of the treatments and their side effects (Bauer et al. 2011). 
Nutrition support should aim to maintain body stores, support body development and 
growth. In order to achieve these aims, NS should meet the patient’s energy 
requirements. However, in this population group meeting the energy requirements 
via NS is extremely challenging. The first limiting factor is the lack of energy 
reference values specific for paediatric cancer patients which have been discussed 
previously in this document (Section 1.4.3). Secondly, cancer treatments affect 
tolerance to feeds, making NS very challenging. The current practice at the RHSC is 
to calculate energy requirements based on the Oxford equation (Henry 2005) 
matched for age and gender. However, because of the reduced tolerance to feeds, NS 
aims to achieve the amount tolerated more the estimated energy requirements.  
Nutrition support to treat undernutrition comprises; additional oral calorie 
supplementation by oral supplements (OS), enteral nutrition (EN) by , introduction 
of nasogastric feeding, with either boluses or overnight feeding or both, insertion of 
a percutaneous endoscopic gastrostomy (PEG) with a combination of bolus and 
overnight feeding or finally total parenteral nutrition (TPN).  
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Many adult studies have reported that nutrition support during cancer treatments 
increases outcome and treatment tolerance (Bozzetti et al. 2000; Dresler, 
Jeevanandam, and Brennan 1987; Odelli et al. 2005). However, some other studies 
have observed significant TPN complication with no effects on improving nutritional 
status (Popp et al. 1981) or no significant advantage on improving survival (Freeman 
et al. 1982). Most of the studies aiming to assess the effectiveness of nutrition 
support in paediatric cancer patients were carried out with regard to TPN (Donaldson 
et al. 1982; Ghavimi et al. 1982), with little attention to the use of enteral nutrition in 
this cohort (Rickard et al. 1979; Rickard et al. 1985). Furthermore, randomized 
control cohorts have not been employed in many of those studies.  
Most of the studies aiming to assess the effectiveness of TPN support in paediatric 
cancer patients have shown a positive effect on reversing, or preventing protein 
undernutrition during the initial phase of cancer treatments (Donaldson et al. 1982; 
Ghavimi et al. 1982; Rickard et al. 1979; Rickard et al. 1985). A prospective 
randomised trial (Donaldson et al. 1982) (n=39) showed a significant improvement 
in weight in the TPN group in comparison to the control group. 64% of the TPN 
group maintained or improved body weight whereas only 17% of the control group 
did so. However, at three months follow up, the TPN group had a decline in weight 
and the differences between the two groups were no longer observed. Similar results 
were also reported by another prospective randomised trial (Ghavimi et al. 1982).  
Only a few studies (Smith et al. 1992; den Broeder et al. 2000; den Broeder et al. 
1998) have been carried out to look at the efficacy of enteral nutrition to counteract 
undernutrition in this cohort. A randomised controlled study (Smith et al. 1992) 
carried out in ten newly diagnosed children with several types of malignancies 
showed an increased energy intake and an improvement in nutritional status as 
measured by MUAC in response to nasogastric feeding. Similar results were 
observed in other studies (den Broeder et al. 1998; den Broeder et al. 2000)  
When the efficacy of TPN and EN has been assessed and compared with regard to 
improving or maintaining nutritional status, it emerged that TPN had a positive 
effect on all the above aspects in the first few weeks of treatments, whereas EN was 
unable to achieve any improvement. Rickard et al. (1985) in a randomised control 
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study showed that TPN improved nutritional status and that EN was not as effective 
as parenteral nutrition in preventing undernutrition in 32 children newly diagnosed 
with Neuroblastoma. Similar results were reported in another two studies (Rickard et 
al. 1989; Rickard et al. 1979). 
The contrasting evidence of the ability of TPN and EN to counteract undernutrition 
reported from the previous studies (den Broeder et al. 1998; Donaldson et al. 1982; 
Ghavimi et al. 1982; Rickard et al. 1979; Rickard et al. 1983; Rickard et al. 1985; 
Rickard et al. 1989; Smith et al. 1992) , may be explained by small patient numbers, 
differences in cancer diagnosis studied, and methodological limitations such as only 
a few studies being randomised (den Broeder et al. 1998; Rickard et al. 1989; Smith 
et al. 1992)
. 
Furthermore, pharmacologic progress of the anti emetic drugs and their 
improved ability to counteract nausea and vomiting as a consequence of 
chemotherapy may have increased the tolerance and efficacy of EN.  
The studies where EN was found to be ineffective in counteracting protein energy 
undernutrition during the intensive phase of treatments (Rickard et al. 1979; Rickard 
et al. 1989; Rickard et al. 1985) are dated compared to those that showed a positive 
effect of EN during intense chemotherapy (den Broeder et al. 2000; den Broeder et 
al. 1998; Smith et al. 1992). Therefore, better management of nausea and vomiting is 
likely to have increased the tolerance to EN and therefore improved its efficacy in 
counteracting undernutrition.  
Altogether, this evidence stresses the importance of more research aiming to improve 
nutritional screening and assessment in this cohort. However, considering the 
increased cancer related obesity risk and the negative effect obesity has in cancer 
treatment, there is now a need for the consideration of overnutrition as well as 
undernutrition in this cohort in the nutritional management of paediatric cancer 
patients.  
1.8 The nutritional risks of children with cancer 
The previous sections extensively described the increased risk of malnutrition in this 
cohort and the imminent need for a specifically designed nutritional screening tool. 
The first step is therefore to identify the risk factors for undernutrition during 
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paediatric cancer and its treatments. However, the literature is lacking in studies 
specifically designed to assess the overall risk of malnutrition in paediatric cancer 
such as age at diagnosis, gender, type of tumour, stage of tumour, treatment 
modalities and protocols and stage of treatments in children treated for cancer. 
The main limiting factors for this type of epidemiological study are the size of the 
sample required to have enough statistical power to allow data analysis. Therefore, 
this type of research requires a multicentre approach, which it is very costly to 
conduct. Furthermore, the attainment of the required sample size in paediatric cancer 
is even more challenging, since the incidence of paediatric cancer is much lower than 
adults. 
An important multicentre study (Pressoir et al. 2010) was carried out to identify the 
risk factors for undernutrition in adult cancer patients. The study was conducted in 
17 centres and included 1545 patients. Nutritional status was assessed based on BMI 
and the risk factors analysed were, age, gender, tumour site, treatment type, disease 
stage, and antibiotic therapy. The univariate analysis showed that in male subjects, 
specific type of cancer (neck and head, GI) the presence of metastases, 
hospitalisation, palliative care and radiotherapy were associated with poor nutritional 
status. Remarkably they did not report any association with chemotherapy or surgery 
alone. This study had the great advantage of a sample size that allowed statistical 
analysis. However, the measurements were taken at baseline and after two months 
and even though they identified several risk factors, they did not assess nutritional 
risk depending on the phase of the treatment. Furthermore, because of the difference 
in cancer and its treatments, it is not possible to assume that those findings would be 
applicable in the paediatric population. 
Little is known about the risk factors for undernutrition during treatments in 
paediatric oncology patients. However, it would appear that the increased risk for 
undernutrition is associated with a specific type of cancer (solid cancer), advanced 
cancer stage , metastasis and undernutrition before diagnosis as well as the extent of 
side effects of the specific protocols employed to treat the disease (Coates et al. 
1986; Rickard et al. 1986; Rickard et al. 1983). Table 1.1 shows the cancer diagnosis 
associated with high nutritional risks for undernutrition during therapy. 
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However, there is not a single study aiming to assess the overall risk of 
undernutrition in paediatric cancer, many studies aimed to assess the prevalence of 
undernutrition at different stages of the disease as an indicator of nutritional risk. 
However, the interpretation of the data can be complicated due to the difference in 
nutritional assessment methods, study design, the type of cancer studied and the 
sample size used.  
A cohort study (Reilly et al. 1999) reported an increased prevalence of 
undernutrition (BMI centile) at diagnosis in 1033 ALL patients compared to 
expected frequencies (Cole et al. 1995) (7.6 % boys and 6.7% of girls vs. 2.3 %). 
Similarly, a higher incidence of undernutrition (W/H percentiles, MUAC) at 
diagnosis was observed in 17 ALL patients in a case control study (Mejia-Arangure 
et al. 1997). This study stratified the patients according to disease severity (high risk 
(HR) ALL vs. low risk (LR). They reported an increased incidence of undernutrition 
in both groups compared to the general population with the HR ALL having a higher 
prevalence of undernutrition compared to the LR (17% normal population vs. 21% 
HR ALL and 24% LR ALL). 
In contrast to the previous studies, other authors have failed to identify 
undernutrition at diagnosis in children affected by ALL (Delbecque-Boussard et al. 
1997; Uderzo et al. 1996). For example, Uderzo and co- workers (1996) compared 
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Table 1.1 Cancer diagnosis associated with high nutritional risks for 
undernutrition during therapy (Betcher and Ablin 1993; Han-Markey 2000; 
Rickard et al. 1986) 
Cancer type Example 
Brain tumour treated with radiotherapy  
Parameningeal, esopharingeal or oral 
tumours treated with radiation therapy 
 
Thoracic area tumours  Neuroblastoma, germ cell tumour, 
lymphoma, rhabdomyosarcoma, Ewing’s 
sarcoma 
Abdominal tumour involving the liver 
and gastrointestinal tract 
Wilm’s tumours, primary hepatic 
tumours 
Pelvic tumours involving the 
gastrointestinal tract or requiring major 
operative procedures, pelvic radiation 
Rhabdomyosarcoma, Ewing’s sarcoma, 
Neuroblastoma, germ cell tumours 
Solid tumours  
Advanced disease at diagnosis ( stage III 
or IV) or relapse 
 
 
Acute non lymphocytic leukaemia, 
moderate and high- risk ALL, juvenile 
chronic myelogenous leukaemia, chronic 
myeloid leukaemia in blast crises. 
 
 
The prevalence of undernutrition (W, W/H, MUAC, and TSF) in 173 newly 
diagnosed Italian children with ALL to children affected by benign acute diseases as 
control. The study did not show any significant difference in prevalence of 
undernutrition between the two cohorts (6.9% ALL vs. 8.5 % with benign disease; 
p>0.05). Therefore, the authors concluded that the oncology cohort was not 
undernourished. However, the study had the methodological limitation of lack of 
comparison to the healthy population. Therefore, the similarity rate of undernutrition 
between the two groups could also be interpreted to be that both groups were 
undernourished. Furthermore, if the results are related to the other Reilly et al. study 
(1999) also carried out in the western world; the prevalence of undernutrition is 
similar. Therefore, the failure to detect undernutrition may be caused by the lack of 
comparison to population frequencies.  
Although there is not a full consensus on the increased risk of undernutrition at 
diagnosis in ALL paediatric patients, the increased prevalence of undernutrition 
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among the solid tumour patients has been extensively reported (Garofolo et al. 2005; 
Jain et al. 2003; Rickard et al. 1983; Yaris et al. 2002). Garofolo et al. (2005) 
reported an incidence of undernutrition among 68 patients newly diagnosed with 
solid tumours ranging from 29.4 % to 45.6 % using respectively BMI and TSF 
measurements. Similarly, a more recent study (Jain, Dubey and Gupta 2003) 
evaluated the nutritional status of 44 children newly diagnosed with many types of 
cancer using haematological, anthropometric and biochemical indices. The 
prevalence of undernutrition varied depending on the criteria used and poor 
nutritional status overall was reported in 56.8 % of patients when using W/A criteria. 
These studies show that children with a solid cancer are at higher risk of 
undernutrition from diagnosis. The probable reasons for this are the metabolic 
changes caused by the tumours which may have persisted for a period of time before 
the cancer was diagnosed. 
Evidence suggest that nutritional status can change dramatically during treatments in 
both solid (Yaris et al. 2002) and haematological tumours (Koskelo et al. 1990; 
Mejia-Arangure et al. 1997). For example, a study (Yaris et al. 2002) reported an 
overall increase in undernutrition rate among 47 paediatric patients affected by 
several types of cancer. At diagnosis the overall prevalence of undernutrition was 
29.8%, after three months it increased to 38.5%. This study proposes a detrimental 
effect of treatments during treatment. However, the study did not stratify the patients 
according to diagnosis nor disease severity, probably because of the limited sample 
size. Therefore, the estimation of the risk of undernutrition based on specific 
diagnosis and disease severity is not possible. 
Koskelo et al (1990) investigated the changes in nutritional status (muscle mass and 
weight) in children with ALL. They reported an extent of muscle wasting after four 
to six weeks of starting treatments in 27% of the 14 children in the study with no 
changes in body weight. Interestingly they also reported a parallel increase in FM 
which caused the weight and the limb circumference to stay the same as when first 
measured. These results highlight the importance of body composition in the 
assessment of nutritional status in this cohort.  
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Moreover, Mejia-Arangure and co-workers (1997) reported an increased rate of 
undernutrition during the course of treatments for ALL (three months). However, the 
nutritional status worsens only in the HR group. The Mejia-Arangure and co-
workers (1997) study suggests that children treated for a high risk ALL are at an 
increased risk of undernutrition, probably due to both disease severity and more 
aggressive chemotherapy. Conversely, Delbeque–Boussand et al. (1997) failed to 
report any indication of undernutrition during the first three months of treatments. 
This lack of agreement is hard to explain and it is unlikely to be caused by the 
masking effect of steroids on body composition, since the authors assessed body 
composition by TSF.  
In summary it has been widely recognised that nutritional status is likely to be 
affected by cancer at some point during the disease. However, the specific risk 
factors for the development of undernutrition have not yet been identified. The 
review of the literature showed that some phases of treatments may be at higher risk, 
however, the evidence on the specific phases in relation to specific treatment 
protocols is still unknown. In regard to the nutritional risk for obesity, some risk 
factors have been identified such as age at diagnosis, female gender, CRT 
treatments, steroid treatments and decreased PA. However, more studies are needed 
to determine the overall risk factors for the development of obesity, especially with 
the recent development in cancer treatments. Therefore, in order to design a specific 
screening tool for the oncology paediatric patients, it is now pivotal to identify the 
specific risks factors for both undernutrition and obesity during paediatric cancer and 
its treatments.  
The overall aim of this series of investigations is to determine the risk factors for 
both undernutrition and obesity in childhood cancer. The specific aims and 
objectives of each single study are explained in the following sections. 
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2 CHAPTER TWO 
THE NUTRITIONAL RISKS OF CHILDREN TREATED FOR 
CANCER: A RETROSPECTIVE STUDY 
 
The poor nutritional status of children treated for cancer has been widely reported 
(Carter et al. 1983a; Carter et al. 1983b; Pietsch and Ford 2000; Smith et al. 1991; 
Uderzo et al. 1996). However, undernutrition in hospitalised children is often 
unrecognised and therefore left untreated (Agostoni et al. 2005). In the United 
Kingdom, the Paediatric Yorkhill Malnutrition Score (PYMS) (Gerasimidis et al. 
2010) is used in some general paediatric populations as an inpatient screening tool, 
identifying those needing full nutritional assessment by a dietitian, and eventual NS. 
 
NS comprises interventions to reverse or prevent undernutrition. It is important to 
assess nutritional status in order to use NS appropriately in children with cancer at 
high risk of the adverse effects of undernutrition at diagnosis and during cancer 
treatment. However, it is also pivotal, to avoid inappropriate increases in energy 
intake, given the later risk of development of overweight and obesity in some 
survivors of childhood cancer (Warner et al. 2002). However, no cancer-specific 
paediatric nutrition screening tool has been developed yet, and the use of a general 
paediatric screening tool is not appropriate as discussed in Chapter 1 . This lack of a 
specific screening tool is therefore a limiting factor for the improvement of 
nutritional management for paediatric oncology. This is because undernourished 
patients may be undetected and therefore not referred to the dietitian for nutritional 
assessment and nutritional intervention. Therefore, there is now a urgent need for the 
development of a specific paediatric cancer screening tool which is able to identify 
paediatric cancer patients at risk of both undernutrition and overnutrition. 
In order to design a screening tool, studies including large numbers of participants 
are needed, often multicenter and even multi-country, which are very expensive, 
lengthy and complex. Preliminary research is therefore required to inform on what 
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are the risk factors for the development of undernutrition and obesity in this cohort, 
in order to then validate these in larger studies. 
The aim of this retrospective study was therefore, to assess the prevalence of 
undernutrition during treatment for childhood cancer and identify the risk factors for 
undernutrition. In this retrospective cohort study, the use of NS during cancer 
treatment was used as proxy to indicate high nutritional risk. This is because, during 
cancer treatments actual weight can be affected by hydration status and tumour mass, 
masking body weight loss (Pietsch and Ford 2000; Smith et al. 1991). Since NS is 
initiated on the basis of a global assessment by the oncology multidisciplinary team 
and the hospital NS team,the use of NS as indication of nutritional risk overcomes 
the limitation of simple weight related measurements on underestimating 
undernutrition.
 
This study quantified the extent of clinical requirement for NS, and studied the 
relationship between NS usage,cancer type and treatment modalities. In addition, it 
aimed to identify subgroups within this population at highest risk of undernutrition 
with the intention to validate these findings in a prospective cohort. Furthermore, 
this study aimed to identify the prevalence of obesity in this cohort. 
2.1 Aims and objectives 
The aim of the retrospective study was to determine the prevalence of poor nutrition 
in children undergoing treatment for cancer, using the need for NS as a proxy for 
nutritional risk and to identify the risk factors for the late on-set of obesity. 
 The main objectives were: 
 to quantify the extent of clinical requirement for NS; 
 to study the relationship between NS usage and cancer type and treatment 
modalities in order to identify those within this population at high risk of 
undernutrition; 
 to determine changes in nutritional status from diagnosis to the last clinical 
appointment; 
 to assess the prevalence of overweight and obesity  
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2.2 Methods 
2.2.1 Subjects and recruitment 
Children < 18 years of age who were diagnosed with any type cancer between 2001 
to 2006 and who were referred to the Royal Hospital for Sick Children, Edinburgh 
(the regional center in SE Scotland serving a population of 1.25 million) were 
included in the study. The study protocol was reviewed and approved by Queen 
Margaret University (QMU) Ethics Committee. Ethical approval from the NHS was 
not required after enquiry to the research ethics committee as the study fallen into the 
category of a retrospective audit of service design and delivery within this cohort. 
Patients’ written consent was also not required for the above reason. The data for the 
prospective study remained anonymous and all the information collected remained 
confidential. Data was collected from medical notes and dietetic notes and entered 
into a database at diagnosis, end of treatment and last clinical appointment. 
The data base was initially designed by Dr Laura Stewart and the data collection was 
partially carried out by Dr Laura Stewart, Ai Ling Koh and Huey Miin Lee. The 
author collected more information regarding NS, survival weight, and analysed the 
data. 
2.2.2 Demographics 
The demographics of the cohort were monitored and the following information was 
recorded; gender, date of birth; diagnosis date and survival at the final collection 
point (31/12/2011). Decimal age was calculated from date of birth at diagnosis and at 
every measurement by using the LMS Growth (Harlow Healthcare, UK) to allow 
growth comparison to the growth standards for the UK population (Cole, Freeman 
and Preece 1995).  
2.2.3 Clinical information 
Clinical information was collected from the medical notes. The type of tumour was 
classified using the international Classification of Childhood Cancer, Third Edition 
(ICCC-3) (Steliarova-Foucher et al. 2005). 
Treatment protocols and treatment modalities were recoded in order to assess the 
nutritional risks according to treatments. However, because of the variability of 
treatment protocols available to treat childhood cancer, treatment modalities were 
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categorised into a broad groups with simpler parameters: chemotherapy only (with or 
without surgery); radiotherapy only (with or without surgery); chemotherapy and 
radiotherapy first line treatment (no recurrence); chemotherapy and radiotherapy 
(relapse treatment); surgery only; or no treatment.  
2.2.4 Anthropometry 
Growth was assessed by extrapolation of weight and height data from medical and 
dietetic notes at diagnosis, the end of treatments and last clinical appointment. Where 
appropriate, growth was also assessed at the initiation and end of NS. Where both the 
weight and height had been recorded, body mass index (BMI) SDS was calculated 
using the using the LMS Growth (Harlow Healthcare, UK) program with 1990 
British growth reference values to assess undernutrition (Cole et al. 1995). In 2007, 
the Scientific Advisory Committee on Nutrition (SACN) and the Royal College of 
Paediatrics and Child Health (RCPCH) published a report on the use of the new 
WHO/UK growth standard (SACN/RCPCH 2007). In 2011 the new WHO/UK 
growth standards have been adopted for the monitoring of children 0-4 years old 
(RCPCH 2011). The new growth reference data includes children that closely reflect 
the current UK recommendation for infant feeding and they are believed to be more 
appropriate for growth monitoring (SACN/RCPCH 2007). However, for this 
retrospective study, the 1990 British growth reference values were used (Cole et al. 
1995). This is because they were the standards used at the time of data collection and 
the clinical management of the children in the study was based upon these growth 
parameters. If height measurements were unavailable, BMI centiles could not be 
calculated. Therefore, undernutrition was defined as the SDS cut off point <-2SD of 
weight for age according to the WHO classification (World Health Organisation 
2011) 
There are no expected frequencies for the prevalence of undernutrition in the UK 
population assessed by using the weight <-2SDS definition. For this reason the 
prevalence of undernutrition in this study was compared against the 2.3 % value, 
which represents the -2SD for the general population. This figure is based on the 
rationale that 95% of the UK population is within the normal range, and it has been 
used elsewhere as expected frequency for comparison in paediatric cancer patients 
(Reilly et al. 1999).  
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Undernutrition was also assessed using the BMI centile ≤ 2.3th (SACN/RCPCH 
2007) whenever both weight and height were available. The prevalence of 
undernutrition using BMI centiles was compared to the expected frequencies of 2% 
for undernutrition for female and male children combined, and 1.9% for boys and 2.1 
% for girls (Scottish Government 2009).  
In this study, where height and weight where available and BMI could be calculated, 
overweight and obesity were defined using the threshold for population monitoring 
as it is a standard UK government practice (Department of Health 2012). Overweight 
was defined as ≥ 85th / < 95th centile and obesity as ≥ 95th centile (Cole et al. 1995; 
Scottish Intercollegiate Guidelines Network 2010). These definitions are widely used 
in UK (Department of Health 2012) therefore it was decided to use this definition to 
maintain consistency and to allow comparison with the published literature. The 
prevalence of overweight and obesity was compared against the most recent 
Nutrition and Diet National Survey (Department of Health 2012). The NDNS was 
chosen over the Scottish Health Survey (Scottish Government 2009) because it 
distinguishes between overweight and obesity and it is the most recently updated 
survey.  
2.2.5 Nutrition support 
Information regarding the need for NS was recorded from clinical notes and dietetic 
notes. NS intervention was categorised as; use of oral calorie supplements (OCS); 
and/or enteral tube feeding (ETF) including nasogastric tube (NGT), gastrostomy 
tube (GT) or jejunal tube (JT); and/or parenteral nutrition (PN). ‘Advanced NS’ was 
defined as the need for ETF and/or PN.  
Date of beginning and end of nutrition support and weight, weight SDS at initiation 
and end of nutrition support were recorded in order to assess the effectiveness of NS 
on improving nutritional status and/or preventing further nutritional deterioration. 
2.2.6 Data analysis 
Data were analysed with SPSS 19
®
 (IBM
®
). Descriptive statistics are presented for 
this cohort in relation to demographic features, cancer diagnosis and its therapy, and 
use of NS.  
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The data were tested for normal distribution by the Shapiro-Wilk Test. The results 
are presented as mean (± SD) for normally distributed data and median (inter quartile 
range (IQR)) when not normally distributed. 
For comparison according to gender (male vs. female) and diagnosis (solid vs. 
haematological) an Independent t- test was carried out. For comparison of the same 
group at two different time points a one sample t-test was carried out. The equality of 
variance was first tested by the Levene’s test. If the test was not significant (p>0.05) 
equal variances were assumed. When the data where non-parametric comparison 
according to gender (male vs. female) and diagnosis (solid vs. haematological) was 
tested by the Mann-Whitney test. For comparison of the differences between before 
and after NS, the Wilcoxon signed-rank test was used. 
When the data were analysed to test changes between measurements, a Kruskal–
Wallis test was used. Difference between observed and expected frequencies of 
undernutrition, overweight and obesity were tested for significance using the Z test. 
The results were considered significant when p<0.05.  
2.3 Results 
2.3.1 Subjects 
Between 1/12/2001 and 30/11/ 2006, 239 patients were diagnosed with childhood 
and teenage cancer. A flow diagram illustrating the composition of the cohort in 
terms of meeting the inclusion criteria is shown in Figure 2.1. 
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Figure 2.1 Diagram illustrating the composition of the cohort in terms of 
meeting the inclusion criteria 
Ultimately, 168 (70%) of total patients were included in this retrospective analysis. 
All 50 (21%) managed mainly in Dundee were excluded. Of the 168 patients 
included, 81 were male (48%); the median age at diagnosis was 6.6 (IQR: 2.0-12.0) 
years. The overall survival rate at the end of the study period to 30/11/06 was 89% 
(n=149) and at the end of the monitoring period to 31/12/11 was 76 % (n=128). 
239 patients diagnosed with cancer between 
12/2001 to 11/2006 
189 patients 
followed in 
Edinburgh  
2 patients 
with missing 
treatment 
modality: 
excluded  
2 patients 
with missing 
diagnosis: 
excluded 
168 patients 
remain in final 
study cohort 
16 patients with 
missing data from 
dietetic cards: 
excluded 
1 patient 
with missing 
survival 
data: 
excluded 
50 patients followed in 
Dundee with data 
inaccessible: 
excluded 
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Table 2.1 indicates the primary cancer diagnosis and the associated survival rate at 
the end of monitoring period of 31/12/2011.  
Table 2.1 Primary cancer diagnosis and survival rate at end of monitoring 
period on 31/12/2011 
Diagnosis Cases (% 
within 
cohort) 
Survivors 
(% with diagnosis) 
I - Leukemia 54 (32) 40(74) 
ALL 45 (27) 37 (82) 
AML 8 (5) 2(25) 
CML 1 (1) 1(100) 
Solid tumours 114 (68) 88 (77) 
II- Lymphoma 18 (11) 17 (94) 
III -CNS tumour 28 (17) 16 (57) 
IV- Neuroblastoma 12 (7) 6(50) 
V- Retinoblastoma 3 (2) 3 (100) 
VI -Renal tumour 11 (7) 11 (100) 
VII -Hepatic tumour 1 (1) 1 (100) 
VIII -Malignant bone tumours 12 (7) 8 (67) 
IX- Soft tissue sarcoma 14 (8) 14 (100) 
X -GCT 7 (4) 6 (86) 
XI- Malignant epithelial neoplasm 2 (1) 1 (50) 
XII- Others and unspecified 
malignat neoplasms 
6 (4) 5 (83) 
 
Of all 168 patients in the cohort, 112 (67%) received chemotherapy only, 21 (13%) 
received chemotherapy and radiotherapy (first line treatment), 13 (8%) received 
surgery only, 11 (7%) received chemotherapy and radiotherapy (recurrence 
treatment); 5 (3 %) received radiotherapy only; and 6 (4 %) received no treatment.  
2.3.2 Prevalence of undernutrition at different time points 
Weight was recorded at diagnosis for 152 (90%) of the 168 patients in the 
retrospective cohort. At the end of treatment, 17 children had died and weight was 
recorded for 105 (70%) of the remaining 151. Weight at the last clinical appointment 
was available for 127 patients. Mean (SD) weight SDS at each time point is shown 
in Table 2.2 according to diagnosis and gender. Comparison between gender and 
diagnostic groups showed that there was no significant difference in weight SDS at 
any time point (p>0.05 for all). 
The prevalence of undernutrition at each time point was compared to the expected 
frequencies of undernutrition for the UK population to assess if the population in this 
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cohort had a higher prevalence of undernutrition than the general UK population 
(World Health Organisation 2011). 
The comparison of undernutrition according to gender indicates an increased 
prevalence of undernutrition at treatment initiation for the male group (p<0.05) and 
during remission for the female group (p<0.05). Data analysed according to 
diagnostic group showed an increased prevalence of malnutrition at each time point 
for both diagnostic group (p<0.05) except for the haematological group at end of 
treatment (Table 2.2). 
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Table 2.2 Weight SDS, mean (SD) at each time point according to gender and 
diagnostic group 
  Weight 
SDS 
mean 
(SD) 
Prevalence of 
undernutritio
n 
% (n) 
Confidence 
of intervals 
(CI) 95% 
P value 
M
a
le
 
Diagnosis n=75 -0.03 (1.3) 9 (7) 0.025-0.155 <0.05 
End of treatment 
n=52 
0.02 (1.2) 3.8 (2) -0.014-0.090 N.S. 
Last clinical 
appointment  
n=52 
0.96 (6.3) 2.0 (4) -0.018-0.058 N.S. 
F
em
a
le
 
Diagnosis n=77 0.47 (2.9) 5.1 (4) 0.002-0.100 N.S. 
End of treatment 
n=53 
0.29 (1.3) 0 (0) 0.000-0.000 N.S. 
Last clinical 
appointment  
n=75 
0.6 (5.0) 7 (9) 0.003-0.137 <0.05 
S
o
li
d
 
Diagnosis 
n=101 
0.11 (1.3) 7.0 (7) 0.020-0.120 <0.05 
End of treatment 
n=81 
0.08 (1.2) 2.5 (2) -0.009-0.059 <0.05 
Last clinical 
appointment  
n=75 
0.74 (5.3) 9.3 (7) 0.027-0.159 <0.05 
H
a
em
a
to
lo
g
ic
a
l Diagnosis 
n=51 
0.34 (3.4) 7.8 (4) 0.004-0.152 <0.05 
End of treatment 
n=24 
0.25(1.3) 0 (0) 0.000-0.000 N.S. 
Last clinical 
appointment  
n=52 
0.79 (6.3) 7.8 (4) 0.001-0.139 <0.05 
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2.3.3 The use of nutrition support 
Because of the lack of recorded growth data and the potential masking effect of the 
cancer and treatments on weight loss (Pietsch and Ford 2000; Smith et al. 1991) NS 
was used as proxy of nutritional risk. Seventy four patients (44%) required NS 
during the period of the retrospective data collection. Forty patients (54% of all 
requiring NS) required OCS, ETF was required by 57 patients (77% of all requiring 
NS) and 32 patients (43% of all requiring NS) required PN. Of the patients requiring 
NS, 56 (76%) received NS through more than one route through the course of their 
treatment. Table 2.3 presents the use of NS according to specific cancer diagnosis. 
Fifty patients (68%) receiving NS had solid tumours, representing 44% of all 
children diagnosed with solid tumours during the data collection period. Twenty-four 
patients (32% of those receiving NS) had haematological malignancies, representing 
44% of those with this diagnosis in the cohort. For all primary cancer types the 
highest needs for NS (where >50% required NS) were in CML at 100%, AML and 
neuroblastoma, at 75% (Table 2.3). Sixty-three (85%) of all those having NS 
required advanced NS (ETF and/or PN), of whom the neuroblastoma and bone 
tumour diagnostic groups had the highest needs (> 50% requiring advanced NS) at 
67% each.   
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Table 2.3 Distribution of the use of nutritional support according to diagnosis 
Diagnosis (n) NS 
cases (% total) 
Frequency of route of NS Advanced 
NS (% total) 
OCS ETF PN 
I – Leukemia (54) 24 (44) 16 21 12 22 (40) 
ALL (45) 17 (38) 11 16 8 16 (36) 
AML (75) 6 (75) 4 6 5 6 (75) 
CML (1) 1 (100) 1 0 0 0 (-) 
Solid tumours (114) 50 (44) 24 36 20 41 (36) 
II- Lymphoma (18)  5 (28) 1 2 3 4 (22) 
III -CNS tumour (18) 16 (57) 5 11 4 12 (42) 
IV- Neuroblastoma (12) 9 (75) 5 8 6 8 (66) 
V- Retinoblastoma (3) 1 (33) 0 1 1 1 (33) 
VI -Renal tumour (11) 2 (18) 2 2 0 2 (18) 
VII -Hepatic tumour (1) 0 0 0 0 0 (-) 
VIII -Malignant bone tumours 
(12) 
8 (67) 6 7 3 7 (58) 
IX- Soft tissue sarcoma (14) 5 (36) 3 4 2 5 (36) 
X –GCT (7) 2 (29) 1 1 2 2 (29) 
XI- Malignant epithelial 
neoplasm (2) 
1 (50) 1 0 0 0 (-) 
XII- Others and unspecified 
malignat neoplasms (6) 
1 (17) 1 0 1 1 (17) 
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Of those 74 patients requiring NS, Table 2.4 describes the use of NS according to the 
treatment modalities received. 
Table 2.4 Distribution of the use of nutritional support according to treatment 
modality 
Treatment modality (n) Nutrition 
support Cases 
(% of total) 
Frequency of route 
of NS 
Advanced NS 
(% of total) 
OCS ETF PN 
Chemotherapy (+/- surgery) 
(112) 
49 (44) 31 42 26 44(3) 
Chemotherapy and radiotherapy 
first line treatment (no 
recurrence) (21) 
10 (48) 5 9 2 9 (43) 
Chemotherapy and radiotherapy 
(recurrence treatment) (11) 
8 (73) 5 4 6 7 (64) 
 
Radiotherapy only (+/- surgery) 
(5) 
2 (40) 0 2 0 2 (40) 
Surgery only (13) 1 (8) 0 1 0 1 (8) 
No treatment (6) 0 (-) 0 0 0 0 (-) 
 
2.3.4 The effectiveness of nutrition support. 
In an attempt to assess the effectiveness of NS on undernutrition, weight SDS was 
compared at the initiation and end of the period of NS. Of the 74 patients receiving 
NS, longitudinal data was only available for 22 patients, with median (IQR) weight 
SDS at the initiation and the end of NS being -0.73 (-1.55- 0.09) and -0.53 (-1.33-
0.13) respectively. There was no significant change in weight SDS for the 22 
patients with available weight at initiation and end of NS over the period of NS 
(p>0.05)  
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2.3.5 Changes in BMI centiles from diagnosis to last clinical appointment 
Changes in BMI centile were investigated to assess if this patients group was at 
higher risk of becoming obese. Only 18 patients had their BMI available at all three 
time points, hence statistical analysis was only possible for this limited number of 
patients. Changes in BMI centiles for these patients between measurements for 
patients (n=18) with BMI available at all three time points are shown in Figure 2.2. 
BMI centile changes from diagnosis to last clinical appointment
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Figure 2.2 Changes in BMI centiles between measurements for patients (n=18) 
with BMI available at all three time points. p> 0.05 
There was no significant change in BMI centile between the three points in time 
(p>0.05). Median (IQR) BMI centile did not differ between the male at diagnosis 
(49.9; 73.9-69.7); end of treatment (33.3; 61.9-38.8); last clinical appointment (67.3; 
81.1-90.5) and female group at diagnosis (58.0; 75.4-88.7); end of treatment (38.1; 
30.7-66.0); last clinical appointment (87.0; 91.9-98.3) at any measurements (p > 0.05 
for all). Comparison of changes in mean BMI centile according to diagnosis was not 
possible because of the sample size. Only two out of 18 patients with BMI available 
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at all time points, had a haematologic diagnosis which did not allow statistical 
comparison. 
2.3.6 Prevalence of overweight and obesity  
The prevalence of overnutrition (≥85th centile) and obesity (≥95th centile) at each 
time point was compared to the expected frequencies for the UK population 
(Department of Health 2012) to assess if the population in this cohort had a higher 
prevalence of overweight and obesity that the general UK population. The 
prevalence of overweight and obesity at each time point is shown in Table 2.5 as 
numbers and percentage of the entire cohort. 
Table 2.5 Prevalence (%) of overweight (BMI ≥ 85th / < 95th centile centile) and 
obesity (BMI ≥ 95th centile) at each study time point 
 Overweight 
n (%) 
Obesity 
n (%) 
Diagnosis n=59 
 
7(12) 5 (8) 
During treatments n=73 
 
12 (16) 13(18) 
 
Last clinical appointment n=95 
 
18 (19) 20 (21) 
 
The observed rates of classification of children as overweight did not differ (p>0.05) 
from the expected frequencies of 15% (Department of Health 2012) at any 
measurement point. Similarly, the observed frequencies of obesity did not different 
to the expected frequencies of 18.5% (Department of Health 2012) at any 
measurement (p>0.05) apart from at diagnosis where they were significantly lower 
(p<0.05; 95% CI 1.0% to 14.9%).  
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Figure 2.3 Prevalence of overweight (BMI ≥ 85th/ <95th centile), obesity (BMI ≥ 
95
th
 centile), according to gender at each measurement presented as percentage 
of patients with BMI available. 
 
The prevalence of overweight and obesity at each measurement according to gender 
is shown in Figure 2.3. The observed occurrences of males classified as overweight 
were significantly lower (p<0.05) than the expected frequencies of 15% (Department 
of Health 2012) at diagnosis. There was not a significant difference at any other 
measurement for both overweight and obesity prevalence for both genders (p>0.05 
for all). 
The prevalence of overweight and obesity was assessed according to diagnosis in 
order to identify those cancer types at higher risk of overnutrition (Table 2.6). 
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Table 2.6 Prevalence of overweight and obesity according to diagnosis at each 
study time point presented as percentage. 
 Diagnosis n (%) End of treatment n 
(%) 
Last Clinical 
appointment n (%) 
overweight obese overweight obese overweight obese 
Haematological: 
n= 4, 21, 29 
- - 7 (33) 6 (29) 7 (24) 5 (17) 
Solid: 
n= 55, 52, 95 
7 (12) 5 (9) 5 (10) 7 (13) 11 (12) 15 
(16) 
 
For all primary cancer types the highest prevalence of overweight and obesity was 
found in the haematological group at end of treatment with 33% of the patients being 
overweight and obese respectively. There was no significant difference between the 
observed frequencies of overweight and obesity according to diagnosis to the 
expected frequencies for the UK population (Department of Health 2012) (p>0.05 
for all). 
2.4 Discussion 
This retrospective cohort study from a regional UK paediatric haematology-
oncology service provides the first longitudinal clinical observations on nutritional 
risk, as determined by the usage of NS in children and adolescents treated for 
childhood cancer. It was not possible to find comparable data available in the 
literature on the use of NS in paediatric cancer patients; therefore, this is the first 
study to measure the extent of use of NS in this patient group. Although 
retrospective, this cohort study has the strengh of containing all types of childhood 
cancer. This study showed a marked risk for the development of undernutrition 
during childhood cancer therapy, with almost half of the patients requiring NS at 
some point during their treatment.  
The most common diagnosis in this retrospective cohort was leukemia followed by 
the CNS tumours, lymphoma, and soft tissue sarcoma. The distribuition of each type 
of childhood cancer appears to reflect the distribuition in the UK population which is 
shown in Chapter 1 (Cancer Research UK 2012) suggesting that this cohort is 
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representative of the UK childhood cancer population as a whole. The average 
survival rate over five to ten years was 76%, with leukemia, renal tumours, and 
lymphoma having the highest rates of survival. The survival rate of each type of 
cancer reflected the survival rate in the UK population which is shown in Chapter 1 
(Cancer Research UK 2012). 
2.4.1 Assessment of undernutrition based on height and weight 
parameters 
Although weight at diagnosis through to the last clinical appointment was well 
recorded, recording of height during both clinical assessment and dietetic assessment 
was lacking. A similar lack of height recording in routine clinical practice has been 
recently reported in a multicentre UK paediatric nutrition survey (Carey et al. 2011). 
Therefore, in both that survey and this cohort study, it was not possible to calculate 
the BMI for most of patients and weight SDS was used in this study to assess 
undernutrition.  
The comparison to the prevalence of undernutrition for the general population 
(World Health Organisation 2011) showed an increased risk of undernutrition for 
both diagnostic groups at all time points, apart from the haematological group at the 
end of treatment. The lack of undernutrition at end of treatment observed in the 
haematological group may be explained by the transient weight gain in response to 
steroid therapy. When the cohort was stratified according to gender, it became 
apparent that boys have a higher risk of undernutrition at diagnosis, whereas for girls 
risk is higher during remission phase. It was concluded that patients treated for 
cancer are at increased risk of undernutrition throughout the treatments.  
However, the limitation of missing BMI data and the use of weight <-2SDS to 
measure undernutrition prevented the precise quantification of the prevalence of 
undernutrition in this cohort. 
Because of limited height recording, it was not possible to analyse the prevalence of 
undernutrition using BMI centiles. It is not clear whether the patients with BMI 
available represented the entire cohort in this study as a whole. The reasons for the 
recording of height for some patients and not for others are unknown. One of the 
possible explanation is the change in clinical practice after the RHSC audit in 2003 
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(Holt 2003) where a lack of appropriate nutritional assessment in children treated for 
cancer emerged. After the audit was completed in 2003, the nursing and medical 
staff was required to start recording height and weight of the patients more regularly. 
Since this retrospective study includes all patients treated between 2001 and 2006, it 
is likely that the patients treated and/or diagnosed after 2003 had their height 
monitored more closely than those treated and diagnosed before the audit. Another 
possible explanation may be that the recording of height has reflected a closer 
monitoring of children with nutritional issues. However, this seems to be unlikely 
since many dietetic cards did not have the patient’s height recorded and 
anthropometrical assessment of NS was done by weight alone.  
Furthermore, obesity was significantly lower at diagnosis for the entire cohort. A 
weight loss greater than 5% in a month is considered a sign of nutritional deprivation 
even when the patients is not classified as undernourished by anthropometrical 
parameters (Jeejeebhoy and Keith 2005). This is because an obese or overweight 
patient in negative energy balance may need to loose extensive amount of weight 
before they are classified as underweight by anthropometric cut off points. 
Therefore, a decreased prevalence of obesity at diagnosis could indicate the extent of 
nutritional deprivation and support further the increased risk of undernutrition at 
diagnosis as previously reported (Garofolo et al. 2005; Reilly et al. 1999; Yaris et al. 
2002). 
Unfortunately, the literature is lacking in any comparable paediatric haematology-
oncology study on the prevalence of undernutrition in the developed world after the 
year 2000. The rate of undernutrition for the general population varies dramatically 
between countries. The undernutrition rate reported in some studies (Lobato-
Mendizabal et al. 1989) must be interpreted in relation to the regional prevalence of 
undernutrition and may not be relevant for this current study. Furthermore, because 
of the constant progresses in paediatric cancer treatments, the research published 
before our data collection period may be not suitable for comparison with the 
prevalence of undernutrition documented in this current study.  
Additionally, other studies on the prevalence of undernutrition in childhood cancer 
may be limited by being of relatively small sample size (≤25)(Kibirige et al. 1987; 
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Yu et al. 1994), or of cross-sectional study design with the incidence of 
undernutrition determined only once during treatment (Pietsch and Ford 2000; Smith 
et al. 1991; Uderzo et al. 1996). Moreover, some studies were conducted only on a 
specific cancer diagnosis (Uderzo et al. 1996; Yu et al. 1994), and using differing 
methods for assessing the prevalence of undernutrition such as BMI, TSF and 
MUAC (Oguz et al. 1999; Pietsch and Ford 2000; Smith et al. 1991). Comparison of 
results on the prevalence of undernutrition between our cohort and other studies of 
paediatric cancer is therefore difficult.  
The lack of recorded height data in this study was a limitation as it did not allow the 
calculation of BMI for the entire sample. Any retrospective analysis of clinical data 
relies on the parameter of interest, in this case NS, not being a focus when the data 
was originally collected. Despite awareness of the importance of nutrition in the 
course of childhood cancer, neither the capture nor monitoring of NS was fully 
embedded into routine clinical care at the RHSC from 2001-2006. However, after the 
audit in 2003 and the findings of this study, more constant and comprehensive 
monitoring of growth is now in place. This lack of available anthropometric data had 
prevented the analysis of the impact of both childhood cancer and its treatment on 
nutrition and growth. Furthermore, it did not allow full evaluation of the long term 
risk of developing obesity in this cohort.  
2.4.2 Nutrition support as proxy of nutritional risk 
The extent of use of NS in relation to cancer diagnosis and treatment modalities has 
not been previously described in children. The advantage of using the need for NS as 
proxy to indicate nutritional risk is that it overcomes the limitation of some simple 
anthropometric methods on assessing nutritional status, given that many can 
underestimate undernutrition (Smith et al. 1991; Uderzo et al. 1996). NS is initiated 
on the basis of a global assessment, including weight loss, energy and nutrient and 
fluid intake, gastro-intestinal and other symptoms, and treatment severity by the 
oncology multidisciplinary team and the hospital NS team. As such, it may provide a 
better indication of nutritional risk in this group. Although if NS is started on a 
prophylactic or preventive basis rather than on a treatment basis this may indicate 
perceived risk rather that actual risk.  
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Remarkably, this study showed that a high proportion of children receiving some 
type of NS required the most advanced nutrition support treatment. This indicated 
the great extent of nutritional depletion. Although almost half of the children 
received at least one type of NS, the data showed that within groups with both solid 
tumours and haematological malignancies, it is specific types of cancer which are 
associated with a particularly high risk of undernutrition. In particular, 100% of 
those with CML, 75% of those with AML and neuroblastoma, 67% of those with 
malignant bone tumours, and more than 57% of patients with CNS malignancies 
required NS. Although 100% of patients with CNL required NS, only one patient 
was diagnosed with CML in our cohort, therefore, it is not possible to draw any 
conclusion on the nutritional risk for this type of leukaemia. Furthermore, 66% of 
those with neuroblastoma and 58% of those with malignant bone tumours required 
advanced NS, confirming that these types of cancers result in the highest nutritional 
risk. This reflects the intensity of the treatment (duration and intensity of 
chemotherapy). Although ALL, the commonest tumour in children, requires 
treatment for two years for girls and three years for boys, the intense treatment phase 
is short in contrast to the six to nine months of intense treatment for bone tumours, or 
high dose therapy for neuroblastoma. These observations reflect the spectrum of 
diagnosis associated with greater risk of undernutrition in the literature (Betcher and 
Ablin 1993; Han-Markey 2000; Rickard et al. 1986). These results may be important 
when considering targeted and enhanced nutritional monitoring to ensure that 
patients known to be at a high risk of undernutrition are correctly identified, although 
the breadth of diagnoses requiring nutrition NS in this cohort suggests that 
comprehensive monitoring is necessary.  
Consideration of the extent of use of NS in relation to the treatment modalities 
indicated that the highest usage was among children receiving chemotherapy, and 
radiotherapy (recurrence treatment) followed by those receiving chemotherapy, and 
radiotherapy as first line treatment and chemotherapy with or without surgery. The 
lowest usage appeared to be amongst children receiving radiotherapy only, with or 
without surgery, and surgery only. The detrimental effects of radiotherapy vary 
depending on the length and dose of irradiation as well as the irradiated area, with 
abdominal pelvic and cervical area being at higher risk (Donaldson 1977; Piquet et 
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al. 2002). Unfortunately, the lack of recorded data on the location and dose of 
radiotherapy in this study made it impossible to determine the specific effect of these 
variables on nutritional deterioration.  
These results suggest that there appears to be an increased risk of undernutrition in 
relation to some treatment modalities, in particular chemotherapy. It is not clear 
whether this is a reflection of the diagnosis itself, the treatment modality alone or, 
more likely, a combination of both. Moreover, the treatment modalities for childhood 
cancer are very complex and heterogeneous, with many different regimens being 
employed for each cancer diagnosis. For example, the treatment category of 
chemotherapy with or without surgery comprised many different treatment protocols 
and therefore it was not possible to identify specific associations between aspects of 
the treatment and nutritional implications. Treatment modalities for childhood cancer 
advance with time and the current treatment modalities in 2012 may be different 
from those in the time span analysed in this study (2001-2006).  
A limitation of this study was the impossibility of distinguishing between the use of 
NS as prophylactic treatment to prevent nutritional depletion and the use of NS as 
nutrition treatment. The current dietetic practice at the RHSC Edinburgh is to start 
nutrition support in those patients treated with protocols likely to cause nutritional 
depletion (bone cancers are the main example) even when they are not 
undernourished. However, this decision is made on a subjective basis and after a 
global assessment and it is not recorded in the patients’ clinical notes. Therefore it 
was not possible to distinguish those in prophylactic treatments from those who were 
not. However, NS is generally stopped if the patients do not develop the nutritional 
side effects of the treatments; consequently it is very likely that those who were 
classified as undernourished by the use of NS as a proxy of undernutrition were truly 
at nutritional risk. 
2.4.3 Effectiveness of NS in counteracting undernutrition 
In the present study no significant difference was seen between mean weight SDS at 
initiation and at end of NS, which suggests the positive effect of NS on preventing 
further nutritional deprivation but not on improving nutritional status. However, only 
a limited number of patients within this cohort had weight SDS available at both 
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time points, which makes the interpretation of these results difficult. The observed 
effect of NS on preventing further nutritional deterioration but not on improving 
nutritional status could be therefore, attributed to a closer monitoring of patients at 
higher nutritional risk, rather than NS being ineffective in counteracting 
undernutrition per se. 
Even though NS is widely used in children with undernutrition, its effectiveness to 
counteract cancer-related undernutrition remains unclear. Some studies have shown a 
positive effect on undernutrition (den Broeder et al. 1998; den Broeder et al. 2000; 
Rickard et al. 1979; Smith et al. 1992) whereas others (Rickard et al. 1985; Rickard 
et al. 1989) found NS to be ineffective in counteracting undernutrition. This 
inconsistency may be explained by the small number of patients studied, differences 
in cancer diagnoses, and methodological limitations. For example, few studies were 
randomised controlled trials (den Broeder et al. 1998; Smith et al. 1992), and some 
studies (Rickard et al. 1979; Rickard et al. 1985; Rickard et al. 1989) are now very 
dated. This is particularly relevant since the recent improvement in management of 
nausea and vomiting is likely to have increased tolerance to ETF and therefore 
improved the effectiveness in counteracting undernutrition, as shown in later studies 
(den Broeder et al. 1998; den Broeder et al. 2000; Smith et al. 1992). 
2.4.4 Overweight and Obesity 
Obesity in children is usually not assessed by weight for age because obesity 
depends on both height and weight. Although BMI centiles in children do not 
necessarily reflect body composition and its changes (Scottish Intercollegiate 
Guidelines Network 2010), there is evidence to support the use of BMI centiles to 
define obesity in this population group (Cole et al. 1995; Scottish Intercollegiate 
Guidelines Network 2010). Therefore, only BMI centiles were used to assess 
overnutrition in this cohort. Hence, the prevalence of overweight and obesity could 
only be assessed for those patients with height available to calculate BMI. 
Although not significant, this current study showed a trend towards an increase in 
BMI centiles from diagnosis to remission. Furthermore, it showed a higher 
prevalence of overnutrition compared to the UK population at end of treatment and 
last clinical appointment, particularly in girls. When the cohort was stratified 
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according to cancer diagnosis, it was observed that the highest prevalence of 
overnutrition was among children with haematological tumours at the end of their 
treatment. Although not statistically significant, quantitative comparison to the 
excepted frequencies of overweight and obesity for the UK population showed an 
increased risk at end of treatment and last clinical appointment in the haematological 
group. 
The observed increased in BMI centile overtime may be explained by both/either an 
improvement in nutritional status of patients during the data collection period and/or 
excess body weight gain. However, if the prevalence of undernutrition and 
overnutrition observed in this study are considered, it appears that no patient was 
classified as undernourished at any measurements. Nevertheless, it is likely that, 
although not statistically significant, children in this cohort experienced excessive 
weight gain.  
The small sample size of those patients with BMI available is likely to have affected 
the statistical analysis and to have caused of the lack of significance. However, is not 
clear whether the data were randomly missing or if there was a particularly reason 
for the increased nutritional monitoring in those patients as, for instance, more 
attention given to those patients with nutritional issues. Furthermore, the data in this 
study were compared to the NDNS (Department of Health 2012) which represents 
the whole UK and it may did not take into account the differences in regional 
prevalence of obesity. However, when the data for obesity and overweight as a 
whole from the NDNS 2011 (Department of Health 2012), are compared to the 
figures from the Scottish Health Survey (SHS) (Scottish Government 2009) for both 
genders , the data from the NDNS (Department of Health 2012) were slightly lower 
that the SHS 2008 for boys ( 33% vs. 36% respectively) but much higher for girls 
(34% vs.26.9% respectively). Therefore, if the data for the females in this current 
study was compared to the Scottish Health Survey (Scottish Government 2009) 
instead of the NDNS 2011 (Department of Health 2012) , it would have resulted on a 
even higher increase on the prevalence of overweight and obesity. 
The trend towards excess weight gain after childhood cancer treatment observed in 
this study is supported by previous research, which has extensively shown an 
96 
 
increased risk for the late onset of obesity in children treated for ALL and 
cranyopharingioma (Dalton et al. 2003; Meacham et al. 2005; Oeffinger et al. 2003; 
Warner et al. 1995). Furthermore, the observed increased risk for girls in this study 
has been reported in several other studies (Gurney et al. 2003; Jarfelt et al. 2005; 
Warner et al. 2002), even though the reasons for this sex related risk is still 
unknown. 
These results suggest that there appears to be an increased prevalence of overweight 
among ALL, lymphoma at end of treatment and CNS patients in remission. The 
association between these three cancer types and the later obesity has been 
previously reported (Nysom et al. 1999; Oeffinger et al. 2003; Razzouk et al. 2007; 
Schell et al. 1992; Muller et al. 1998; Nysom et al. 2003). However, comparison of 
the prevalence of obesity observed in this cohort and those reported in the 
haematology-oncology studies is complex because of the different methodologies 
used to assess obesity in the literature. For example, most of the studies were carried 
out only in childhood ALL survivors (Meacham et al. 2005; Sainsbury et al. 1985; 
Schell et al. 1992; Zee and Chen 1986). Moreover, some authors used the cut off 
points of BMI >25 and >30 Kg/m
2
 to adults to define overweight and obesity in their 
study (Schell et al. 1992; Warner et al. 2002) which are not recommended in children 
because of the body composition changes during growth the dependence on gender 
(Scottish Intercollegiate Guidelines Network 2010). 
The literature suggests many risk factors for the late development of obesity such as, 
age at diagnosis (Dalton et al. 2003) CRT , chemotherapy (Odame et al. 1994; 
Oeffinger et al. 2003; Reilly et al. 2001), fat overshooting (Dulloo et al. 2012) and 
early adiposity rebound (Reilly et al. 2001b). Unfortunately, it was not possible to 
determine the reasons for the increased prevalence of obesity observed in this study. 
The lack of recorded height and weight did not allow the calculation of BMI for 
many patients making it impossible to analyse the data in relation to the variables 
believed to play a role in the development of obesity such as for instance steroid 
therapy or age at diagnosis. 
Furthermore, it is not clear whether the extent of the starvation state in children 
during treatment for cancer is enough to lead to fat overshooting (Dulloo et al. 2012) 
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causing the patient’s weight to exceed the pre-illness weight. In this current study, 
pre-illness weight was not available; therefore it was not possible to compare weight 
in remission with pre-illness weight to demonstrate whether the patients were 
overshooting their set-point or not. 
This current study suggests a trend towards excess body weigh as long term 
consequence of childhood cancer. This is particularly worrisome given the fact that it 
is likely that the presence of excess body weight will be carried into adulthood with 
the consequent increased the risk for CVD , diabetes and reduced quality of life 
(Sinaiko et al. 1999). Clearly, elucidation of the mechanisms involved in this excess 
weight gain and the identification of treatment protocols and cancer types at higher 
risk have important implications for the long term management of those children 
identified at great risk. 
2.5 Conclusions 
This research was a preliminary step towards identifying the risk factors for 
malnutrition in childhood cancer. This retrospective analysis assessed the incidence 
of undernutrition in this cohort, using the need for NS as a proxy for high nutritional 
risk, and the relationship of NS usage to cancer type and treatment modalities. These 
findings underlined the common need for NS in this childhood cancer cohort, and 
also indicated apparent differences in nutritional risk according to diagnosis and 
treatment. 
Despite awareness of the importance of nutrition in childhood cancer, the lack of 
comprehensive longitudinal growth and nutrition support would suggest that clear 
guidelines for monitoring are urgently required. Use of an appropriate screening tool 
would not only allow early identification of those at risk of undernutrition, but would 
also serve to guide monitoring of the effectiveness of NS. In order to develop a 
comprehensive screening tool specifically for use in this population, it is essential to 
conduct a large prospective cohort study to monitor nutritional status in children 
with cancer from diagnosis through to the end of treatment. These findings could 
identify the factors that influence nutritional status and facilitate clinical guidelines 
for the routine monitoring and assessment of risk. The development of a screening 
tool would allow early and effective nutritional intervention to reduce the risk of 
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nutritional problems in children with cancer throughout the course of the disease and 
its treatment. 
This retrospective study aimed to identify those children and young people treated 
for cancer at risk of nutritional problems and the important parameters to determine 
nutritional risk with the intention to initially validate those findings in the 
prospective cohort. However, because of the lack or recorded height and weight it 
was not possible to do so. Therefore, instead of validating the findings from the 
retrospective study, the prospective study was carried out aiming to monitoring 
paediatric cancer patients to identify factors influencing nutritional risk. 
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3 CHAPTER THREE 
PILOT STUDY: ‘ASSESSMENT OF RELIABILITY AND 
PRECISION OF ANTHROPOMETRICAL MEASUREMENTS 
PERFORMED IN HEALTHY CHILDREN’.  
 
The prospective study was designed to longitudinally assess the nutritional status of 
children and teenagers treated for childhood cancer. The prospective monitoring of 
nutritional status included regular anthropometric measurements to assess growth 
(height, weight and BMI) and body composition (MUAC and TSF). Both random 
and systematic errors can occur in anthropometrical measurements which may affect 
precision and reliability (Atkinson and Nevill 1998; Jamaiyah et al. 2010; Ulijaszek 
and Kerr 1999).  
Random errors may limit the degree to which repeated measurements provide the 
same value (Gibson 2005). High precision corresponds with low variability in 
successive measurements and it indicated a high probability that the measurement is 
close to the true value (Gore et al. 1996). Random measurement errors can be 
minimised by the use of standardised protocols, a single trained observer and 
suitable and calibrated equipment (Jebb and Elia 1993). However, such errors can 
never be completely eliminated (Gibson 2005), therefore the precision and reliability 
of the measurement must be established prior to the research. This strategy will 
allow the error to be accounted for when interpreting the data. 
The precision of measurements can be calculated by quantifying the technical error 
of measurement (TEM) and the %TEM, which overcomes the difficulty of TEM 
being dependent on the size of original measurement. It has been suggested that the 
% intra-observer error for a beginner is acceptable when it is below 1.5% (Ulijaszek 
and Kerr 1999). Reliability is calculated by measuring the Interclass Correlation 
Coefficient (ICC), and indicates the proportion of between-subject variance in a 
population which is free from TEM (Gibson 2005). It describes how strongly 
measurements in the same group resemble each other. An ICC of 0 is classified as 
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not reliable and not valid, whereas an ICC equal to 1 is considered highly reliable 
and valid (Atkinson and Nevill 1998; Jamaiyah et al. 2010; Ulijaszek and Kerr 
1999).  
None of the studies that aimed to assess nutritional status using TSF and MUAC 
(Garofolo et al. 2005; Oguz et al. 1999; Smith et al. 1991) calculated the TEM and 
the ICC, making the precision and reliability of the measurement questionable. 
In general the precision of weight and height measurements is high; however, the 
precision of anthropometrical measurements is highly dependent on the researcher’s 
skills. Training and the use of standard techniques are critical. Moreover, the degree 
of error and inaccuracy must be minimised and accounted for when interpreting the 
data. For the purpose of the prospective study it was essential that the techniques of 
measurements were optimised and the TEM and ICC calculated. 
3.1 Study aim and objectives 
The aim of the study was to asses the reliability and precision of the anthropometric 
measurements used in the prospective study (see Chapter 4). Therefore, the intra-
observer of technical error (TEM) and interclass correlation coefficient (ICC) were 
measured. 
The objective of the pilot study was: 
 To quantify the intra-observer TEM and ICC for height, weight TSF and 
MUAC.  
3.2 Materials and methods 
3.2.1 Study population 
The literature suggests a minimum of ten children, including both genders (Ulijaszek 
and Kerr 1999), to be included in the study to assess the ICC and TEM. Furthermore, 
since TEMs vary according to target population, the cohort incorporated in the pilot 
study should reflect the age of the study cohort (Norton and Olds 1997). However, 
since the study aimed to assess the reliability and precision of the researcher 
technique, it could be carried out on healthy children. Hence the inclusion criteria for 
the study were any healthy child and adolescent between the age of 1 and 18.The 
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exclusion criteria were children younger than 1 year or older than 18 years of age, 
children with any medical conditions. 
Even though children younger than one year of age were to be included in the 
prospective study, their length measurement at the hospital was taken by the nursing 
stuff. Furthermore, for safety, the arm measurements require the use of the cot, 
which was not available at QMU. Considering that, the input on assessing the TEM 
and ICC would have been minimal, and due to the practical and safety issues of 
measuring babies, it was believed that their exclusion was preferable.  
The participants were recruited by the QMU moderator email system. Written and 
oral age- appropriate information were given to both parent and child (Children 6 to 
11 were given the children’s information sheet and those older than 11 the adult’s 
one) (Appendix 4). A period of time to consider about taking part to the project was 
given to both parent and child. Afterward, both parents and child were asked if they 
agreed to participate. Only if both the parent and the child agreed, the recruitment 
took place. The measurements where taken on one occasion at QMU. The study had 
ethical approval from QMU Ethics Committee (Appendix 1).The data were coded 
with an identification number to ensure anonymity. The raw data were stored at 
QMU. 
3.2.2 Anthropometrical measurements 
Age and gender were recorded for each participant. Height was measured using the 
wall-mounted stadiometer (SECA Hamburg, Germany) available at QMU. The 
participant was measured without shoes and thick socks and he/she was positioned to 
touch the back plate with his/her back, heels and buttocks. The head was positioned 
to look straight ahead with the lower border of the boney orbit and the upper margin 
of the external opening of the auditory canal in the same horizontal line. The child 
was asked to breathe in while supporting the head in the right position and then 
asked to breathe out. The measuring board was placed on the top of the head and the 
height recorded. Height was measured to the nearest 0.1 cm  
Children were weighed without shoes, in light clothing, on the standing scales 
available at QMU SECA 599 (SECA Hamburg, Germany).Weight was measured to 
the nearest 0.1 kg. 
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The TSF measurements were taken by the same investigator, on the non-dominant 
arm half way between the olecranon and acromion by a skinfold caliper (Holtan LtD. 
Crymych, UK) for each subject. The measurement was taken by pulling the skin and 
adjacent subcutaneous tissue between the thumb and the forefinger away from the 
muscle tissue far enough to allow the caliper to be placed. The measurement was 
taken once to the nearest 0.2 mm at the marked arm midpoint.  
The MUAC was measured by the same investigator three times from the non-
dominant arm half way between the olecranon and acromion with a non stretchable 
measuring tape (Holtan LtD. Crymych, UK) to the nearest 0.1 mm. The 
measurements were taken once at the marked arm midpoint.  
The full set of measurements was taken two times. 
3.2.3 Data analysis 
The intra-observer TEM and %TEM for the set of anthropometrical measurements 
were calculated as follows (Ulijaszek and Kerr 1999). The mean of the two 
measures, for each anthropometrical measurement were compared by a two-way 
ANOVA to test for any significant difference between the means. 
The following equations were then used to calculate both TEM and %TEM 
TEM= √ error mean square 
% TEM = (TEM/mean) x 100 
ICC is the correlation coefficient (r) and it measures reliability. It functions on data 
organized as groups, rather than data organized as paired observations (Field 2009). 
ICC was calculated using the One-way random single measures test available in 
SPSS®. 
3.3 Results 
3.3.1 Study population 
A total number of ten children were recruited for the pilot study, 50% were female 
and 50% were male. The median age was 8.5 (IQR 6.5, 10.7) years.  
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3.3.2 TEM and ICC 
There was no significant difference between the means of the two measurements for 
height, weight, TSF and MUAC. Therefore TEM, %TEM and ICC could be 
calculated for each anthropometrical measurement (Table 3.1) 
Table 3.1 TEM and ICC 
 Height Weight TSF MUAC 
F 0.00 0.00 0.02 0.00 
p value 1 0.99 0.97 0.99 
TEM cm 0.02 0.02 0.17 0.12 
TEM% 0.06 0.02 1.3 0.6 
ICC 0.99 0.99 0.94 0.96 
 
3.4 Discussion 
The TEM indicates that the true value of the subject at 68% of confidence interval is 
included between the measurement ± TEM. The technical errors estimated from the 
pilot study, are below the acceptable value of 1.5% and they were comparable to the 
target TEM for the accreditation level 2 post-course anthropometrist (Gore et al. 
1996) for both MUAC and TSF.  
The one way ANOVA of the data with two measurements of weight, height, TSF 
and MUAC showed a high level of agreement. It is therefore permissible to assume 
that the measurement procedures will have a high level of reliability.  
3.5 Conclusions  
The assessment of precision and reliability demonstrated a high level of reliability 
and a small measurement error. Therefore, it is permissible to assume that the 
researcher is able to detect with confidence anthropometrical changes. The technical 
error of the measurement and the ICC will be taken into consideration when 
interpreting the data from the prospective study. 
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4 CHAPTER FOUR 
 
THE NUTRITIONAL RISKS OF CHILDREN TREATED FOR 
CANCER: A PROSPECTIVE STUDY 
 
The findings from the retrospective study showed that children treated for cancer are 
at high risk of nutritional depletion and it indicated apparent differences in 
nutritional risk according to diagnosis and treatment modalities. However, the lack 
of comprehensive growth and nutritional status monitoring during paediatric cancer 
treatments in this centre from 2001-2006 prevented the identification of important 
parameters to determine nutritional risk. Therefore, it was not possible to validate 
these findings in the prospective cohort as intended. Thus, instead of validating the 
findings of the retrospective study, the prospective study was carried out aiming to 
monitor paediatric cancer patients to identify factors influencing nutritional risk. 
This single centre prospective study provides the exceptional opportunity to 
investigate factors contributing to the development of malnutrition in children and 
teenagers treated for cancer.  
4.1 Prospective study aims and objectives 
The aim of this study was to investigate factors contributing to the development of 
malnutrition (obesity or undernutrition) among children with cancer.  
 The main objectives were 
 To prospectively monitor changes in nutritional status indices (BMI, growth, 
body composition and blood parameters) from diagnosis through the 
progression of disease in response to treatments, and nutritional intervention. 
 To prospectively follow for 18 months a cohort of children newly diagnosed 
with cancer to assess determinants for the development of undernutrition. 
 To prospectively follow for 18 months a cohort of children newly diagnosed 
with cancer to assess early determinants for the development of overnutrition. 
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 To prospectively follow micronutrient status in response to treatments and 
nutritional intervention.  
 To evaluate the effectiveness of NS in maintaining or improving nutritional 
status and counteracting undernutrition. 
 
4.2 Methods 
The study design aiming to explore the nutritional issues and risks involved in 
paediatric oncology followed a descriptive quantitative research method.  
The prospective study had ethical approval from NHS Scotland (NHS REC 
06-51104-52) until Dec 2012 (Appendix 2). Ethical approval was not required from 
QMU Ethics Committee as the project had secured ethical approval from the NHS 
(Appendix 3). The researchers working on this project had the relevant enhanced 
disclosure enabling them to work with this population.  
Patient data remained confidential and all data was anonymised. 
4.2.1  Subjects and recruitments 
The cohort consisted of all children diagnosed with any type cancer and benign brain 
tumour between August 2010 to December 2011 at the Royal Hospital for Sick 
Children, Edinburgh, the regional centre in SE Scotland serving a population of 1.25 
million.  
Patients in palliative care and those patients not receiving ongoing care where 
excluded from the study. Moreover, those patients who were recruited and became 
palliative during cancer treatments, were withdrawn from the study as soon as they 
were confirmed palliative by the consultants. 
The child and the parents or guardians were provided with full written information 
regarding the project to give them the opportunity for ‘informed consent’ and given 
at least 24 h to think about the project before making the decision to take part to the 
study or not. The information were given orally and in a written format explaining 
what the study involved, the possible consequences for the child and that the child 
was not under any type of obligation to take part to the study, and he/she may 
withdraw at any time. Furthermore the child and the parents or guardians were given 
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the opportunity to take part in all or any parts of the study that they wished. Written 
consent was obtained from all parents and children.  
4.2.2 Demographics 
The cohort was monitored in term of demographics. The following information was 
recorded: gender, date of birth; diagnosis date, and survival at the final collection 
point. Decimal age was calculated from date of birth at every time point, by using 
the LMS Growth (Harlow Healthcare, UK) to allow growth comparison to the 
expected frequencies for the UK population (Cole, Freeman and Preece 1995).  
4.2.3 Clinical information 
Clinical information was collected from the medical notes. The type of tumour was 
classified using the international Classification of Childhood Cancer, Third Edition 
(ICCC-3) (Steliarova-Foucher et al. 2005) in order to assess the nutritional risks 
according to cancer type. Analysis of the data according to cancer stage was not 
possible due to the limited sample size. 
Treatment protocols and treatment modalities were recoded in order to assess the 
nutritional risks according to treatments. However, due to the limited numbers 
available in the study and the wide range of treatment protocols used to treat 
childhood cancer, the cohort was grouped according to the wider treatment 
modalities of: chemotherapy only (with or without surgery); radiotherapy only (with 
or without surgery); chemotherapy and radiotherapy; surgery only; or no treatment. 
This information was recorded to allow data analysis in relation to cancer treatment.  
The use of steroids was also recorded because of their effect on appetite and body 
composition. The use of steroids was classified depending on whether they were 
used as part of treatment protocol, as antiemetic, or to reduce intracranial pressure. 
This distinction was necessary because the dosage and length of treatment changes 
dramatically between intended purposes. 
4.2.4 Anthropometric measurements 
The patients were recruited after diagnosis as soon as advised it was appropriate to 
do so by the consultants. The first set of measurements was taken at the time of 
recruitment. Because of the time lapse between, diagnosis and actual recruitment, 
retrospective information for height and weight at diagnosis date was also collected 
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from the clinical notes. These provided essential information on growth pre-
treatment. 
The following measurements were collected every three months ± 4 weeks 
thereafter, up to a year. From a year after diagnosis, the measurements were taken 
every six months (± 3 months). This was to adjust to less frequent hospital 
attendance following the reduction in the intensity of treatments after the first year. 
The flexibility in the timing of follow up measurements was essential to 
accommodate the timing of the clinical practice. 
4.2.4.1 Growth measurements  
Height for children under the age of one and children unable to stand were measured 
using supine length on the supine measuring device SECA 399 (SECA Hamburg, 
Germany) available at clinics and in the ward. The child was measured with the help 
of a nurse or the child’s parent using standard techniques. The parent was asked to 
hold the child’s head with the eyes facing the ceiling, against the headboard. The 
researcher or nurse straightened the leg by placing a hand on both knees, keeping the 
toes pointing upwards and sliding the footplate up to the sole of the feet. Children 
over one year of age were measured using the wall-mounted stadiometer (SECA 
Hamburg, Germany) available in the ward and in clinic. The patient was measured 
without shoes and thick socks and he/she was positioned to touch the back plate with 
his/her back, heels and buttocks. The head was positioned to look straight ahead with 
the lower border of the bony orbit and the upper margin of the external opening of 
the auditory canal in the same horizontal line. The child was asked to breathe in 
while supporting the head in the right position and then asked to breathe out. The 
measuring board was placed on the top of the head and the height recorded. Height 
was measured to the nearest 0.1 cm.  
Infants up to one year were weighed unclothed using a baby scale SECA 399 (SECA 
Hamburg, Germany). Children over one year of age were weighed without shoes on 
and with light clothing on the standing scales available in the ward or at clinic SECA 
599 (SECA Hamburg, Germany). Weight was measured to the nearest 0.1 kg. 
Whenever it was not possible to measure height and weight of a child, the 
measurement was taken from the weight and height record file available in ward two 
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using the most recent recorded measurements. BMI was calculated as weight divided 
by height squared. In this study UK 1990 reference values were used to assess 
growth (Cole et al. 1995). At the end of 2010 new growth standards (RCPCH 2011; 
SACN/RCPCH 2007) for children aged 0-4 were introduced. However, they were 
not adopted in this study because they were published after the study was designed 
and at the final phase of data collection. Moreover, the use of the previous reference 
standards was believed to be more appropriate since clinical and nutritional 
judgment was based on the previous reference data (Cole et al. 1995). Height, weight 
and BMI centiles for children were calculated using LMS Growth (Harlow 
Healthcare, UK). 
Height and weight before diagnosis were collected based on parents recall, to 
establish weight loss before diagnosis. 
In this study BMI centiles were presented according to gender and diagnostic group 
(solid vs. haematological). Undernutrition was defined as BMI ≤ 2.3th centile (SACN 
2012). The prevalence of undernutrition observed in this study was compared to the 
expected frequencies of 2% for undernutrition for all children, 1.9% for boys and 2.1 
% for girls (Scottish Government 2009).  
In this study, overweight and obesity were defined using the threshold for population 
monitoring, as it is standard UK government practice (Department of Health 2012). 
Overweight was defined as ≥ 85th / < 95th centile and obesity as ≥ 95th centile (Cole 
et al. 1995). These definitions are widely used in UK (Department of Health 2012; 
Scottish Government 2009) therefore it was decided to use this definition to maintain 
consistency and to allow comparison with the published literature. The prevalence of 
overweight and obesity was compared against the most recent Nutrition and Diet 
National Survey (Department of Health 2012) result of 15% for overweight, and for 
obesity, 18% for boys and 19% for girls. The NDNS (Department of Health 2012) 
was chosen over the Scottish Health Survey (SHS) (Scottish Government 2009) 
because SHS 2008 provides data on Scottish children but does not distinguish 
between overweight and obesity, and the former is the most up to date survey.  
 
109 
 
4.2.5 Weight loss 
Since a weight loss ≥ 5% in a month is a sign of nutritional deprivation (Jeejeebhoy 
and Keith 2005), in this study weight loss from the preceding measurement was 
assessed. This was expressed as a percentage of actual body weight. The prevalence 
of patients with a weight loss ≥5% was reported. Data were presented according to 
gender and diagnostic group. 
4.2.6 Arm anthropometry measurements 
The triceps skinfold (TSF) and mid upper arm circumference measurements were 
taken by the same investigator using standard technique as described in 
Chapter 3.2.2 (page 101). The full set of measurements was taken three times, and 
the mean of the three measurements was used for the analysis of data. Whenever 
only two or one measurement were available the mean of the two measurements or 
the single measurement was used for the analysis of data. 
The raw data were compared to arm anthropometry reference values adjusted for age 
and gender. There are two sets of reference value for arm anthropometry available in 
the literature (Frisancho 1981; World Health Organisation 2011). In the current 
study, the Frisancho (1981) reference values were used. The decision was made 
because WHO (2011) reference values are only available for children up to five 
years of age and are therefore not suitable for this study. Moreover, the WHO (2011) 
data are based on figures from many countries over the world, whereas the 
Frisancho’s (Frisancho 1981) are based on US children, which was believed to be 
more similar to the population in this study. Furthermore, the Frisancho reference 
values are those used at the RHSC by clinicians and dietitians. However, since the 
Frisancho (1981) reference values do not include children less than one year of age, 
the WHO reference values (World Health Organisation 2011) were used for those 
patients.  
Since arm anthropometry parameters depend on growth, they could not be analysed 
as raw values and they were converted to centiles. However, Frisancho (1981) , only 
provides cut off points and not specific centile values ( ≤5th centile; 6-10th centile; 
10-25
th
 centile; 26-50
th 
centile; 51-75
th
 centile; 76-90
th
 centile; 91-95
th
 centile; ≥95th 
centile). Therefore, to allow comparisons between genders and diagnostic group, arm 
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anthropometry measurements were also normalised for age and gender by expressing 
the as percentage of standard (50
th
 centile) (Frisancho 1981). 
The crude measures of TSF (mm) and MUAC (mm) were used to calculate muscle , 
fat mass area and FM% using the following equation (Frisancho 1981). 
A (mm
2) = π/4 * d2  
M (mm
2
) = (C-πT) 2/4π 
FM% = F x A/100 
Where: 
T= Triceps skin fold; A= Upper arm area; M= upper arm muscle area; F= upper arm 
fat area  
d= MUAC/π. 
Undernutrition was classified as TSF and MUAC ≤5th centile (Frisancho 1981; 
Garofolo et al. 2005; Oguz et al. 1999; Smith et al. 1991). The cut off points to 
define obesity and overweight by arm anthropometry measurement are ≥ 85th centile 
and ≥ 95th centile respectively (Must et al. 1991). However, since Fisancho (1981) 
provides different cut off points, in the current study overweight and obesity were 
classified as ≥91-<95th centile and ≥ 95th centile respectively. The prevalence of 
malnutrition according to TSF and MUAC was presented according to gender and 
diagnostic group. 
4.2.7 Bioelectrical Impedance Analysis 
Bioelectrical impedance analysis was performed with an SF-BIA Quantum II RJL 
System at a single frequency of 50 KHz. The electrodes were placed following the 
manufacturer instructions. The instrument was calibrated at the beginning of the 
study and then monthly as per manufacturer instructions. The two upper electrodes 
were placed on the right hand skin covering the third metacarpal bone and the wrist, 
between the protruding portion of the ulnar and radial bone. The two lower 
electrodes were placed on the skin of the right foot covering the third metatarsal 
bone and the ankle on the level of protruding parts of the tibial and fibular bone. The 
patient was supine, with arms at 45° from the body in a position to guarantee that the 
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current would not pass through the bed. Those patients who were able to urinate 
were asked to do so before the measurements were taken. For those patients wearing 
nappies, the parent or the guardian where asked to remove the nappy before the BIA 
measurement. For the estimation of FM and FFM the only equation validated for the 
use in paediatric oncology was used (Brennan 1998).  
Total body water (TBW) and FM were calculated using the following equations; 
TBW =1.24+0.56 (HT
2
/l) (Brennan 1998) 
Where: HT= height; I= impedance.  
FM and fat mass % were calculated to allow comparison to standard values. They 
were calculated using the following formula; 
FM = BW-TBW 
FFM% = FFM x BW/100 
Where BW=body weight; 
FM% was compared to reference values matched for age and gender. Because of the 
lack of a reference value covering the entire age range of this study, two separate 
reference values were used for comparison. For children from birth to five years of 
age, the Fomon et al. reference (Fomon et al. 1982) was used, whereas for the age 
range five to 18 years the Laurson et al. (2011) reference value was used. For the age 
range where both reference values were available the Laurson et al. (2011) was used, 
due to the bigger sample size used to establish the reverence values. Laurson et al. 
(2011) provide reference values according to centiles. For this study, the population 
group was compared to the 50
th
 centile. FM% was presented according to gender and 
diagnostic group. 
4.2.8 Physical activity 
Each patient who entered the study was asked to wear an accelerometer (Actigraph 
GT1M) for seven days at diagnosis, six months 12 months and 18 months. The 
Actigraph was worn around the waist above the iliac crest. Patients were offered the 
option to wear it using an elastic belt or using tegaderm
TM
 pads. The Actigraph was 
initialised for each patient using the manufacturer’s software. The patients were 
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asked to wear the device during waking hours and to take it off when bathing, 
showering, during water sports and at bed time. Furthermore, they were asked to 
record in a diary provided to them the times when they wore the Actigraph and the 
time they went swimming or cycling. The Actigraph was returned by post (pre-paid 
envelope) or in person and then analysed using the manufacturer’s software. 
 The Actigraph measures vertical accelerations and converts them to a number 
(counts) which is in turn summed over a period of time (15 seconds). The sedentary 
time was defined using total durations of counts below 50 counts/min
-1 
and in 
increments of 50 counts/min
-1 
up to 850 counts/min
-1 
(Ridgers ND et al. 2012). PA 
was presented according to gender and diagnostic group. 
4.2.9 Dietary intake and nutrition support 
Information regarding referral to a dietitian, and the reasons and the need for NS 
intervention (type and dosage) were recorded during the period of data acquisition. 
NS intervention was categorised as; use of oral calorie supplements (OCS); and/or 
enteral tube feeding (ETF) including nasogastric tube (NGT) gastrostomy tube (GT) 
or jejunal tube (JT); and/or parenteral nutrition (PN). ‘Advanced NS’ was defined as 
the need for ETF and/or PN. OCS was prescribed by the specialist paediatric 
oncology dietitians. ETF and PN were used after discussion between the oncology 
multidisciplinary team and the hospital NS team (NST). The need for NS was 
presented according to diagnostic group and treatment modalities. 
The dietary intake for macronutrients was assessed at each time point. Dietary intake 
was assessed both ad libitum and with NS. This was essential to assess the energy 
and macronutrients contributed by the NS towards meeting the energy and dietary 
requirements. The type and dosage of NS were used to calculate nutrient intake with 
NS by adding the energy and micronutrients coming from the nutrition support to 
those coming from the intake ad libitum. 
Initially, the dietary assessment method of choice to assess dietary intake ad libitum 
was the three day diet diary. However, from the beginning, it became evident, that 
the parents were under too much pressure to be able to complete the diary. Therefore 
it was decided to use the 24 h multiple pass diet recall instead. In the current study 
the protocol developed by the United States Department of Agriculture for use in its 
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food survey was used (Guenther et al. 1994). This method is less of a burden for the 
family hence it was believed to increase compliance. Even though it is subject to 
some error at individual level (Johnson et al. 1996), it still provided useful 
information on energy macronutrients intake.  
The patient or guardian was asked if the previous 24 h were a typical day of the 
previous two weeks diet. If so they were ask to recall all the food and beverage 
consumed in the previous 24 h. In the case that the previous 24 hours were not 
representative of the patients’ last two weeks intake, the guardian or parents were 
asked to recall all the food and beverage consumed in 24 h of a representative day. In 
cases where the previous two weeks intake was heterogeneous the guardian or 
parents was asked to recall all the food and beverage consumed in 24 h for an 
example of both good days and bad days proportionally, so the intake could be 
averaged accordingly.  
The parent was asked to provide a list of food and beverages the child consumed the 
day before from midnight to midnight. After the first listing of food, the parent was 
asked questions on the time the food and beverages were consumed and the name of 
the eating occasion (e.g. breakfast, mid morning snack etc.). The parent was then 
asked to review the previous day’s dietary intake again. This time details of portion 
sizes, brand names and preparation methods were recorded. The 
patient/parent/guardian was asked to remember if any food was left on the plate, and 
to describe the food as clearly as possible with attention to combination dishes. The 
estimation of food portion size was done using description of portion sizes. The 
patient/parent/guardian was also asked to provide packaging of pre-packaged food 
where available. 
Once the 24 h multi pass recall was completed, the investigator asked about food 
groups such as meat, fish, dairy, vegetables, fruit, sweets, chocolate, and beverages, 
to countercheck if any food was forgotten. Finally, the list was read back to the 
participant to check further if the recall was correct or if they forgot to mention any 
food that was consumed. 
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The information gained from 24 h diet recall was then analysed using the computer 
programme WINDIETS (Univation Ltd 2005) to calculate daily intake of 
macronutrients. Due to the limitation of the 24 h diet recall on estimating 
micronutrients intake only estimates of energy (kcal) protein (g) fat (g) and 
carbohydrates (g) were obtained. When the composition of a food consumed by a 
patient was not available on WIN diet, the manufacturer’s information was used. The 
composition of NS was obtained from the manufacturer and used to calculate 
nutrient intake in relation to the quantity consumed.  
In the time period the research took place, new energy reference values for the UK 
population were published by the Scientific Advisory Committee on Nutrition 
(SACN 2011) which replacing the Estimate Energy Requirements (EARs) from the 
Department of Health (1991). The EARs from the Department of Health (1991) are 
based on TEE derived by the Schofield prediction equation (Schofield et al. 1985) 
which also formed the basis for the document Energy and protein requirement 
(FAO/WHO/UNU 1985). Schofield et al. (1985) reviewed 114 published papers on 
basal metabolic rate (BMR) totalling 7173 data points to produce a predictive 
equation for BMR. However, this study had the major limitation of containing a 
disproportionate number of Italian subjects (47%) and relatively few subjects from 
the tropical region. This equation has been reported to overestimate BMR and its use 
in the present day with an increase prevalence of obesity has been questioned 
(SACN 2011). For this reason a new equation (Henry 2005) was developed using a 
data set which included a much larger number from the tropics compared to the 
Schofield et al. (1985) and excluded all Italian subjects. This new equation was 
adopted by the SACN (2011) to establish the new EARs for energy and has been 
recently embraced in dietetic clinical practice 
Therefore, to assess whether the patients were meeting their energy requirements, the 
energy intake of the study population both ad libitum and with NS were compared to 
total daily energy expenditure calculated for each patient using the Henry (2005) 
prediction equation matched for age and gender. Considering the health condition 
and the reduced physical activity of this study cohort in response to the disease and 
treatments, (Aznar et al. 2006; Jacob et al. 2007; Jansen et al. 2009; Sanford et al. 
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2008), the daily rate of total energy expenditure for both equations was calculated by 
multiplying the basal metabolic rate by the activity level factor for less active 
children (FAO 2004) as shown in Table 4.1. 
In the dietetic management of adults cancer patients a stress factor is added to BMR 
to account for the metabolic demand of cancer (Barak et al. 2002; Delarue et al. 
1990). However, the energy requirements in children are estimated without 
accounting for the metabolic demand of cancer. This is because, the is no evidence 
for increased REE during cancer therapy in children (den Broeder et al. 2001; 
Schmid et al. 2005; Stallings et al. 1989; Vaisman et al. 1993). The literature lacks 
information regarding stress factors specific for pediatric cancers, and those 
available for adults are believed to be to high: i.e. 25-34% (leukaemia)(Barak et al. 
2002) and 0-20% (lymphoma)(Barak et al. 2002; Delarue et al. 1990), especially 
considering the increased risk of late onset of obesity in this patient group. 
Therefore, in the current study, the estimated energy requirement was calculated 
based on the Henry equation (Henry 2005) adjusted for age, gender and physical 
activity, without adding a stress factor. 
Table 4.1 Physical activity level (PAL) values for use in calculation of EARs of 
children and adolescents with low physical activity adjusted for growth (FAO 
2004)  
Age group ( years) PAL 25
th
 centile for less active children 
1-<3  1.36 
3<10 1.43 
10-18 1.68 
 
Adequacy of intake for protein, fat and carbohydrates was assessed by comparing 
intakes to the reference values for healthy subjects matched for age and gender 
(Department of Health 1991; Department of Health Report on Health and Social 
Subjects 1994). 
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Date of beginning and end of NS, and BMI centile at initiation and end of nutrition 
support were recorded in order to assess the effectiveness of nutrition support on 
improving nutritional status and/or preventing further nutritional deterioration. 
Vitamin supplements (dose, type and brand name when available) were recorded to 
allow interpretation of plasma vitamins. 
4.2.10 Blood parameters  
Blood was taken by NHS staff, ideally on the same day as the other measurements. 
However, for ethical reasons blood could only be collected when the patient’s veins 
were accessed for routine blood test or therapy. If it was not possible to collect the 
blood the same day as the measurements, the blood was collected at the closest time 
possible, dictated by clinical practice. All blood was analysed by the RHSC 
Edinburgh Lab, apart from the vitamins and minerals which were analysed using 
standard techniques by the RHSC in Glasgow. The results were compared with the 
NHS RHSC Edinburgh Lab reference values. 
Nutritional status of Vitamin A, D (25-Hydroxycholecalciferol) Vitamin 
E/Cholesterol Selenium, Zn, Cu, folate, Vitamin B12 was assessed by measuring 
plasma levels. Because of the effect of low plasma 25 (OH) D on PTH secretion and 
bone turnover, plasma PTH was also measured. 
Since the liver has a pivotal role in nutrient metabolism, liver function was assessed 
measuring bilirubin, alanine transaminase (ALT), albumin, g-glutamyl transferase 
(GGT) and alkaline phosphatase (ALP) at each time point. 
Serum High Sensitivity C-reactive protein (hsCRP) was used as biochemical marker 
of inflammation. In order to assess whether, plasma changes in ferritin, Cu, Zn were 
caused by changes in nutritional status rather than inflammation, a cross sectional 
analysis was conducted.  
Since the kidneys regulate fluid homeostasis, acid-base balance and renal function 
were assessed by measuring blood urea, creatinine and electrolytes (Na+, K+, Mg
2+
, 
PO4, HCO3 & Ca
2+
).  
The study experimental protocol is shown in Figure 4.1 
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Figure 4.1 Schematic experimental protocol 
  
Referral to  
haematology/ oncology 
team RHSC 
ICCC-3 diagnosis 
meeting inclusion 
criteria 
Consented 
Time point 0- Diagnosis 
Retrospective data collection; Height and weight 
Time point one- Recruitment 
Anthropometry, blood,physical activity , dietary intake. 
Time point two- 3 months 
Anthropometry, blood,dietary intake. 
Time point three - 6 months 
Anthropometry,blood, physical activity,dietary intake. 
Time point four- 9 months 
Anthropometry, blood, dietary intake 
Time point five- 
12 months 
Anthropometry, blood, physical activity, dietary intake. 
Time point six 15/18 months  
END OF STUDY 
Anthropometry, blood,physical activity,dietary intake. 
 
Refused 
Not meeting inclusion criteria 
EXCLUDED 
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4.2.11 Data analysis 
Data were analysed using SPSS 19
®
 (IBM
®
). The data were tested for normal 
distribution by the Shapiro-Wilk Test. The results are presented as mean (± SD) for 
normally distributed data and median (IQR) when not normally distributed. 
For comparison according to gender (male vs. female) and diagnosis (solid vs. 
haematological) an Independent t- test was carried out. For comparison of the same 
group at two different time points a one sample t-test was carried out. The equality of 
variance was first tested by the Levene’s test. If the test was not significant (p>0.05) 
equal variances were assumed.When the data where non-parametric comparison 
according to gender (male vs. female) and diagnosis (solid vs. haematological) was 
tested by the Mann-Whitney test. For comparison of the differences between before 
and after NS, the Wilcoxon signed-rank test was used. 
Correlation between variables was tested using Pearson correlation for parametric 
data and Spearman’s correlation for non-parametric data. Difference between 
observed and expected frequencies of undernutrition, overweight and obesity were 
tested for significance using the Z test.  
The limit of agreement between anthropometric parameters for detecting 
undernutrition was identified by the Kappa test.The results were considered 
significant when p<0.05. 
4.3 Results 
4.3.1 Subjects 
Sixty-four patients in total were referred to the oncology and haematology clinic 
between 1
st 
August 2010 and 31
st 
December 2011. Of those, 13 were not diagnosed 
with cancer and discharged from the service. The remaining 51 patients were 
diagnosed with malignant cancer and benign brain tumours and met the diagnostic 
inclusion criteria for the study. A flow diagram illustrating the composition of the 
cohort in terms of meeting the inclusion criteria and consent is shown in Figure 4.2 
Ultimately, 35 patients were eligible and 26 connsented to take part to the study 
representing a 74% recruiment ratio. Of these patients, 18 were male (69%) and 8 
(31%) were female ; the median age at diagnosis was 5.1 (inter-quartile range (IQR) 
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2.3, 7.9). The overall survival rate at the end of the study period 31/1/2012 was 91%. 
Table 4.2 indicates the primary cancer diagnosis percentage within the whole cohort, 
and the associated survival rate at the end of monitoring period. 
Due to the limited numbers available in the study, it was not possible to carry out 
data analysis according to primary cancer diagnosis. Hence the cohort was grouped 
according the wider definition of solid and haematological cancer. Of the total cohort 
16 patients (62%) had solid tumours (including benign brain tumours) and ten (38%) 
had haematological cancer. 
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Figure 4.2 Patient accrual flow diagram of the patients referred to the RHSC 
with a cancer and benign brain tumour diagnosis 
  
Total number diagnosed 
with childhood cancer 
51 
Total number eligible 
35 
Number consented 
26 
Number refused 
9 
 
Reason refused 
 9 -too stressful 
Total number not eligible  
16 
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Table 4.2 Primary cancer diagnosis percentage within the cohort and survival 
rate at end of monitoring period on 31/1/2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the limited numbers available in the study and the wide range of treatment 
protocols used to treat childhood cancer, the cohort was grouped according the wider 
Diagnosis Cases 
(% within cohort) 
Survivors 
(% with diagnosis) 
I - Leukemia 10 (38) 10 (100) 
ALL 8 (31) 8 (100) 
AML 2 (7) 2 (100) 
CML 0 - 
 Solid tumours 13 (50) 12 (88) 
II- Lymphoma 2 (8) 2 (100) 
III -CNS tumour 1 (4) 0 (-) 
IV- Neuroblastoma 3 (11) 3 (100) 
V- Retinoblastoma 1 (4) 1 (100) 
VI -Renal tumour 2 (8) 2 (100) 
VII -Hepatic tumour 0 (-) - 
VIII -Malignant bone tumours 0 (-) - 
IX- Soft tissue sarcoma 3 (11) 3 (100) 
X -GCT 1 (4) 1 (100) 
XI- Malignant epithelial neoplasm 0 (-) - 
XII- Others and unspecified 
malignat neoplasms 
0 (-) - 
III-Benign brain tumour 3 (11) 3 (100) 
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classification of the treatment modalities received as described in the section 4.2.3. 
Table 4.3 shows the distribution of the treatment modality as percentage of the entire 
cohort measured. 
Table 4.3 Treatment modality 
Treatment modality Cases (% within cohort) 
Chemotherapy alone  15 (58) 
Chemotherapy with surgery 4 (15) 
Chemotherapy with surgery and radiotherapy 6 (23) 
Surgery alone 1 (4) 
Radiotherapy alone 0 (-) 
 
Because of their effect on appetite and body composition, the use of steroids was 
recorded. Since steroid treatments are very complex to report as dose and length of 
treatment , they were classified as shown in Table 4.4 ( i.e. use as per protocol)  
Table 4.4 The use of steroids during data collection and reasons. 
Reasons Recruitment 
n= 26 
3 
months 
n= 20 
6 
months 
n= 13 
9 
months 
n= 10 
12 months 
n= 7 
15/18 months 
n= 2 
As per 
protocol 
10 9 5 4 3 2 
Antiemetic 4 2 0 0 0 0 
No steroids 10 0 7 6 4 0 
 
4.3.2 Assessment of nutritional status using body mass index (BMI) , arm 
anthropometry and bioelectrical impedance measurements 
Nutritional status was assessed at each measurement by several anthropometric 
parameters (weight, BMI, weight loss, TSF and MUAC).  
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4.3.2.1 Body mass index (BMI) measurements 
The prevalence of undernutrition and overnutrition was investigated at each time 
point according to gender and cancer type. With only 26 patients and 13 diagnostic 
categories assessment of the nutritional status according to diagnosis was not 
possible. Therefore the cohort was divided in two subgroups: solid and 
haematological malignancies. Figure 4.3 shows median (IQR) according to gender 
(a) and diagnosis (b) at each time point.  
Median BMI centiles were within normal ranges for both genders and type of cancer 
during the entire data collection period. For the entire sample of males, the lowest 
BMI centile was found at diagnosis (median 39.9, IQR 16.2-69.5) whereas for the 
entire sample of females, the lowest median BMI centile was observed at recruitment 
(median 38.5, IQR 10.0-86.2).  
When analysed according to diagnostic group, it emerged that for the entire sample 
of haematological patients, the lowest mean BMI centile was found at 12 months 
(median 24, IQR 17.5-55.5), whereas for the entire sample of solid cancer patients, 
the lowest median BMI centile was observed at recruitment (median 18.0, IQR 7.5-
54.2). Interestingly, there was not a significant difference in nutritional status 
between the male and the female group measured by BMI centiles at any 
measurement (p<0.05 for all). On the other hand, BMI centile was significantly 
higher in the haematological group compared to the solid group at recruitment and at 
three months (p<0.05 for all). 
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BMI centile according to diagnosis (b)
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Figure 4.3 BMI centile according to gender (a) and diagnosis (b)* p<0.05 
haematological vs. solid 
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Because of the small sample size, the prospective nature of the study, and the many 
drop outs due to patients deceasing or becoming palliative during the data collection 
period, it was not possible to carry out a general linear model for repeated 
measurements to assess BMI changes over time. 
The highest prevalence of undernutrition according to BMI centile ≤ 2.3th centile 
(Figure 4.4) was observed at diagnosis and recruitment (21%, n = 3; 12 %, n= 2 
respectively) for the male group, and at three months for the female group (14%, 
n = 1).  
 
 
Figure 4.4 Prevalence of malnutrition according to gender at each measurement 
expressed as percentage (%). Undernutrition (BMI ≤2.3th centile), obesity (BMI 
≥ 95th centile), overweight (BMI ≥ 85th/< 95th centile).* p<0.05 vs. UK prevalence 
(Department of Health 2012) 
The observed frequencies of undernutrition and overnutrition were compared to the 
expected frequencies for the UK population (Department of Health 2012) according 
to gender. There was a significant increase in the prevalence of undernutrition 
measured as BMI ≤2.3th centile in the male group at diagnosis (p<0.05; 95% 
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CI -0.9% to 40.9%) and recruitment (p<0.05; 95% CI -3.0% to 27.4%) and in the 
female group at recruitment (p<0.05; 95% CI -10.2% to 36.5%) and three months 
(p<0.05; 95% CI -11.7% to 39.7%). The prevalence of overweight and obesity did 
not differ from the expected frequency at any measurements in either group. 
 
Figure 4.5 Prevalence of malnutrition according to diagnostic group at each 
measurement expressed as percentage (%). Undernutrition (BMI≤2.3th centile), 
overweight (BMI ≥ 85th / < 95th centile).* p<0.05 vs. UK prevalence (Department 
of Health 2012) 
When the data were analysed according to diagnostic group (Figure 4.5), the highest 
observed frequency of undernourished children with BMI centile ≤2.3th was among 
the solid tumour group. In this group, 27 % (n = 3), 25% (n = 4) and 17% (n = 2) of 
patients were undernourished at diagnosis, recruitment and three months 
respectively, compared to 0% at every time point for haematological cancers. The 
highest observed frequency of obesity occurred in the haematological group at both 
three months (50%, n = 4) and six months (50%, n = 2). 
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There was a significantly higher prevalence of undernutrition (measured as BMI 
≤2.3th centile) in the solid tumour group at diagnosis (95% CI 0.7% to 53.2 %), 
recruitment (3.8% to 46.2%) and three months ( -4.2% to 38.2 %; p<0.05 for all). 
However, the prevalence of undernutrition did not differ from the expected 
frequencies for the UK population (p>0.05) for the group with haematological 
tumours. The observed frequency of children with a BMI centile above 95
 
was 
statistically higher than
 
the expected frequency of 18% (Department of Health 2012) 
for the haematologic group at three months (p<0.05; 95% CI 19% to 80.6%). The 
observed frequency of overweight for both diagnostic groups was not significally 
different from the expected frequency (p>0.05 for all).  
4.3.2.2 Weight loss over 5% from previous measurement 
Weight loss ≥5% from previous measurement, was observed in three different 
patients at both recruitment (n= 2 solid tumour; n= 1 haematological cancers) and 
three months (n= 1 solid tumour; n =2 haematological cancers). Five out of six 
patients with a weight loss ≥5% were classified as normally nourished by all 
anthropometric measurements. All the patients apart from one with a solid tumour 
were started on NS.  
4.3.2.3 Arm anthropometry 
In order to assess the prevalence of malnutrition at each time point, arm 
anthropometry measurements (MUAC and TSF) were converted to gender and age 
specific centiles (Frisancho 1981). However, the conversion of TSF and MUAC to 
centiles (Frisancho 1981) generates categorical data, hence calculation of centile 
mean and SD was not possible. Therefore, in order to normalise the data for age and 
gender and to allow statistical comparison between genders and diagnostic groups, 
the results where also expressed as percentage of standard value as described in the 
methodology section. Since only one patient had arm anthropometry measured at 15-
18 months, the data for the last time point is not presented. Figure 4.6 shows arm 
anthropometry expressed as % of standard value at each time point according to 
gender and diagnosis. 
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MUAC % of standard according to diagnosis (b)
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TSF % of standard according to gender (c)
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TSF % of standard according to diagnosis (d)
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UAMA % of standard according to gender (e)
R
ec
ru
itm
en
t  
f=
5,
m
=1
1
3 
m
on
th
s 
f=
5,
 m
=9
6 
m
on
th
s 
f=
3,
 m
=5
9 
m
on
th
s 
f=
4,
m
=4
12
 m
on
th
s 
f=
2,
m
=4
50
100
150
Female
Male
Time point
U
A
M
A
 %
 o
f 
s
ta
n
d
a
rd
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UAFA % of standard according to gender (g)
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UAFA % of standard according to diagnosis (h)
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Figure 4.6 Arm anthropometry expressed as % of standard value. 
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Patients with solid tumours had lower TSF, MUAC, UAMA and UAFA than 
haematological patients for the first nine months of treatments. However, only 
MUAC at recruitment and three month, and UAMA at recruitment, reached 
statistical significance (p<0.05). Additionally, comparison of TSF, MUAC, UAMA 
and UAFA according to gender, showed no apparent differences between males and 
females. 
In the solid group, the highest nutritional depletion was observed at three months, 
where TSF and UAFA were 73.3 % (IQR 68.3-93.0) and 70.8 %(IQR 62.6-124.8) of 
the standards, respectively. On the contrary, the haematlogical goup showed excess 
body fat accumulation at three months with the median UAFA being 129.4 % (IQR 
96.5-202.6) of standard. In both groups, all arm anthropometry parameters returned 
to normal values by 12 months. 
There was a positive association between BMI centile and UAFA centile measured 
by arm anthropometry at recruitment (p<0.001, r= 0.743) (Figure 4.7). 
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Figure 4.7 Spearman’s correlation between arm fat mass centiles and BMI 
centile. 
Due to the longitudinal design, the limited number of patients and the many drop 
outs, it was not possible to statistically analyse the changes in arm anthropometry 
over time either as raw data or centiles. 
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The prevalence of malnutrition at each time point was assessed using MUAC and 
TSF centiles. Undernutrition was classified as TSF and MUAC ≤5th centile 
(Frisancho 1981; Garofolo et al. 2005; Oguz et al. 1999; Smith et al. 1991). 
Overweight was classified as ≥91-<95th centile and obesity as ≥95th centile 
(Frisancho 1981). 
The prevalence of malnutrition assessed by MUAC is presented according to gender 
(Figure 4.8) and diagnosis (Figure 4.9) at each time point. For the male group the 
highest prevalence of undernutrition was observed at diagnosis (n= 5; 29%) whereas 
for the female group it was observed at three months (n= 2; 28%). The highest 
prevalence of obesity was observed at nine months in the male group (n= 4; 25%) 
and at six months (n= 1; 25%) in the female group.  
For the solid cancer group the highest prevalence of undernutrition was observed at 
diagnosis (n= 6; 37.5%). From six months onwards none of the patients were 
classified as undernourished. Moreover, none of the patients with solid tumours were 
classified as overweight or obese during the entire data collection period.  
For the haematological group, the highest prevalence of obesity was observed at six 
months (n= 3; 66%) and nine months (n= 2; 66%). None of the patients with 
haematological malignancies were classified as undernourished by arm 
anthropometry during the entire data collection period.  
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Figure 4.8 Prevalence of malnutrition according to gender at each measurement 
expressed as percentage (%). Undernutrition (MUAC≤5th centile), overweight 
(MUAC ≥ 91th/ <95th centile), obesity (MUAC≥ 95th centile). 
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Figure 4.9 Prevalence of malnutrition according to diagnostic group at each 
measurement expressed as percentage (%). Undernutrition (MUAC≤5th centile), 
overweight (MUAC ≥ 91th/<95th centile), obesity (MUAC≥ 95th centile). 
 
The prevalence of malnutrition assessed by TSF is presented according to gender 
(Figure 4.10) and diagnosis (Figure 4.9) at each time point. For the male group the 
highest prevalence of undernutrition was observed at diagnosis (n= 5; 36%) whereas 
for the female group it was observed at six months (n= 1; 25%). The highest 
prevalence of obesity was observed at six months in the male group (n= 1; 20%), and 
at six months (n= 1; 25%) and nine months (n= 1; 25%) in the female group.  
For the solid cancer group the highest prevalence of undernutrition was observed at 
diagnosis (n= 6; 35%). From nine months onwards none of the solid cancer patients 
were classified as undernourished. For the haematological group, the highest 
prevalence of obesity was observed at six months (n= 2; 66%). No individual child 
with haematological cancer was undernourished for the entire collecting period  
0
10
20
30
40
50
60
70
R
e
cr
u
it
m
e
n
ts
 n
=9
3
 m
o
n
th
s 
n
=
7
6
 m
o
n
th
s 
n
=
3
9
 m
o
n
th
s 
n
=
3
1
2
 m
o
n
th
s 
n
=2
R
e
cr
u
it
m
e
n
t 
n
=
1
6
3
 m
o
n
th
s 
n
=
1
0
6
 m
o
n
th
s 
n
=
6
9
 m
o
n
th
s 
n
=
6
1
2
 m
o
n
th
s 
n
=4
Haematological Solid
%
 
Prevalence of malnutrition (MUAC) 
according to diagnosis at each 
measurement 
Undernutrition Overweight Obesity
136 
 
 
Figure 4.10 Prevalence of malnutrition according to gender at each 
measurement expressed as percentage (%). Undernutrition (TSF≤5th centile), 
overweight (TSF ≥ 91th/<95th centile), obesity (TSF≥ 95th centile). 
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Figure 4.11 Prevalence of malnutrition according to diagnostic group at each 
measurement expressed as percentage (%). Undernutrition (TSF≤5th centile), 
overweight (TSF ≥ 91th <95th centile), obesity (TSF≥ 95th centile). 
 
4.3.3 Bioelectrical impedance (BIA) 
FM expressed as percentage of body weight was calculated from BIA measurements 
at each time point as explained previously (Section 4.2.7). FM% was significantly 
higher than reference standards (Fomon et al. 1982) for both genders (p<0.05) and 
diagnostic group (p<0.05) at every time point. The results showed a peak in FM% at 
six months in the haematological group (median 34.0%, IQR 28.9-38.9) and at nine 
months in the solid group (median 34.3 %, IQR 27.7-36.2). When stratified 
according to gender, FM% was highest in females at three months (median 37.2%, 
IQR 31.1-37.7) and at six months in boys (median, IQR 32.0 26.2-34.0; Table 4.5) 
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Table 4.5 Median (IQR) percentage of standard value (Fomon et al. 1982) at 
each time point for the entire according to gender and diagnosis. * p<0.05 
measurement vs. standard  
 
 Recruitment  3 months 6 months 9 months 12months 
M
a
le
 
FM% 28.9 *  
(20.1-34.3) 
27.9 * 
(24.1-36.4) 
32.0 * 
(26.2-34.0) 
26.0 * 
(24.4-31.6) 
25.7 * 
(23.4-28.7) 
Standard 17.5  
(14.1-18.8) 
17.5  
(14.1-20.5) 
17.5 
(14.617.5) 
16.7  
(15.6017.6) 
15.3  
(14.3-15.9) 
F
em
a
le
 
FM% 31.5 * 
(30.4-32.2) 
37.2 * 
(31.1-37.7) 
37.1 * 
(29.3-44.0) 
35.2* 
(32.7-36.7) 
36.3* 
(34.7-37.9) 
Standard 23.7 
(20.4-24.2) 
24.0 
(21.2-24.2) 
21.9 
(18.7-24.4) 
21.6 
(18.8-23.8) 
21.1 
(19.8-22.4) 
H
a
em
a
to
lo
g
ic
a
l 
FM% 30.1 *  
(24.0-34.8) 
28.0 * 
(25.4-35.1) 
34.0 * 
(28.9-38.9) 
25.1 * 
(23.8-35.2) 
27.1 * 
(25.1-29.0) 
Standard 17.6  
(14.6-19.3) 
17.5  
(14.6-20.9) 
17.5  
(16.1-17.6) 
15.9  
(15.3-16.8) 
15.3  
(14.9-15.6) 
S
o
li
d
 
FM% 31.0 * 
(23.1-33.4) 
33.0 * 
(25.3-38.7) 
32.3 * 
(27.7-39.4) 
34.3 * 
(27.7-36.2) 
30.5 * 
(26.8-34.7) 
Standard 19.7  
(14.3-23.8) 
21.8  
(18.0-24.1) 
18.5  
(16.7-23.0) 
19.5  
(17.5-23.7) 
17.2  
(15.3-19.8) 
 
There was no significant association between FM% obtained from BIA and FM% 
(recruitment p>0.05, r= -0.61) or BMI centile (recruitment p>0.05). 
There was no significant difference in FM% between genders or diagnostic group at 
any point in time. Because of the longitudinal design, the limited number of patients 
and the many drop offs, it was not possible to statistically analyse the changes FM%. 
4.3.4 Comparison between incidence of undernutrition according to 
different assessment methods 
Overall, the highest numbers of undernourished patients were reported by TSF 
(29%) and MUAC (24%). The Kappa limit of agreement test showed a poor 
agreement between BMI and both TSF (K 0.083 p<0.05), and MUAC (K 0.063, 
p<0.05) at recruitment, which suggests that MUAC and TSF identified more 
undernourished patients than BMI alone. 
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4.3.5 The use of nutrition support 
Twenty one patients (81%) were referred to the oncology dietitian at some point 
during their cancer treatments. Of these cases, 15 (58%) were referred to the dietitian 
due to decreased oral intake or undernutrtion, and six (23%) for eating advice and/ or 
micronutrient supplementation. 
15 patients (58%) were recorded as having a need for NS as defined by the use of 
OCS (n= 9, 35%) , ETF (n= 9, 35%) or PN (n= 1, 4%), or any combination of these. 
A PEG was inserted for three of these patients (12%). Two patients (8%) were 
treated in Dundee and their dietetic information was not available. Four (16%) of 
these patients received NS via more than one route through the course of their 
treatment. Ten patients (67%) receiving NS had solid tumours, representing 77% of 
all children diagnosed with solid tumours during the data collection period; five 
patients (33%) had haematological malignancies, representing 50% of those with this 
diagnosis in the cohort. Eight (53%) of all NS required advanced NS (ETF +/- PN).  
Of those 15 patients requiring NS,Table 4.6 describes the use of NS according to the 
treatment modalities undergone.  
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Table 4.6 Distribution of the use of nutritional support according to treatment 
modalities 
Treatment modality Nutrition 
support 
Cases/total (%) 
Frequency of route of 
NS 
Advanced 
NS (% of 
total) 
OCS ETF PN 
Chemotherapy (13) 9 (69) 7 4 0 4 (31) 
Chemotherapy and surgery (5) 2 (40) 2 1 0 1 (20) 
Chemotherapy and radiotherapy (2) 1 (50) 0 1 0 1 (50) 
Chemotherpy, radiotherapy and 
surgery (4) 
2 (50) 0 2 1 2 (50) 
Radiotherapy only (-) 0 (-) 0 0 0 0 (-) 
Radiotherapy and surgery (-) 0 (-) 0 0 0 0 (-) 
Surgery only (1) 1/1 (100) 0 1 0 1 (100) 
No treatment(-) 0 (-) 0 0 0 0 (-) 
 
For all treatment modalities the highest needs for NS were in the chemotherapy only 
group, chemotherapy and radiotherapy, and chemotherapy, radiotherapy and surgery, 
at 69 % and 50% respectively. Chemotherapy and radiotherapy, and chemotherpy, 
radiotherapy and surgery had the highest needs for advanced NS (ETF +/- PN) with 
50% each.  
4.3.6 Energy and macronutrient intake 
4.3.6.1 Energy intake 
Energy intake with NS and ad libitum intake was calculated to verify adequacy at the 
individual level. Energy intake both ad libitum and with NS was compared to the 
energy requirements for each subject using the Henry prediction equation (Henry 
2005) adjusted for gender, age and physical activity. Table 4.7 shows the energy 
intake (kcal/d; median, IQR) ad libitum and with NS at each time point, according to 
diagnostic group and as percentage of energy individual requirements (Henry 2005). 
There were no significant differences between energy intake and energy 
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requirements according to gender or diagnosis (p>0.05). However, even though not 
significant, intake ad libitum expressed as percentage of EARs for the 
haematological group was higher (163%, IQR 131-196) than recommendations at 
recruitment (2076 kcal/d, IQR 1340-2525 vs. 1069 Kcal/d 1044 -1288, p>0.05) but 
lower (57%, IQR 46-62) at three months (928 kcal/d, IQR 906-1017 vs. 1532, IQR 
1422-1896).  
Similarly, intake with NS expressed as percentage of EARs for the haematological 
group was higher (163 %; IQR 141-196) than recommendations at recruitment (2076 
kcal/d, IQR 1453-2525 vs. 1069 Kcal/d 1045 -1288 p>0.05) but lower (62%, IQR 
46-72) at three months (1078 kcal/d, IQR 919-1206 vs. 1532, IQR 1423-1896). The 
daily energy intake expressed as a percentage of energy requirements was lower 
(p<0.05) in the haematological than solid group with both ad libitum food 
consumption and NS at three months. 
Table 4.8 shows the energy (kcal/d) intake (median, IQR) ad libitum and with NS at 
each time point according to gender and as percentage of energy individual 
requirements (Henry 2005). However, even though not significant (p>0.05), energy 
intake ad libitum (930 kcal/d, IQR 888-1200) was much lower (63%) that 
requirements (1326 Kcal/d, IQR 1260-1513) in the male group at three months. This 
was not observed with NS (89%).There was no significant difference in daily energy 
intake expressed as percentage of energy requirements between the two genders. 
Moreover, even though the energy intake ad libitum and with NS for the entire 
cohort and every subgroup were not significantly lower than energy requirements, 
few patients were identified as having their intake <80% of recommendation. The 
highest number of patients not meeting their requirements was observed at three 
months (n=8; 40%) followed by at six months (n=3; 27%).  
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Table 4.7 Energy (kcal/d) intake (median, IQR) ad libitum and with NS is shown at each time point according to diagnostic group. 
Energy intake ad libitum and with NS is also shown as a percentage of individual energy requirements. p<0.05 haematological 
group vs. solid group 
 Time point Energy requirement 
Kcal/d 
(Henry 2005) 
Energy intake  
ad libitum Kcal/d 
 
Energy intake ad 
libitum as % of EARs 
(Henry 2005 ) 
Energy intake Kcal/d 
With NS 
 
Energy intake with NS  
as % of EARs 
(Henry 2005)) 
H
a
em
a
to
lo
g
ic
a
l 
Recruitment 
n=10 
1069 (1045-1288) 2076 (1340-2525) 163 (131-196) 2076 (1453-2525) 163 (141-196) 
3 months 
n=8 
1532 (1423-1896) 928 (906-1017) 57 (46-62)* 1078 (919-1206) 62 (46-72)* 
6 months 
n=4 
980 (925-1176) 1453 (1316-1577) 140 (125-148) - - 
9 months 
n=4 
1448 (1375-1879) 2067 (1620-2641) 132 (81-193) 2100 (1762-2641) 146 (103-193) 
12 months 
n=3 
1366 (1355-1414) 1231 (774-1573) 90 (57-111) - - 
15-18 months 
N=2 
1388 (1377-1399) 1160 (939-1381) 83 (68-98) - - 
S
o
li
d
 
Recruitment 
n=16 
873 (463-951) 782 (321-1747) 136 (121-237) 1200 (866-1970) 194 (123-256) 
3 months 
n=12 
1165 (620- 1340) 1214 (778-1316) 105 (91-178)* 1305 (901-1488) 115 (90-186)* 
6 months 
n=8 
904 (827-1024) 1637 (1065-1835) 182 (101-209) 1677 (1359-1835) 182 (136-209) 
9 months 
n=6 
1257 (1152-1374) 1125 (363-1308) 103 (26-128) 1173 (1013-1342) 107 (90-128) 
12 months 
n=4 
1230 (1073-1375) 1254 (1130-1350) 111 (84-136) - - 
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Table 4.8 Energy (kcal/d) intake (median, IQR) ad libitum and with NS is shown at each time point according to gender. Energy 
intake ad libitum and with NS is also shown as percentage of energy individual requirements. 
 Time point Energy requirement 
Kcal/d 
(Henry 2005) 
Energy intake libitum 
Kcal/d 
 
Energy intake at libitum  
as % of EARs 
(Henry 2005 ) 
Energy intake Kcal/d 
With NS 
 
Energy intake with NS  
as % of EARs 
(Henry 2005)) 
M
a
le
 
Recruitment 
n=18 
951 (877-1056) 1696 (1340-2525) 124 (72-150) 1453 (1069-2525) 171 (102-234) 
3 months 
n=13 
1326 (1260-1513) 930 (888-1200) 63 (55-98) 1176 (930-1226) 89 (63-98) 
6 months 
n=7 
980 (914-1083) 1595 (1400-1714) 152 (137-176) - - 
9 months 
n=5 
1387 (1361-1509) 1807 (1714-2421) 133 (89-175) 1807 (1779-2421) 133 (118-175) 
12 months 
n=5 
1366 (1343-1462) 1205 (906-1231) 84 (57-93) - - 
15-18 months 
N=2 
1388 (1377-1399) 1160 (939-1381) 83 (68-98) - - 
F
em
a
le
 
Recruitment 
n=8 
841 (656-1284) 782 (322-1331) 123 (122-144) 1129 (982-1569) 123 (79-127) 
3 months 
n=7 
1080 (836-2305) 1213 (998-1255) 91 (67-164) 1446 (998-1680) 118 (56-187) 
6 months 
n=5 
827 (812-947) 1065 (1049-1637) 168 (90-224) 1379 (1081-1677) 201 (95-224) 
9 months 
n=5 
1153 (1152-1378) 1014 (146-1236) 90 (5-116) 1014 (1013-1333) 98 (88-116) 
12 months 
n=2 
987 (9020-1073) 1396 (1350-1442) 144 (136-152) - - 
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4.3.6.2 Protein, fat and carbohydrate intake. 
Protein intake ad libitum and with NS was significantly higher than RNI at each 
measurement in each diagnostic group (p<0.05 for all; Table 4.9) and for both 
gender (p<0.05 for all; Table 4.10). CHO intake at each time point for the entire 
cohort and according to gender and diagnosis are shown in Figure 4.12. Fat as 
percentage of total energy intake/d according to gender and diagnosis is shown in 
Figure 4.13. 
Althought fat intake as % of total energy intake for children over the age of five was 
higher than the reccomendations (35%) at three months (median 37.2, IQR 34.8-
38.0), the difference was not statistically significant (p>0.05).There was no 
significant difference in fat or CHO intakes between the two diagnostic groups 
(p<0.05) or genders (p<0.05) at any time point. 
Table 4.9 Median (IQR) protein intake g/d with NS and ad libitum according to 
gender  
  Protein intake with 
NS g/d 
Protein intake  
ad libitum g/d 
RNI (g/d) 
M
a
le
 
Recruitment 
n=18 
70.8 
(45.8-95.6) 
62.4 
(29.1-95.6) 
19.7 
(14.5-28.3) 
3 months 
n=13 
33.4 
(17.0-46.5) 
33.4 
(14.0-44) 
19.7 
(14.5-28.3) 
6 months 
n=7 
51.1 
(41.2-52.0) 
51.1 
(41.2-52.0) 
19.7 
(15.8-26.1) 
9 months 
n=5 
57.1 
(56.7-85.9) 
56.7 
(56.4-85.9) 
19.7 
(14.5-19.7) 
12 months 
n=5 
37.2 
(35.5-49.1) 
37.2 
(35.5-49.1) 
19.7 
(19.7-19.7) 
15-18 months 
N=2 
29.1 
(28.3-29.8) 
29.1 
(28.3-29.8) 
19.7 
(19.7-19.7) 
F
em
a
le
 
Recruitment 
n=8 
32.8 
(25.8-54.0) 
32.8 
(25.8-54.0) 
32.8 
(25.8-54.0) 
3 months 
n=7 
45.4 
(31.4-58.0) 
45.4 
(31.4-58.0) 
45.4 
(31.4-58.0) 
6 months 
n=5 
14.5 
(14.5-36.7) 
14.5 
(14.5-36.7) 
14.5 
(14.5-36.7) 
9 months 
n=5 
38.2 
(30.0-41.5) 
38.2 
(30.0-41.5) 
38.2 
(30.0-41.5) 
12 months 
n=2 
67.6 
(59.9-75.2) 
67.6 
(59.9-75.2) 
67.6 
(59.9-75.2) 
Recruitment 
n=8 
- - - 
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Table 4.10 Median (IQR) protein intake g/d with NS and ad libitum according 
to diagnostic group 
  Protein intake with 
NS g/d 
Protein intake ad 
libitum g/d 
RNI (g/d) 
H
em
a
to
lo
g
ic
 
Recruitment 
n=10 
70.8 
(63.8-101.3) 
70.8 
(60.0-101.3) 
28.3 
(19.7-42.1) 
3 months 
n=8 
31.6 
(25.9-47.6) 
31.6 
(25.9-35.6) 
28.3 
(19.7-42.1) 
6 months 
n=4 
45.2 
(35.5-53.3) 
45.2 
(35.5-53.3) 
19.7 
(18.4-25.3) 
9 months 
n=4 
71.5 
(56.9-90.7) 
71.2 
(55.8-90.7) 
19.7 
(19.7-25.3) 
12 months 
n=3 
35.5 
(25.9-45.9) 
35.5 
(25.9-45.9) 
19.7 
(19.7-19.7) 
15-18 months 
N=2 
29.1 
(28.3-29.8) 
29.1 
(28.3-29.8) 
19.7 
(19.7-19.7) 
S
o
li
d
 
Recruitment 
n=16 
45.8 
(21.4-68.4) 
31.7 
(9.6-61.6) 
19.7 
(14.5-19.7) 
3 months 
n=12 
44.7 
(27.4-49.0) 
40.7 
(11.2-46.4) 
14.5 
(14.5-28.3) 
6 months 
n=8 
50.7 
(35.1-51.2) 
38.5 
(35.1-51.2) 
14.9 
(14.5-28.3) 
9 months 
n=6 
39.9 
(32.1-47.9) 
41.5 
(38.2-50.0) 
14.5 
(14.5-14.5) 
12 months 
n=4 
50.7 
(46.1-59.9) 
17.1 
(14.5-21.9) 
17.1 
(14.5-21.9) 
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CHO as % of total energy intake according to gender (a)
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CHO as % of total energy intake according to diagnosis (b)
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Figure 4.12 CHO intake with NS as percentage of total daily energy intake 
according to gender (a) and diagnosis (b). 
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FAT as % of total energy intake according to gender (a)
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FAT as % of total energy intake according to diagnosis (b)
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Figure 4.13 Fat intake with NS as percentage of total daily energy intake 
according to gender (a) and diagnosis (b). 
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4.3.7 Effectiveness of NS on counteracting undernutrition 
The effectiveness of NS on counteracting undernutrition was tested by comparing 
mean BMI centiles before and after NS. On average, patients had an increased in 
BMI centile from initiation (median 17.0; IQR 3-48.5) to the end of NS (median 
34.5; 10.2-59.5), but the changes were not statistically significant (p>0.05). 
Median BMI centile was then compared according to the specific NS sub groups (OS 
and ENT). For the entire group of patients treated with NS the results showed a 
decrease in BMI centile from initiation (median 38.0, IQR 8.0 - 75.0) to the end of 
NS (median 32.0, IQR 10.0 - 91.0). However, this was not significant (p>0.05). On 
the other hand, for the entire group of patients treated with ENT the results showed a 
non-significant (p>0.05).increase in BMI centile from initiation (median 6.0, IQR 
0.2 - 36.5) to the end of NS (median 37.0, IQR 37.0 - 53.5).  
4.3.8 Physical activity 
Of the 26 patients recruited five were ineligible for the physical activity monitor 
since they were too young to stand and walk by themselves. Of the 21 patients 
available only two patients decided to take part to this part of the study. Of these 
two, one patient did not wear the Actigraph and the device was lost. The other 
patients returned it but data was unreadable. The patient then became palliative and it 
was not possible to repeat the measurement. Therefore physical activity was not 
measured for any of the patients. 
4.3.9 Biochemical profile 
The results for the screening of blood parameters are reported in Table 4.11 (median; 
IQR). Interpretation of the data based on median values in this cohort is problematic 
because the reference ranges for many blood parameters varies depending on the age 
and gender of the patient. Therefore, Table 4.11 also shows the prevalence of 
patients with higher or lower values as percentages of total cohort, and numbers for 
each time point according diagnosis. The blood results were compared against the 
reference values in use at the RHSC Edinburgh. 
4.3.9.1  Liver and renal function test 
The overall liver function test (ALP, ALT, bilirubin and GGT) showed a damaging 
effect of treatments on liver function. In the solid group, alkaline phosphatase (ALP) 
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was below the normal ranges for age in 15% (n=2), 11% (n= 1), 30% (n=1) of 
patients at recruitment, three moths and nine months respectively. In addition, ALP 
was below the normal range in 30% (n=3) and 13% (n=1) of patients in the 
haematological group at recruitment and three months respectively. 
Plasma alanine transaminase (ALT) was elevated in 15% (n=2), 11% (n=1) and 50% 
of patients in the solid group at recruitment, three months and six months 
respectively. In addition ALT was elevated in 60% (n=6), 38% (n=3), 25% (n=1) 
and 33% of patients in the haematological group at recruitment, three months, six 
months and 12 months respectively. 
The bilirubin median was within normal ranges in both solid and haematological 
group at all measurements. Although bilirubin median was normal, 20% (n=2) and 
25% (n=1) patients in the haematological group at recruitment and three months 
respectively had elevated plasma bilirubin. 
G-glutamyl transferase (GGT) was elevated in 20% of patients in the solid group at 
recruitment and in 50% (n=1) and 25% (n=1) of patients at six months in the solid 
and haematological group respectively  
Renal function assessment, showed that overall the patients in the study had 
electrolytes (potassium, sodium, magnesium) and plasma creatinine umol/l within 
the normal ranges for age for both solid and haematological groups at all 
measurements. 
Plasma urea (mmol/l) was elevated in 50% (n=5) of the haematological patients at 
recruitment (mean 6.6, SD 2.4). Low plasma urea was found in 15% (n=2) and 33% 
(n=3) of patients with solid tumours at recruitment and three months respectively. In 
addition, low plasma urea was observed in 25% (n=1), 33% (n=1), 33% (n=1), and 
50% (n=1) of patients with haematological cancers at six, nine, twelve and 
fifteen/eighteen months respectively. 
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4.3.9.2 Nutritional blood screening 
All the subjects had adequate concentration of plasma vitamin E/cholesterol at all 
measurements. Plasma folate was within normal ranges for age for all patients in 
both groups at all measurements except for one haematological patient (25%), who 
was found to have plasma folate below the normal range at six months. 
Plasma vitamin B12 was below normal range for 11% (n=1) and 33% (n=1) of solid 
tumour patients at three months and nine months respectively, and for 11% (n=1) 
and 33% (n=1) at recruitment and nine months respectively.  
Plasma selenium was decreased in 16 % (n=2), 11 % (n=1) and 33% (n=1) of the 
solid tumour group at recruitment and three months, respectively. In addition one 
hematologic patient (13%) had elevated selenium at recruitment and 3 patients 
(43%) at three months. 
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Table 4.11 Blood screening presented as median (IQR) at each time point according to diagnostic group, with prevalence of 
patients with abnormal plasma levels: ↑ = higher that reference range, ↓ = lower than reference range, T = toxicity level, B = 
borderline low 
  Solid Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal 
plasma level  
n (%) 
n Median (IQR) Abnormal 
plasma level  
n (%) 
Albumin g/l 
birth-3months maturity dependent 
>3-12 months 
27.0-42.0 
1-16 years 
28.0-45.0  
*b borderline low is referred to those 
patients with albumin equal to the 
lowest normal value in the normal 
range 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
12 
9 
2 
3 
- 
- 
 
37.0(34.0-38.0) 
39.5(34.0-40.25) 
39.5 (37.2-41.75) 
37.0 (34.5-38.0) 
- 
- 
 
0(-) 
0(-) 
0(-) 
0(-) 
- 
- 
 
7 
7 
4 
3 
2 
2 
 
5.9 (5.2-8.7) 
6.7 (6.2-7.6) 
5.4 (4.8-6.6) 
4.9 (3.7-6.4) 
8.7 (7.2-10.1) 
4.7 (4.1-5.2) 
 
0(-) 
0(-) 
↓1(25) 
0(-) 
0(-) 
0(-) 
Vitamin A µmol/l 
Birth – 12months 
 0.5 – 1.5 
1 – 7years 
 0.7 – 1.5 
7 – 13years 
 0.9 – 1.7 
13 – 19years 
 0.9 – 2.5 
Toxic levels >3.3 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
9 
8 
2 
2 
- 
- 
 
0.9 (0.7-1.3) 
1.2 (1.1-1.5) 
1.1 (1.0-1.2) 
1.3 (1.3-1.4) 
- 
- 
 
0(-) 
↓1(11) 
0(-) 
↓1(33) 
- 
- 
 
9 
7 
4 
3 
2 
2 
 
304.0(255.0-465.0) 
455.0 (310.0-636.0) 
364.0 (332.8-403.3) 
739.0 (371.6-762.0) 
830.5 (616.3-1044.8) 
417.0 (416.5-417.5) 
 
↓1(11) 
0(-) 
0(-) 
↓1(33) 
0(-) 
0(-) 
Vitamin D (25-Hydroxychole-
calciferol) nmol/l 
All ages 
<25.0 deficient 
25.0-49.0 
Borderline low. >50.0Adequate 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month  
 
9 
8 
2 
3 
- 
- 
 
53.0 (21.0-73.0) 
55.5 (45.8-82.0) 
30.0 (24.5-35.5) 
58.0 (42.5-81.5) 
- 
- 
 
↓1(13)↑2(25) 
↓2(33) 
0(-) 
0(-) 
- 
- 
 
8 
3 
2 
3 
2 
2 
 
3.2 (2.8-4.6) 
2.4 (2.1-3.5) 
3.4 (2.7-4.2) 
1.4 (1.3-1.6) 
2.7 (2.5-2.8) 
4.5 (4.3-4.8) 
 
↓1(13) 
0(-) 
0(-) 
↓2(67) 
0(-) 
0(-) 
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  Solid 
 
Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal 
plasma level  
n (%) 
n Median (IQR) Abnormal plasma 
level  
n (%) 
Folate µg/l 
1 – 12months 
 >7 
1-4years 
4 – 30 
4-16years 
3 – 20 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
5 
11 
2 
3 
- 
- 
 
16.5 (15.1-34.8) 
9.1 (8.0-12.1) 
15.1 (14.3-15.8) 
7.1 (5.5-11.2) 
- 
- 
 
0(-) 
0(-) 
0(-) 
0(-) 
- 
- 
 
7 
7 
4 
3 
2 
2 
 
5.9 (5.2-8.7) 
6.7 (6.2-7.6) 
5.4 (4.8-6.6) 
4.9 (3.7-6.4) 
8.7 (7.2-10.1) 
4.7 (4.1-5.2) 
 
0(-) 
0(-) 
↓1(25) 
0(-) 
0(-) 
0(-) 
Vitamin B12 ng/l 
0 – 5 years 
 280 – 1400 
5 – 16years 
 200 – 1100 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
8 
9 
1 
3 
- 
- 
 
565.5 (367.3-697.0) 
521.0 (273.0-822.0) 
802.0 (-) 
728.0 (456.5-856.0) 
- 
- 
 
0(-) 
↓1(11) 
0(-) 
↓1(33) 
- 
- 
 
9 
7 
4 
3 
2 
2 
 
304.0(255.0-465.0) 
455.0 (310.0-636.0) 
364.0 (332.8-403.3) 
739.0 (371.6-762.0) 
830.5 (616.3-1044.8) 
417.0 (416.5-417.5) 
 
↓1(11) 
0(-) 
0(-) 
↓1(33) 
0(-) 
0(-) 
PTH pmol/l 
All ages 1.6 - 7.5 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
8 
6 
2 
3 
- 
- 
 
 
3.4 (2.9-14.0) 
2.3 (1.3-2.8) 
3.2 (2.9-3.4) 
3.5 (3.5-3.7) 
- 
- 
 
↓1(13)↑2(25) 
↓2(33) 
0(-) 
0(-) 
- 
- 
 
8 
3 
2 
3 
2 
2 
 
3.2 (2.8-4.6) 
2.4 (2.1-3.5) 
3.4 (2.7-4.2) 
1.4 (1.3-1.6) 
2.7 (2.5-2.8) 
4.5 (4.3-4.8) 
 
↓1(13) 
0(-) 
0(-) 
↓2(67) 
0(-) 
0(-) 
 
↑= higher that reference range,↓ = lower than reference range, T = toxicity level, B = borderline low 
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  Solid 
 
Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal 
plasma level  
n (%) 
n Median (IQR) Abnormal plasma 
level  
n (%) 
Calcium mmol/l 
Birth-7 days  
1.6-2.7 
7days-1 month  
2.3-3.0 
 1-12 months  
2.3-2.8 
1-16 years 
2.2-2.7 
 
Recruitment 
3 month 
6 month 
9 month 
12month 
15/18 month 
 
13 
9 
2 
3 
- 
- 
 
2.3 (2.3-2.4) 
2.4 (2.3-2.5) 
2.5 (2.4-2.5) 
2.4 (2.4-2.4) 
- 
- 
 
↓1(8) 
↓2(22) 
(0) 
(0) 
- 
- 
 
 
10 
8 
4 
3 
3 
2 
 
2.1 (2.1-2.2) 
2.3 (2.2-2.4) 
2.4 (2.4-2.4) 
2.4 (2.4-2.5) 
2.4 (2.4-2.4) 
2.3 (2.3-2.3) 
 
↓6(60) 
↓2(25) 
(0) 
(0) 
(0) 
(0) 
Ferritin ug/l 
Birth-5 years  
12.0-80.0 
5-16 years  
15.0-80.0 
 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
10 
10 
2 
3 
- 
- 
 
249.5 (135.5-886.5) 
497.5 (41.0-952.0) 
2434.5(1521.8-3347.3) 
527.0 (296.0-996.5) 
- 
- 
 
↑9(90) 
↑5(50) 
↑2(100) 
↑2(67) 
- 
- 
 
9 
8 
4 
3 
2 
2 
 
449.0 (226.0-674.0) 
1165.0 (665.8-2468.8) 
1159.5 (724.8-2641.3) 
1188.0 (906.5-1579.0) 
609.5 (570.3-648.8) 
426.0 (320.0-532.0) 
 
↑9(100) 
↑8(100) 
↑4(100) 
↑3(100) 
↑2(100) 
↑2(100) 
Selenium umol/l 
Birth - 2years 
 0.2 – 0.9 
2 – 4years 
 0.5 – 1.3 
4 – 16years 
 0.7 – 1.7 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
12 
9 
2 
3 
- 
- 
 
0.8 (0.7-0.9) 
0.8 (0.7-1.0) 
0.8 (0.8-0.8) 
0.8 (0.7-0.9) 
 
↓2(16) 
↓1(11) 
0(-) 
↓1(33) 
- 
- 
 
8 
7 
4 
3 
2 
2 
 
1.4 (1.0-1.9) 
0.7 (0.7-1.0) 
0.8 (0.8-0.9) 
0.9 (0.8-1.0) 
1.0 (0.9-1.1) 
0.8 (0.8-0.8) 
 
↑1(13) 
↓3(43) 
0(-) 
0(-) 
0(-) 
0(-) 
↑= higher that reference range,↓ = lower than reference range, T = toxicity level, B = borderline low 
 
 
  
 
 
1
5
4
 
  Solid Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal plasma 
level  
n (%) 
n Median (IQR) Abnormal plasma 
level  
n (%) 
Cu µmol/l 
0-4 months 
1.5-7.0 
4-7 months 
4.0-17.0 
8-12 months 
8.0-20.5 
1-6 years 
12.5-20.5 
6-10 years 
13.0-21.5 
10-14 years 
12.5-19.0 
>14 years 
Male 10.0-22.0 
Female 11.0-25.0 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
12 
9 
2 
3 
- 
- 
 
22.0 (18.8-27.9) 
18.4 (17.3-23.0) 
22.2 (22.1-22.2) 
21.1 (17.9-22.5) 
- 
- 
 
↑7(58) 
↑2(22) 
↑2(100) 
0(-) 
- 
- 
 
8 
7 
4 
3 
2 
2 
 
10.8 (6.8-15.3) 
17.6 (16.9-22.0) 
18.2 (16.3-21.0) 
16.0 (13.5-19.0) 
14.9 (13.9-15.8) 
13.9 (12.4-15.5) 
 
0(-) 
↑2(29) 
0(-) 
0(-) 
0(-) 
0(-) 
 
 
Zn µmol/l 
All age 
12.8-18.0 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
12 
8 
2 
3 
- 
- 
 
10.2 (9.8-10.9) 
11.0 (10.2-11.1) 
8.7 (8.4-9.1) 
13.0 (11.0-13.2) 
- 
- 
 
↓12(100) 
↓7(88) 
↓2(100) 
↓1(33) 
- 
- 
 
8 
7 
4 
3 
2 
2 
 
 
9.3 (7.9-12.0) 
10.1 (10.0-10.6) 
12.0 (11.0-27.3) 
11.0 (11.0-19.0) 
12.0 (11.0-13.0) 
11.4 (11.3-11.6) 
 
 
↓6(75) 
↓7 (100) 
↓2(50) 
↑1(33) 
(0) 
↓2(100) 
 
HSCRP mg/l 
All ages <5 
 
Recruitment 
3 month 
6 month 
9month 
12 month 
15/18 month 
 
10 
9 
2 
3 
- 
- 
 
4.0 (2.0-13.3) 
2.0 (2.0-8.0) 
34.0 (20.5-47.5) 
1.0 (1.0-2.5) 
- 
- 
 
↑4(40) 
↑3(33) 
↑2(100) 
0(-) 
- 
- 
 
9 
6 
3 
3 
1 
2 
 
2.0 (2.0-3.0) 
18.0 (2.0-37.0) 
2.0 (1.5-4.5) 
1.0 (1.0-1.5) 
2.1 (-) 
1.0 (1.0-1.0) 
 
↑2(22) 
↑3(50) 
↑1(33) 
0(-) 
0(-) 
0(-) 
↑= higher that reference range,↓ = lower than reference range, T = toxicity level, B = borderline low 
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↑= higher that reference range,↓ = lower than reference range, T = toxicity level, B = borderline low 
 Solid Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal plasma 
level  
n(%) 
n Median (IQR) Abnormal 
plasma level 
n (%) 
Bilirubin umol/l 
All ages <20.0 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
12 
9 
2 
3 
- 
- 
 
4.5 (4.0-5.3) 
5.0 (3.0-9.0) 
9.5 (8.8-10.3) 
7.0 (4.5-8.5) 
- 
- 
 
0(-) 
0(-) 
0(-) 
0(-) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
12.0 (9.5-16.3) 
7.0 (5.8-9.5) 
10.0 (8.3-16.8) 
6.0 (5.5-19.0) 
7.0 (6.0-14.0) 
5.5 (5.3-5.8) 
 
 
↑2(20) 
0(-) 
↑1(25) 
0(-) 
0(-) 
0(-) 
G-glutamyl transferase 
(GGT)units/l 
Birth-2 months <200.0 
1-16 years <40.0 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
13 
9 
2 
3 
- 
- 
 
18.0 (11.0-39.0) 
24.0 (10.5-30.0) 
107.0 (70.0-144.0) 
14.0 (12.5-17.0) 
- 
 
↑3(20) 
0(-) 
↑1(50) 
0(-) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
19.5 (14.0-30.5) 
17.5 (17.0-21.3) 
23.5 (14.3-35.5) 
12.0 (11.5-32.0) 
13.0 (12.0-19.5) 
9.5 (8.3-10.8) 
 
0(-) 
0(-) 
↑1(25) 
0(-) 
0(-) 
Alkaline phosphatase(ALP) 
birth – 1 month 
 80 – 440 
1 – 6 months  
120 – 580 
6 months – 1year 
 110 – 430 
1 – 12years  
100 – 400 
12 – 16 years  
Males 100 – 400 Females 60 – 400 
 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
 
13 
9 
2 
3 
- 
- 
 
133.0(118.0-180.0) 
155.5 (122.3-194.8) 
220.0 (215.5-224.5) 
136.0 (112.5-142.5) 
- 
- 
 
 
↓3(23) 
↓1(11) 
0(0) 
↓1(30) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
115.5 (86.8-140.0) 
129.0 (105.8-152.8) 
161.0 (154.8-164.8) 
159.0 (144.0-171.0) 
182.0 (163.5-187.0) 
170.5 (151.8-189.3) 
 
↓3(30) 
↓1(13) 
0(0) 
0(0) 
0(0) 
0(0) 
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↑= higher that reference range,↓ = lower than reference range, T = toxicity level, B = borderline low 
  Solid Haematological 
Test  
Normal range 
Measurement n Median (IQR) Abnormal plasma 
level  
n(%) 
n Median (IQR) Abnormal plasma 
level 
n (%) 
Alanine transaminase (ALT) 
unit/l 
birth-12 months <65.0 
1-16 years <50.0 
 
 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
13 
9 
2 
3 
- 
- 
 
26.0 (22.0-36.0) 
28.0 (14.0-45.3) 
77.5 (65.8-89.3) 
15.0 (12.5-22.5) 
- 
- 
 
↑2(15) 
↑1(11) 
↑1(50) 
0(0) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
62.0 (29.8-76.8) 
56.0 (32.5-103.0) 
43.0 (28.5-77.5) 
28.0 (21.0-31.5) 
19.0 (17.5-46.0) 
19.0 (16.5-21.5) 
 
↑6(60) 
↑3(38) 
↑1(25) 
0(0) 
↑1(33) 
0(0) 
 
Urea mmol/L 
2 weeks-1month 
 0.08-0.39 
1 months-12months 
1.2-5.0 
1-16 years  
2.4-6.5 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
13 
9 
2 
3 
- 
- 
 
3.5 (2.6-4.4) 
3.1 (2.0-4.3) 
4.2 (3.3-5.0) 
2.8 (2.8-3.0) 
- 
- 
 
↓2(15) 
↓3(33) 
0(-) 
0(-) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
 
7.8 (4.7-8.8) 
3.9 (3.2-4.2) 
3.5 (3.1-3.8) 
4.0 (3.1-5.0) 
3.7 (2.9-4.7) 
3.1 (2.2-3.9) 
 
↑5(50) 
0(-) 
↓1(25) 
↓1(33) 
↓1(33) 
↓1(50) 
Phosphate mmol/l 
1-12 months 
0.8-2.6 
1-16 years 
1.0-2.1 
 
Recruitment 
3 month 
6 month 
9 month 
12 month 
15/18 month 
 
 
13 
9 
2 
3 
- 
- 
 
 
1.4 (1.1-1.6) 
1.4 (1.3-1.5) 
1.5 (1.3-1.6) 
1.6 (1.3-1.6) 
- 
- 
 
 
↓2(15) 
0(0) 
0(0) 
0(0) 
- 
- 
 
10 
8 
4 
3 
3 
2 
 
1.1 (1.0-1.3) 
1.5 (1.4-1.6) 
1.6 (1.5-1.7) 
1.5 (1.3-1.6) 
1.6 (1.5-1.6) 
1.6 (1.5-1.6) 
 
 
↓1(10) 
0(0) 
0(0) 
0(0) 
0(0) 
0(0) 
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4.3.9.3 Vitamin D, PTH and calcium axis 
Median levels of plasma 25(OH) D, the prevalence of vitamin D deficiency and 
borderline low according to plasma 25(OH) D concentrations are shown in Table 
4.12. 
Table 4.12 25 (OH) D nmol/l plasma concentration (median IQR) and 
prevalence of vitamin D deficiency (plasma 25(OH) D < 25 nmol/l) and 
borderline low (plasma 25(OH) D >25 <50 nmol/l) at each measurements. 
Measurement  Deficiency  
(plasma 25(OH) D 
< 25 nmol/l) 
Borderline low  
(plasma 25(OH) D >25 
<50 nmol/l) 
Median (IQR) 
Diagnosis (n=16) 31% (n=5) 44% (n=7) 40.0 (23.0-71.0) 
3 month 
(n=14) 
14% (n=2) 43% (n=6) 49.0 (44.5-66.0) 
6 month 
(n=3) 
33% (n=1) 67% (n=2) 40 (34-46.25) 
9 month 
(n=6) 
- 16.7 % (n=1) 56.5 (45.0-69.5) 
12 month 
(n=2) 
- - 69.0 (63.0-75.0) 
15/18 month 
(n=1) 
- 100 (n=1) 23.0 (19.0-28.5) 
 
The difference between plasma 25(OH) D in the two diagnostic groups was not 
significant at any measurement (p > 0.05). However, the prevalence of vitamin D 
deficiency at diagnosis was higher in the solid tumour group (44%) compared to the 
haematological group (29%). At three months 33% of haematological group were 
vitamin D deficient compared to 0% for the solid tumour group. There was no 
statistical difference (p>0.05) between the plasma 25(OH) D (nmol/l) during summer 
months (beginning of May to the end of September: recruitment median 44.0, IQR 
25.8-75.7, three month median 39.0, IQR 18.8-101.2) and winter months 
(recruitment median 38.5, IQR 16.0-53.5; three month median 51.0, IQR 47.5-51.0).  
Vitamin D status has been reported to negatively correlate with BMI (Baradaran et 
al. 2012; Goshayeshi et al. 2012; Zwart et al. 2011). However, the non significant 
association between BMI and centile at baseline and vitamin D status was observed 
in the current population. However, from the graphical representation (Figure 4.14), 
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it is apparent that low plasma 25(OH) D was associated with both very low and very 
high BMI centiles. 
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Figure 4.15 Correlation between BMI centile and plasma 25(OH) D at baseline 
Reporting of the results for vitamin D took between two to three months from the 
time of the blood tests. Therefore vitamin D supplementation was initiated based on 
these results, but took several months to begin. During data collection vitamin D 
supplements (10 µg /d ergocalciferol) were prescribed to seven patients after being 
found to have hypovitaminosis D. Only two patients supplemented with vitamin D in 
this period, had plasma 25(OH) D available before and after intervention. For both 
patients, plasma 25(OH) D increased up to the normal range. 
Because of the effect of low plasma 25 (OH) D on PTH secretion and bone turnover, 
plasma PTH was also measured. Of the patients with vitamin D deficiency at 
diagnosis, 50% had secondary hyperparathyroidism. Hyperparathyroidism was not 
present thereafter. Hypoparathyroidism presented in 13 % of both solid and 
haematological cases with normal concentrations of plasma 25(OH) D. There was no 
statistical difference in plasma PTH at any of the time point (p>0.05). Neither was 
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there any significant correlation between PTH and 25(OH) D variables (p>0.05) at 
any point in time (Figure 4.16). 
0 25 50 75 100 125 150
0
10
20
50
60
Recruitment p>0.05, r=0.35
3 Months p>0.05 r=0.61
Correlation between PTH pmol/l and 25(OH)D nmol/l
25-hydroxyvitamin D, nmol/l
P
T
H
 p
m
o
l/
l
 
Figure 4.16 Relationship between 25- hydroxyl vitamin D and PTH. 
Because of the role of vitamin D in calcium absorption and metabolism, calcium was 
also measured. Plasma calcium according to diagnostic group is shown in Table 
4.11. Of the patients with solid and haematological cancers, 8% and 60% 
respectively had low plasma calcium upon recruitment. Moreover, 22% and 25% of 
patients with solid and haematological cancers respectively had low plasma calcium 
at three months. Plasma calcium was within the normal ranges after this point (Table 
4.11). Comparison between the solid and haematological group was not possible 
because of the difference age ranges and the small sample size. 
Figure 4.17 shows the relationship between plasma calcium and 25(HO) D at 
recruitment and three months. There was no significant correlation between the two 
variables (p>0.05). However, many patients with low plasma 25(OH) D, had plasma 
calcium below the normal ranges. 
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Figure 4.17 Relationship between plasma calcium and 25-(OH) D. The patients 
with plasma calcium between 2.2 and 2.3 and 25-(OH) D below 50 mmol/l were 
older than one year therefore within the normal values. 
Low plasma phosphate can be caused by vitamin D deficiency. At recruitment 
phosphate (mmol/l) was below normal ranges for age, for 15% (n=2) patients in the 
solid group and 10% (n=1) patients in the haematological group. There was no 
significant correlation between the two variables (p>0.05) at any point in time. 
However, the patients with low plasma 25(OH) D had also plasma phosphate below 
normal. 
4.3.9.4 Serum vitamin A supplementation and toxicity. 
Plasma vitamin A was elevated but below toxicity levels in 11% (n=1) of patients in 
the solid group at recruitment and 26% (n=2), and 25% (n=2) of patients in the solid 
and haematological group respectively, at three months. The patients with elevated 
vitamin A were not supplemented with vitamins at the time of measurement and 
plasma vitamin A returned within normal ranges thereafter. However, plasma 
vitamin A was below normal ranges in 25% (n=2) in the haematological group at 
three months. During data collection four patients were supplemented with a 
multivitamin solution for children (ABDEC, Parke-Davis/Pfizer) containing retinol 
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as vitamin A palmitate, at 733 mg/ day for children and 362.5 mg/d for babies. One 
of the supplemented patients had elevated vitamin A before starting 
supplementation. Of the four supplemented patients, plasma vitamin A was only 
available for two patients, because one started supplementation after the last blood 
test recorded and one did not have further blood test carried out after 
supplementation was started.  
 
Figure 4.18 Vitamin A plasma levels in the two supplemented patients. 
Figure 4.18 shows vitamin A plasma levels in the two supplemented patients. 
Supplementation started after the third month for patient 9 and after the ninth month 
for patient 1. Remarkably plasma vitamin A reached toxicity level after three months 
supplementation, upon which point supplementation was stopped. Plasma vitamin A 
returned to normal in patient 1 after supplementation was stopped. It was not 
possible to assess plasma vitamin A after the supplementation was stopped for 
patient 9 because the blood was not collected thereafter.  
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4.3.9.5  C reactive proteins, albumin copper, zinc, selenium and ferritin 
Median hsCRP mg/l (Table 4.11) was above the normal range in the solid group at 
six months (median 34, IQR 20.5-47.5) and in the haematological group at three 
months (median 18, IQR 2.0-37.0). In the solid cancer group, 40% (n=4), 33% (n=3) 
and 100% (n=2) of patients had elevated plasma hsCRP at recruitment, three months 
and six months respectively. Similarly, in the haematological malignancies group, 
22% (n=2), 50% (n=3) and 33% (n=1) of patients had elevated plasma hsCRP at 
these time points. 
At recruitment, albumin was borderline low in 15% (n=2) patients in the solid group 
and in 33% (n=3) patients in the haematological group. Serum albumin returned to 
normal at three months. 
Zinc was decreased in both groups at each measurement apart in the haematological 
group at 12 months when plasma zinc was within normal range, and with one 
haematological patient observed to have high levels at nine months. Ferritin was 
elevated in 100% of haematological patients at each measurement and in 90% (n=9), 
50% (n=5) 100% (n=2), 67% (n=2) of the solid group at recruitment, three months, 
six months and nine months respectively. 
In order to assess whether low serum levels of albumin, Se and zinc and elevated 
serum copper and ferritin were caused by inflammation they were then analysed in 
relation to increased plasma hsCRP. Table 4.13 shows the numbers and percentage 
of patients with levels of albumin, Se, copper, zinc and ferritin seen in acute phase 
response in relation to hsCRP.  
  
  
163 
 
Table 4.13 Number and % of patients with abnormal plasma value which also 
had hsCRP above normal range 
 Recruitment 
n (%) with 
hsCRP >5 
mg/L 
3 Months 
n (%) with 
hsCRP >5 
mg/L 
6 Months 
n (%) with 
hsCRP >5 
mg/L 
9 Months 
n (%) with 
hsCRP >5 
mg/L 
12 Months 
n (%) with 
hsCRP >5 
mg/L 
15/18 
Months n 
(%) with 
hsCRP >5 
mg/L 
↑Albumin 2 (40) 
2 CRP not 
available 
- - - - - 
↓Selenium 1 (50) 2( 50) 
2 CRP not 
available 
- 0(-) - - 
↓Zinc 3 (25) 
3 hsCRP not 
available 
6 (43) 
2 hsCRP 
not 
available 
3(75) 
1 hsCRP 
not 
available 
- - - 
↑Copper 4(36) 
1 hsCRP not 
available 
4(100) 4(100) - - - 
↑Ferritin 5(28) 6(46) 
2 hsCRP 
not 
available 
3(50) 
1 hsCRP 
not 
available 
0(-) 0(-) 
1 hsCRP 
not 
available 
0(-) 
 
Many hsCRP values were missing. However, this comparison shows that between 
25% and 100% of the abnormal levels of those acute phase reactants occurred at 
elevated plasma hsCRP concentration. 
4.4 Discussion 
The current study has prospectively examined the changes in nutritional status with 
simultaneous anthropometry, BIA, and dietary intake in children with several types 
of cancer, from diagnosis. This study followed the patients for an extended period of 
time, from diagnosis through the progression of disease. Therefore, it allowed 
analysis of changes in nutritional status in response to treatment, and nutritional 
intervention. 
In the current investigation, the risks for both undernutrition and obesity were 
explored. Despite the strong evidence of an increased risk of undernutrition during 
cancer therapy, the evidence base on nutritional care in children and young people 
with cancer is scarce and fragmented. Moreover, despite strong evidence to show an 
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increased risk of late onset of obesity in this cohort, little attention has been paid to 
the clinical management of obesity during childhood cancer therapy. The causes of 
obesity in this cohort remain unclear. Therefore understanding the factors that 
contribute to the development of malnutrition, both undernutrition and obesity will 
prove central in the better nutritional management during childhood cancer therapy. 
A novel aspect of this study is that it longitudinally investigated the micronutrient 
status during childhood cancer therapy. This study showed that micronutrient status 
can be negatively affected during treatment for childhood cancers. The evidence 
generated in this study suggests that micronutrient status should also be a focus of 
nutritional care in this patient group. 
4.4.1 Study population 
An average of 55-60 patients is referred to the oncology/haematology team at the 
RHSC in Edinburgh every year. During the 18 month data collection period of the 
current study, only 64 patients were referred to the oncology/haematology service, 
which is a third smaller than average recorded by the service. Of those patients, 13 
were not diagnosed with cancer and hence discharged from the service. Only 51 
were diagnosed with childhood / teenager cancer, or with benign brain tumours, of 
which a third did not meet the inclusion criteria for different reasons. Many patients 
with benign brain tumours were diagnosed after they were discharged and did not go 
back to the service for many months. Hence, they were considered ineligible as they 
did not have any on-going care. A few patients were palliative or died soon after they 
were diagnosed, and could not be included in the study. Other patients were 
unsuitable because of social circumstances, as one of the parents was in palliative 
care. Finally a patient was considered unsuitable due to clinical reasons as advised 
by the consultants.  
Of those eligible, a quarter did not take part to the study because they felt it was to 
stressful at the time. Because of the study design and its prospective nature, the 
patients and their families were approached soon after diagnosis, when advised 
appropriate by the oncology/haematology team. However, this period is extremely 
traumatic for the family and they are overwhelmed with information regarding the 
  
165 
 
diagnosis and the treatments to follow. Furthermore, there are other priorities such as 
deciding whether to participate to a clinical trial. Clinical trials are standard care in 
the treatment of childhood cancer, and the decision to join a clinical trial must be 
made very rapidly after diagnosis. There are both benefits and risks of taking part in 
a clinical trial; hence making the decision can be quite stressful for the families. 
Because of the above reasons, this study had been sometimes perceived as additional 
stress for something which would not have benefit for the patient. Even thought the 
importance of research and the role of nutrition in cancer care were comprehensively 
explained at recruitment, the recruitment rate is reflective of the nature of the 
disorder. The recruitment ratio was comparable to recruitment of a previous study 
carried out in the same cohort (Reilly et al. 2001). 
The most common diagnosis in this prospective cohort was leukemia followed by 
the soft tissue sarcoma and neuroblastoma. The incidence of each type of childhood 
cancer does not appear to reflect the incidence in the UK population (Cancer 
Research UK 2012) or Scottish population (Information Service Division Scotland 
2012). Because of the small sample size and low recruitment rate, some diagnosis 
were missing from this cohort such as bone, epithelial and haepatic cancers.  
The results of the prospective study showed unequal distribution of childhood and 
teenage cancers between the genders, which does not reflect the national data 
(Cancer Research UK 2012; Information Service Division Scotland 2012). This 
discrepancy is likely to be caused by the small sample size and by the high 
percentage of patients with ALL, as this particular diagnosis is more common in 
boys than girls. The age distribution was comparable to the data collated by Cancer 
Research (Cancer Research UK 2012) with some cancers such as leukaemia and soft 
tissue sarcoma having the highest incidence rate in the first few years of life, and 
lymphomas having the peak in adolescence (Information Service Division Scotland 
2012). However, when analysed according to the more general definition of 
haematological and solid tumours, the data reflected the national population (Cancer 
Research UK 2012; Information Service Division Scotland 2012). Furthermore, this 
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study covered similar age groups to the published literature that included all the 
childhood cancer diagnosis (Pietsch and Ford 2000; Smith et al. 1991). 
The survival rate was analysed at the last collection point. However, in comparison 
to the national data was not possible because the data on survival are generally based 
on five year survival (Cancer Research UK 2012; Information Service Division 
Scotland 2012), whereas the survival rate in this study was recorded between a 
minimum of two months from diagnosis to maximum 18 months. Due to the limited 
numbers available and the extent of protocols and regimens used to treat childhood 
cancer, it was not possible in this study to analyse the data according to treatment 
protocol. The treatments were therefore categorised according to more general 
definitions. 
The diagnostic information on the patients who refused to participate could not be 
recorded for ethical reasons. Therefore, it was not possible to assess whether their 
demographic and diagnosis reflected those of the participants, and it was not possible 
to statistically establish if a selection bias was present. 
In this current study, patients with a diagnosis associated with high nutritional risk 
(Betcher and Ablin 1993; Han-Markey 2000; Rickard et al. 1986), were either 
diagnosed in the final months of the study, or became palliative very quickly; 
therefore, they could not be monitored for an extended period. Consequently, some 
extent of bias may have been introduced, and it could be possible that the 
observation in this study may be responsible for underestimating the risk of 
undernutrition. 
4.4.2 Nutritional status 
The assessment of nutritional status is essential in the nutritional management of 
children treated for cancer. However, it has been proven difficult because of the 
limitation of the assessment methods in this particularly cohort. Studies of nutritional 
status of children have been based on a variety of anthropometric measurements such 
as arm anthropometry, BMI centile and BIA. The aim of this current study was to 
prospectively assess nutritional status changes and the prevalence of malnutrition 
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(both undernutrition and overnutrition) using BMI centiles, MUAC, TSF and BIA 
techniques. This has allowed a more comprehensive assessment of nutritional status 
and the evaluation of the differences in measurements in this specific cohort. 
This current study showed that the highest prevalence of nutritional deprivation was 
among the solid group with BMI centile median below the 50
th
 centile for the first 
nine months of treatments. The low BMI centiles were associated with an increased 
prevalence of undernourished children compared to the expected prevalence of 
undernutrition for the UK population (Department of Health 2012). In contrast, the 
haematological group had a BMI centile median above the 50
th
 centile for the first 
nine months of treatment, and none of the patients were classified as undernourished. 
Although, the prevalence of obesity and overweight observed in the current study 
among the haematological group was higher that the expected prevalence for the UK 
population, the difference was significant only at six months. The lack of 
significance is likely to be caused by the small sample size.  
When the cohort was stratified according to gender it become apparent that both 
boys and girls had a higher prevalence of undernutrition at diagnosis compared to the 
expected prevalence for the UK population. In contrast, the prevalence of obesity 
and overweight was comparable to the expected prevalence for the UK population. 
Due to the limited numbers and the many drop outs it was not possible to statistically 
analyse the changes over time by ANOVA. Although the median and the 
percentages provide important information in respect to a specific time point, it is not 
possible to draw any conclusions regarding changes over time. Thus, the data from 
this study can only be interpreted in relation to each individual time point. 
The variance observed in BMI centiles in this study could put doubt on the 
interpretation of the results. However, because the cohort were children treated for 
cancer, the degree of variation observed is likely to be a reflection not only on the 
cancer and its treatments on nutritional status, but also the small sample size. BMI 
centiles are based on reference data and interpretation of the data requires a degree of 
confidence on the adequacy of the standard used. In this study the revised version of 
  
168 
 
the 1990 UK reference value (Cole et al. 1995) was used which have been reported 
to be adequate to assess growth in children (Savage et al. 1999). Therefore, the use 
of this reference was believed not to be a concern when the study was designed. 
However, in 2011 new standards for children 0-4 years were adopted (RCPCH 2011) 
which closely reflects the current UK recommendations for infant feeding. They are 
believed to be more appropriate for growth monitoring (SACN/RCPCH 2007). 
It has been reported that the new reference data identifies fewer children as 
underweight, but it is likely to identify more obese children (SACN/RCPCH 2007). 
Therefore, it could be argued that the prevalence of malnutrition observed in this 
study may not represent the cohort accurately and that this current study may have 
overestimated undernutrition and underestimated obesity. However, when the 
prevalence of malnutrition is considered in conjunction with arm anthropometry it 
appears that BMI centiles alone tend to underestimate the prevalence of 
undernutrition.  
Additionally, malnutrition was assessed using BMI centile cut off points. There are a 
number of thresholds to which BMI can be compared to and it is unknown which 
one is the most suitable for children with cancer. Recently the SACN/RCPCH (2011) 
recommended < 2.3
nd
 centile as cut off point for undernutrition for children 2-18 
years. This value corresponds to -2SDS and it has been widely used in the literature 
to assess undernutrition in children with cancer (Pietsch and Ford 2000; Reilly et al. 
1999). However, WHO recommend a more rigorous definition of undernutrition in 
adolescents as BMI below the 5
th
centile (World Health Organisation 1995). 
Moreover some authors have employed an even more severe definition of 
undernutrition (<15
th 
centile= moderate undernutrition; <5
th
 severe undernutrition) 
(Sala et al. 2012). This inconsistency in the threshold used to assess undernutrition 
for the general population casts into doubt the adequacy of these cut off points to 
assess undernutrition in children during cancer therapy. It has been shown that most 
undernutrition related mortality occurs with both mild and moderate undernutrition 
(Pelletier and Frongillo 2003). Therefore, if the likelihood of a rapid nutritional 
deterioration during cancer therapy is also considered, it may be important to 
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distinguish between grades of undernutrition during childhood cancer treatments and 
to use more rigorous definition of undernutrition.  
Another limitation of the use of BMI centiles to assess nutritional status during 
cancer treatments is the accuracy of the height and weight measurements. However, 
in this study the observers’ TEM was shown to be low. Therefore, it is unlikely to 
have influenced the results and conclusions drawn in this study. However, if the 
TEM influenced the results, it would have increased the variance but would have not 
biased the results. 
The findings in this study support the observation that nutritional depletion is 
common during treatment for solid cancer especially at diagnosis (Garofolo et al. 
2005; Smith et al. 1991). On the other hand, nutritional depletion appeared to be 
uncommon in children in the haematological group in this study. Although 
undernutrition is a well known problem at diagnosis in solid cancer patients, the 
evidence for undernutrition in haematological patients remains controversial.  
Comparison of the findings of this study and the prevalence of undernutrition 
reported in other studies is difficult due to the variation in the diagnosis studied, the 
anthropometrical parameters used and the cut off points used to define 
undernutrition. Several authors have reported no indication of nutritional deprivation 
in children treated for ALL at diagnosis (Uderzo et al. 1996) or during treatment 
(Delbecque-Boussard et al. 1997) when compared against healthy subjects. 
However, others (Reilly et al. 1999; Yu et al. 1994; Yu et al. 1994) have identified 
poor nutritional status at diagnosis.  
Reilly et al. (1999) showed a significant increase in the prevalence of undernutrition 
assessed by BMI SDS compared to the expected frequencies for the UK population 
in a cohort of 1019 patients. Although the study (Reilly et al. 1999) used comparable 
methodology to this current study, the results are in contrast. This is probably due to 
the small sample size in this current study. Moreover, Reilly et al. (1999) were likely 
to have included a broader variety of ALL risk groups, and hence to have included 
patients with high risk ALL which are at higher risk of nutritional deprivation 
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(Betcher and Ablin 1993; Han-Markey 2000; Rickard et al. 1986). This group were 
not present in the current study. Another important aspect that may have affected the 
results in the current study is the masking effect of obesity on undernutrition. BMI 
centiles should be interpreted in relation to pre-illness weight and weight loss. 
However, in the current study, this information was not recorded, mainly because 
most of the parents were unable to recall the information. Therefore, although 25% 
of the haematological patients were classified as obese by BMI centiles at diagnosis, 
they might have been undernourished if assessed using a weight loss parameter. 
A unique aspect of the current study is the assessment of the prevalence of 
overweight and obesity during childhood cancer treatments. Previous studies have 
documented the increased risk of obesity during both treatment (Odame et al. 1994; 
Reilly et al. 2000; Reilly et al. 1996; Van Dongen-Melman et al. 1995) and in later 
life (Dalton et al. 2003; Meacham et al. 2005; Oeffinger et al. 2003; Warner et al. 
1995). Although, the observed increase in the prevalence of obesity in this study is in 
line with the literature, quantitative comparison is very difficult. For example, Reilly 
et al. (2000) reported an increased prevalence of obesity measured as BMI SDS > 2, 
from 5% at diagnosis, to 4% at one year and 9% at three years, in 98 newly 
diagnosed ALL patients. However, these figures are much lower that those observed 
in the current study. This inconsistency is likely to be caused by the small sample 
size in this cohort. The small sample size is also likely to have caused the lack of 
significance observed when the cohort was compared to the UK prevalence of 
obesity. However, although not significant, this finding highlights the issue of excess 
body weight during treatment for ALL and should not be underestimated.  
It has been previously suggested that cranial radiotherapy, may cause increased 
energy intake or/and reduced REE (Groot-Loonen et al. 1996; Odame et al. 1994; 
Oeffinger et al. 2003). However, in the past 20 years CRT is not given routinely, and 
no patients in this current study were treated with CRT. Therefore, CRT can not be 
an underlying cause of the excess fat gain observed in this study. A study in ALL 
patients experiencing excess weight gain showed that the positive energy balance 
was not caused by decreased REE (Reilly et al. 1996), and recently, reduced physical 
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activity has been recognised as the main cause of reduced energy expenditure (Reilly 
et al. 1998). Moreover, steroid therapy leads to an increase in energy intake during 
ALL treatments, contributing further to the positive energy balance (Reilly et al. 
2001). Therefore, the excess body weight and fat deposition observed in this study is 
likely to be a consequence of steroid treatment and reduced physical activity. 
However, in this study physical activity was not measured due to the lack of patient 
compliance. Consequently, the contribution of reduced physical activity on excess 
weight gain is unknown.  
Reilly et al. (2000) identified low BMI SDS at diagnosis, and young age as risk 
factors for excess weight gain during ALL treatments. These patient characteristics 
at diagnosis are routinely measured and recorded during the clinical management of 
ALL. Therefore, they could form the basis for targeting a prevention programme. 
However, in the current study, due to the limited sample size, it was not possible to 
test the influence of those factors on excess weight gain. Moreover, none of the 
patients in this current study had particularly low BMI at diagnosis. 
In the current study, TSF and MUAC measurements were used to estimate energy 
stores of subcutaneous fat, and protein reserves stored as lean body mass during 
treatments. This research showed that BMI changes overtime were associated with 
anthropometrical changes that were outwith the technical error of measurement of 
the researcher. Arm fat mass centile correlated with BMI centiles.  
Although not statistically significant, this study showed that the solid tumour group 
had depleted fat stores during the first three months of treatments, with upper arm fat 
area values decreasing from 78% at diagnosis to around 70% of standard at three 
months. Fat stores returned to normal levels by six months. On the other hand, 
haematological patients had excess fat reserves during treatments. Upper arm fat 
area, expressed as percentage of standard value, reached a peak at three months after 
diagnosis, with a value of 130% of standard. Similarly, the muscle reserves were at 
their peak at three months (134% of standards). Interestingly, arm muscle mass 
decreased by up to 88% of standards after nine months of treatment. The prevalence 
of obesity peaked at three months with more than 60% of the haematological patients 
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having their TSF and MUAC over the 90
th
 centiles. A very interesting finding of this 
study is that none of the haematological patients was classified as undernourished by 
arm anthropometry during the entire collection period. Prevalence of undernutrition 
was highest at diagnosis and disappeared after six months. Interestingly none of the 
patients treated for solid cancer was classified as obese. However, statistical 
comparison of the observed frequencies of malnutrition assessed by arm 
anthropometry in this study against the prevalence of malnutrition for the UK 
population was not possible because there are no expected frequencies of 
malnutrition obtained based on these measurements. 
It can be assumed that solid cancer and its treatments cause FM depletion but not 
muscle mass depletion, especially at diagnosis. Therefore, this suggests a negative 
energy status existing from pre-diagnosis. These findings are in line with the 
published literature which indicates an increased REE in relation to tumour burden 
and a normalising effect of cancer therapy (den Broeder et al. 2001; Schmid et al. 
2005; Stallings et al. 1989; Vaisman et al. 1993). Moreover, it could also be 
postulated that the depleted fat stores may be a reflection of anorexia and resultant 
decreased energy intake caused by the acute phase response (Falconer et al. 1994; 
Staal-van den et al. 1995). The replenishment of the fat stores after diagnosis 
suggests a positive energy balance, which could be attributable to the successful 
nutritional management of the patients, and the decreased tumour burden in response 
to chemotherapy, as observed elsewhere (den Broeder et al. 2001; Schmid et al. 
2005; Stallings et al. 1989; Vaisman et al. 1993). Although not significant the 
increased BMI in response to NS observed in this study would suggest a pivotal role 
of nutritional management during cancer therapy in children with solid tumours. 
The present study showed that patients with haematological cancers experience a 
rapid increase in FM during the first few months of treatments. This rapid and 
dynamic FM gain is an important finding when considered he fact that none of the 
patients was obese at diagnosis and 65% became obese by six months. This study 
had the major limitation of small sample size which reduced as the data collection 
was carried out. This is likely to have an impact on the results, and affected the 
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percentages of malnutrition observed, especially after the six month measurements. 
However, the results show a trend toward excess fat gain during the first six months 
treatment for leukaemia, which should not be underestimated, especially considering 
the increased risk in this group for the late onset for obesity (Nichol et al. 1998; 
Reilly et al. 1998; Reilly 2009; Ventham and Reilly 1999).  
An uninvestigated dimension of ALL-increased risk of obesity is the effect of 
alternative phases on and off steroids during maintenance therapy, on body 
composition and the risk of late obesity. It is known that subjects who experience 
large FM losses tend to compensate with hyperphagia, with a consequent excess of 
body weight regain (weight over-shooting) (Dulloo et al. 2012). It could be argued 
that the alternating phases of low energy intake when off steroids and high energy 
intake when on steroids (Jansen et al. 2009) may cause FM losses during the off 
steroids period, followed by excess fat accumulation in response to hyperphagia 
during the steroid period. This could cause overshooting of the FM set point. 
Although, this study showed an increased in FM and weight gain, it is unknown if 
the patients studied returned to their pre-illness set-point FM or if they exceeded it. 
Future studies should aim to assess FM before ALL treatments and prospective 
measured body composition according to treatments phases. 
When the cohort was stratified according to gender no differences in arm muscle 
area and arm fat area were observed between boys and girls, showing that there is no 
gender-associated risk of malnutrition. 
In this study, BIA measurements were converted to FM% to standardise the results 
for age and gender and to allow statistical analysis. The studies (Delbecque-Boussard 
et al. 1997) carried out to assess longitudinal changes in children treated for cancer, 
presented the data as mean TBW, FFM and FM for the entire cohort. However, this 
approach was not applicable to the current study. This is because the number of 
patients measured at each time point varied greatly, and presenting the data as 
changes in mean TBW, FFM, and FM, would have not reflected the changes in body 
composition but changes due to age and gender. 
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This study showed that FM% was significantly higher than standard values at all 
time points. The lack of association between the FM% measured by BIA, BMI 
centile, and FM% measured by arm anthropometry would suggest some 
methodological bias. These results indicate that BIA may not reflect body 
composition in children treated for cancer. It could be argued that arm 
anthropometry only provides information on localised fat deposit, and should not 
have been compared to total FM%. However, fat deposition in children is more 
evenly distributed than adults (Roche et al. 1981) suggesting that they should be 
positive correlated.  
The BIA technique had several methodological limitations which are likely to have 
affected its ability to measure body composition in this cohort. Firstly, the use of 
BIA to assess nutritional status during cancer treatments depends on the extent of 
accuracy of the prediction equation. In the current study, the only available equation 
for the paediatric cancer cohort was used (Brennan and Thomas 1997). However this 
equation has a wide limit of agreement (mean 0.9, limit of agreement = -2.46 to 
4.06) with the deuterium technique. This is likely to have introduced some 
inaccuracy. Moreover, in the current study the SF-BIA was used, which has been 
indicated to be accurate only when assessing patients with normal hydration 
(Gudivaka et al. 1999) but not when measuring subjects with altered hydration (Patel 
et al. 1996). Since paediatric cancer patients are likely to have altered hydration 
status caused by the treatments and the disease (Warner et al. 2004) the accuracy of 
the measurement using the SF- BIA could be questioned. Moreover, during the data 
collection some of the conditions recommended for BIA measurement could not be 
met (Kyle et al. 2004a). For example a fasting condition was not observed for 
clinical reasons. Moreover it was not always possible for the patient to void their 
bladder before the measurement. This is because they were in isolation or bed bound, 
or they refused to void their bladder before the test. In addition, the repeated 
measurement was not carried out at the same time of the day. 
Furthermore, the adequacy of the standard used for comparison may be in question. 
In this study it was not possible to use a single set of reference data because the 
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difference age groups covered by standards available in the literature. For patients 
between zero to five years the Fomon (1982) standard was used, which has the major 
limitation of using only one subject. For subjects aged five years above, the Laurson 
et al. (2011) standard was adopted. However, this has the limitation of being 
obtained using skinfold thickness. Therefore, considering the current study findings, 
the use of BIA in children during cancer therapy may not be indicated.  
Because of weight and body composition variation associated with tumour size and 
treatment, it is pivotal to understand the ability of other anthropometric methods to 
assess nutritional status in children with cancer. Thus, in the present study, the 
agreement between BMI and arm anthropometry measurements to classify 
undernutrition in children treated for cancer was assessed. 
This investigation showed that MUAC and TSF identified more patients as 
undernourished than BMI at recruitment (24%, 29% and 16% respectively). 
Moreover, this increased prevalence was associated with a very poor limit of 
agreement between arm anthropometry measurements and BMI. These results 
suggest that arm anthropometry measurements are able to identify more 
undernourished patients that BMI centile alone. It is unlikely that the increased 
prevalence of undernutrition, measured by TSF and MUAC in this prospective study, 
is a consequence of false positives leading to higher observed undernutrition rates. 
This is because it has been shown that arm anthropometry correlates with FM% 
obtained from air displacement plethysmography in children undergoing cancer 
therapy (White et al. 2011) which is a reliable and valid technique to assess body 
composition in children (Fields et al. 2002). Therefore it could be advocated that in 
children with cancer, arm anthropometry is a better indicator of nutritional 
deprivation than BMI centile alone. 
A unique aspect of the present study is that it has not solely examined the prevalence 
of undernutrition according to several anthropometric measurements, but also 
assessed the limit of agreement between measurements. This approach gives more 
robust evidence that percentage alone, since it takes into account the agreement 
between measurements and the agreement occurring by chance. However, although 
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the kappa statistic is widely used in measuring inter-analyst agreement, it is known 
that this test behaves poorly in small samples. (Sim and Wright March 2005). Future 
studies with a bigger sample size are needed to test the agreement on assessing 
undernutrition between BMI and arm anthropometry in this specific cohort. Of all 
the studies (Murphy et al. 2009; Nething et al. 2007; Oguz et al. 1999; Pietsch and 
Ford 2000; Smith et al. 1991; Smith et al. 1991) available in the literature aiming to 
compare the prevalence of undernutrition according to different anthropometric 
parameters, none had determined the limit of agreement between the measurements 
investigated. Therefore, although they all show an increased percentage of 
undernutrition when assessed by arm anthropometry, it is unknown if that occurred 
by chance. 
The findings in the current study highlight the importance of anthropometric 
monitoring during childhood cancer treatments from diagnosis onwards. Although 
BMI has the limitation of not measuring body composition, it is still a very valuable 
tool to assess nutritional status and its changes during cancer therapy. The 
advantages of this method are its simplicity for performance and interpretation. 
However, the findings of this study also suggest that given the known masking effect 
of cancer and its treatment on nutritional status assessed by weight related 
measurements (Pietsch and Ford 2000; Smith et al. 1991), the use of BMI centile 
alone may leave some undernourished patients undetected. Therefore, TSF and 
MUAC measurements should become part of the nutritional assessment of children 
treated with cancer especially in those subjects where the tumour can have a masking 
effect on weight. Nutritional assessment is important in order to assess the 
prevalence of malnutrition during the different phases of treatment, but also to allow 
comparison from a baseline measurement. With this approach NS can be promptly 
initiated and the patients’ response closely monitored. 
4.4.3 Nutrition support  
This prospective investigation showed that 58% of children in the study cohort 
required some type of NS at some point during their cancer treatments. The 
haematological group had a higher need for OCS (50%) compared to the solid group 
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(33 %). On the other hand, only 10% of the haematological group required the most 
advanced nutrition support available, compared to 62% of the solid tumour group. 
This indicates a greater extent of nutritional depletion in children treated for solid 
tumours. These results reflect the spectrum of diagnosis associated with greater risk 
of undernutrition in the literature (Betcher and Ablin 1993; Han-Markey 2000; 
Rickard et al. 1986).  
However, due to the small sample size in this prospective study, it was not possible 
to identify specific types of cancer associated with a particularly high risk of 
undernutrition. Moreover, the limited sample size did not allow the analysis of the 
need for NS in relation to the stage of disease, which is a known risk factor for 
undernutrition (Rickard et al. 1983). Consideration of the extent of use of NS in 
relation to treatment modalities indicated that the highest NS usage was among 
children receiving chemotherapy, followed by those receiving chemotherapy and 
radiotherapy with surgery. The lowest usage appeared to be amongst children 
receiving chemotherapy and surgery. Therefore, these results suggest an increased 
risk of undernutrition in relation to some treatment modalities, in particular 
chemotherapy alone. However, the limited sample size in the current study did not 
allow the analysis of the extent of nutrition support in relation to specific cancer 
diagnosis, treatments protocols and regimens. Althought these results are likely to be 
a reflection of both the diagnosis it self and the treatment, the specific associations 
between aspects of the treatment and nutritional implications could not be identified.  
In the present study BMI centiles increased from initiation to the end of NS, however 
the changes were not significant. When the cohort was analysed according to 
nutrition support modality, it was observed that BMI centiles in those patients treated 
with OCS were decreasing, whereas BMI centiles in those patients treated with ETF 
increased. However, these results were not statistically significant. This lack of 
significance is probably caused by the limited sample size in this study. These 
findings suggest the positive effect of NS on preventing further nutritional 
deprivation and on improving nutritional status. These conclusions are further 
supported by the decreased prevalence of undernutrition from recruitment to six 
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months. Therefore, even though the changes were not significant, the results should 
not be underestimated. 
 
In this study children were prescribed OCS but they did not take them regularly. 
Therefore, the decreased BMI centile in patients in OCS observed in this study may 
be a reflection of the lack of compliance to the oral supplement, rather than the 
inefficacy of OCS on counteracting undernutrition. It is a well known issue that in 
children, compliance in consuming OCS is poor (Han-Markey 2000). Moreover, 
even though OCS is largely used in undernourished patients, its effectiveness in 
counteracting cancer-related undernutrition and its effect on outcome is still unclear. 
A study conducted in cystic fibrosis patients showed that OCS did not improve 
energy intake, but rather disrupted food consumption (Kalnins et al. 1996). However, 
new more palatable formulations have been designed since that study was published. 
Therefore, there is now the need for more research to assess the efficacy of OCS on 
counteracting undernutrition in this population using these new formulations.  
As with other studies (den Broeder et al. 1998; den Broeder et al. 2000; Rickard et 
al. 1979; Smith et al. 1992), the current investigation demonstrated a positive effect 
of ETF on counteracting undernutrition in children undergoing cancer therapy. It 
could be argued that the observed improvement in nutritional status was a 
consequence of an overall clinical improvement rather than a consequence of NS. 
However, in the present study the patients on ETF were undergoing aggressive 
chemotherapy, and although the treatments may have reduced the cancer burden, 
chemotherapy caused severe side effects which would have had negative effect on 
nutritional status (Betcher and Ablin 1993). 
In this study it was not possible to examine the changes in body composition in 
response to NS. Therefore, it was not possible to assess whether the increase in BMI 
centile observed was a consequence of an increase FM, FFM, or both. Although arm 
anthropometry and BIA measurements were taken regularly every three months, the 
initiation and the end of NS did not coincide with these measurements and for ethical 
reasons it was not possible to take extra measurements between time points. On the 
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other hand, calculation of BMI at initiation and the end of NS was possible because 
the weight and height were closely monitored by the dietitian and noted at NS 
initiation and end.  
The literature is lacking in studies aiming to assess body composition changes in 
response to NS during cancer treatment in children. A significant increase in 
skinfolds in response to nutrition support has been shown (Rickard et al. 1985), 
which demonstrates a positive effect of NS on replenishing body endogenous energy 
stores. However the authors did not assess whether, those changes were affecting FM 
and FFM equally. Therefore, research should now be addressed to understand the 
effect of NS on body composition with special consideration towards those patients 
who were obese at presentation or who became obese during childhood cancer 
therapy. 
In summary, this study has identified some specific cancer types that had an 
increased requirement for NS during cancer treatment. The increased need for 
advance nutrition therapy observed in the solid group highlights the high risk for 
nutritional depletion in this specific group. Further studies, with a sample size 
adequate to allow stratification of the patients according to cancer type, stage and 
treatment protocol are now essential. These will require a multi-centre and even a 
multi-country approach. However, these types of epidemiological studies are very 
expensive, lengthy and complex. Therefore, robust data are required prior this type 
of studies to inform on the sample size required to achieve a clinically meaningful 
result, and evaluate areas that need to be investigated. This will allow the 
understanding of the association between those variables and the need for the 
nutrition support, hence, the development of specific guidelines for the nutritional 
care of this group.  
4.4.4 Energy Balance and macronutrient intake 
A major concern in the treatment of childhood cancer is that patients may not meet 
their energy requirements to support growth and sustain the body’s needs. 
Additionally, increased energy intake may lead to the excess body weight gain 
observed in childhood cancer survivors (Odame et al. 1994; Reilly 2009; Ventham 
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and Reilly 1999). It is pivotal for the nutritional care of a childhood cancer patient to 
identify the phases during treatment where there is a higher risk of energy imbalance. 
As discussed in Section 1.3, undernutrition and the consequent impaired growth are 
a consequence of an imbalance of the energy balance equation, where energy 
expenditure exceeds energy intakes, and obesity is a consequence of energy intake 
exceeding requirements. Therefore, when investigating both undernutrition and 
overnutrition during treatment for childhood cancer, it is essential to take into 
consideration dietary energy intake, energy losses consequent to malabsorption, and 
the metabolic requirements. However, in the current study, the substrate losses (e.g. 
from stools) were not determined for a range of logistical reasons. This research 
approach would have been an excessive burden to the nursing staff, the families and 
the patients. Moreover it would have been too costly.  
Although one of the study objectives was to assess physical activity every six 
months, the level of patients’ physical activity in this cohort could not be assessed. 
This was for the reasons discussed in section 4.3.8. Many studies have been carried 
out using the same physical activity measuring technique, in both healthy children 
(Reilly et al. 2004) and children treated for cancer (Aznar et al. 2006; Jacob et al. 
2007; Jansen et al. 2009; Sanford et al. 2008) without any compliance issues. The 
discrepancy with this current study may be explained by differences in treatment 
phase when the participants were recruited. Recruitment in the current study 
occurred in the early stages of treatment, were everything is frightening and painful 
for the child, whereas the studies above were either carried out in healthy subjects 
(Reilly et al. 2004) or during maintenance phase (Aznar et al. 2006; Jacob et al. 
2007; Jansen et al. 2009; Sanford et al. 2008). 
During the data collection period the use of alternative methods to assess physical 
activity was considered. However, the subjective methods available, both 
questionnaires and interviews, were believed to be inadequate to assess physical 
activity in this cohort. First of all, these two methods rely on the ability to recall 
physical activity, which may be influenced by the judgment of the reporter or 
interviewer (Sallis 1991). Secondly, energy expenditure is obtained using a 
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prediction equation developed using adult subjects; hence it may not apply to 
children (Sallis 1991). Therefore, it was concluded that these two methods were not 
accurate and they would not have provided a good measurement of PA in children. 
The present study examined spontaneous intake and intake with nutrition support. In 
order to ensure consistent data was collected, dietary intake was measured by the 24h 
multiple pass recall dietary recall technique. The method of choice to assess 
macronutrients intake in this study was the three day diet diary. This method has 
been shown to provide a relatively reproducible estimate of energy and 
macronutrients (Willett 1998). Although, it is subject to extent degree of error, 
provision of three days of data would have largely overcome the error resulting from 
memory lapses, making this error acceptable (Gibson 2005). However, immediately 
after the study was initiated; it became clear that this method of choice was too 
onerous for the family of this particular patient group. A consultation with the ward’s 
dietitian confirmed that the families are too overwhelmed and they tend not to return 
the diaries. Moreover, similar issues with use of diet diaries in newly diagnosed 
pediatric cancer patients have been reported by other authors (Delbecque-Boussard 
et al. 1997; Poslusna et al. 2009; Sgarbieri et al. 1999). Therefore, it was decided to 
use the 24h multiple pass recall (Guenther et al. 1994). A similar dietary assessing 
method, the 24h dietary recall has been previously used in other paediatric cancer 
studies (Delbecque-Boussard et al. 1997; Poslusna et al. 2009; Sgarbieri et al. 1999)  
The literature lacks studies aiming to assess the accuracy of dietary intake 
assessment methods in children treated for cancer. Therefore, to date there is no a 
valid dietary assessment method to estimate intake in this particular cohort, and the 
extent of error in estimating energy and macronutrients intake is unknown. 
The 24h multiple pass recall was developed in the US with the aim of reducing the 
underreporting issue found with the standard 24h dietary recall technique (Guenther 
et al. 1994). However, the use of the 24h multiple pass recall outside the US, and 
particularly in children, is very limited. A study (Reilly et al. 2001) carried out in 3-4 
year olds, showed that the 24h multiple pass recall was well tolerated by the families 
as very quick to be completed. However, regardless of this advantage, the dietary 
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assessment method was found to overestimate energy intake by 11%. The authors 
suggest that the bias may have been caused by the estimation of portion sizes. These 
results are of particular importance when interpreting the results in the current study. 
However, despite the limitations of methodologies used to determine energy and 
macronutrient intake, the current study provided useful information on changes in 
nutrient intake during cancer therapy, and the results should not be underestimated. 
The current investigation demonstrated that, overall, childhood cancer patients met 
their daily energy requirements both ad libitum and with nutrition support, during the 
entire data collection period. However although not statistically significant, intakes 
both ad libitum and with nutrition support were lower than requirements at three 
months. Moreover, if the overestimation caused by the 24h multiple pass recall is 
taken into consideration; it is likely that actual dietary intake was even lower than 
quantified in this study. Additionally, when the patients were stratified according to 
diagnostic group, it was evident that the daily energy intake during the entire data 
collection period was different between the two diagnostic groups, with some time 
points being at increased risk of low or high energy daily intake such as diagnosis 
and three months.  
Although the cohort was meeting their daily energy requirements overall, many 
patients were found to have intakes below 80% of individual requirements (Henry 
2005). It should be highlighted that even though not significant, the reduced energy 
intake, if cumulative, may result in a prolonged energy imbalance which can lead to 
depletion of energy reserves impact on growth. The highest percentage of patients 
not meeting their energy requirements including those in NS, were observed at three 
months (40%), followed by nine months (20%), which was also the time with the 
highest observed incidence of undernutrition (section 4.4.2). 
When the patients were stratified according to diagnosis, it was observed that the 
average daily energy intake both ad libitum and with NS for the haematological 
group at recruitment was much higher (163%) than the individual daily energy 
requirements. However, at three months, the daily energy intake was 57% and 62% 
of the individual energy requirements ad libitum and with NS respectively. Daily 
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energy requirements were not met by 30% and 80% of ad libitum and NS patients, 
respectively. Energy daily intake met the daily energy requirements thereafter.  
The reasons for the dramatic energy intake fluctuations in the patients treated for 
ALL in the present study may be explained by the treatments with steroids as part of 
the protocol for ALL. This increases energy intake and causes steroid cushingoid 
appearance (Loprinzi 1995). In the first phase of treatment, ALL patients are treated 
with daily high doses of steroids to induce remission. After remission is achieved, a 
course of steroids is given for a week every month. In the induction of remission 
phase, the steroids are likely to increase appetite and minimise the emesis and nausea 
caused by chemotherapy. However, during remission phase, where the patients are 
still treated with aggressive chemotherapy, the effect on appetite and nausea of the 
steroids therapy is transient, during the week of treatments, but for the rest of the 
time this group of patients can experience the same side effects as their solid tumour 
counterparts. Therefore, they are likely to experience phases of excessive intake 
when on steroids, followed by a reduced intake for the rest of the month (Jansen et 
al. 2009). Since the data collection in this study was based on time intervals (three 
months) more than events (chemotherapy protocol phases), many patients were 
assessed during the off-steroid period. Even though an attempt was made to record 
whether they were on- or off- steroids, data analysis taking into account this variable 
was not possible due to the limited number of patients in this cohort.  
On the other hand, median daily energy intakes both ad libitum and with NS in the 
solid group were above 100% of the energy requirements at each time point. 
However, at three months and six months 10% and 18% of the patients in the solid 
group where still not meeting their requirements (as >80% of individual 
requirements) even with NS. This is important in relation to the fact that this patient 
group had the highest prevalence of undernutrition at recruitment. Therefore, energy 
intake should not only meet the requirements but exceed them, to allow 
replenishment of their endogenous energy reserves, and to minimise wasting and 
sustain growth. 
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When the cohort was stratified according to gender, it appeared that although not 
significant, male patients had a reduced intake ad libitum (63%) compared to their 
requirements at three months. However, their intakes met the energy requirement 
when the NS was accounted for (89%). On the other hand, the female group had an 
adequate energy intake overall at each time point. It is not clear if there is a specific 
increased risk for reduced daily energy intake among male patients, or if the higher 
proportion of male patients and the small number of subjects used in this study 
biased the differences in energy intakes observed. 
This study showed an increased overall energy intake from diagnosis to three months 
in the solid group, which was associated with an overall increase in BMI centile. 
Although the group was meeting the requirements as a whole, 17 % of the patients 
were still below the 80% of their daily energy requirements. These results further 
underline the increased risk of undernutrition among specific diagnosis groups, such 
those with advanced stage and unfavourable biology (Rickard et al. 1983). It also 
indicated the need for a large cohort size when investigating the nutritional risks for 
children treated for cancer, to allow stratification according to specific diagnosis, 
rather than the generic solid vs. haematological groups used here. 
In contrast, whilst daily energy intake was reduced at three months in the 
haematological group, BMI centiles and FM were at their peak. It could be argued 
that a decreased daily energy intake in this specific childhood cancer group is 
essential to allow depletion of excess fat stores accumulated during the first phase of 
treatments. However, many aspects must be considered in the nutritional 
management of children treated for ALL. For example, obtaining adequate 
micronutrients from a low energy diet can be very challenging. This becomes even 
more complex if the overall dietary quality is affected due to the emotional stress of 
the family, the fear that the child is experiencing, chemotherapy’s side effects, and 
the perception that the child is not eating enough. As a response, favourite foods, 
frequently those high in fat and energy, but poor in micronutrients, are consumed 
and those less favoured (e.g. vegetables), which are rich in micronutrients, are 
omitted. However, presently there is an absence of guidelines for the management of 
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obesity in children treated for cancer. Moreover the typical dietary advice given by 
the dietitian when a patients has a decreased energy intake and weight loss 
(regardless of actual BMI), in both solid and haematological cancers, is to increase 
the intake of energy dense food. This approach aims to increase the energy density of 
the diet in order to prevent nutritional deprivation (Alexander et al. 1997). However, 
this may not always be appropriate. Considering the increased risk for the late onset 
obesity in ALL survivors (Ventham and Reilly 1999), the reported increased 
mortality rate and increased risk of relapse among obese children during cancer 
therapy (Butturini et al. 2007; Lange et al. 2005) there is now evidence to support the 
need for specific nutritional strategies aiming to address obesity in this particular 
cohort. 
The overall reduced daily energy intake ad libitum observed in this study is in 
agreement with other studies (Bond et al. 1992; Carter et al. 1983b; Delbecque-
Boussard et al. 1997; Smith et al. 1991), and it has been reported to be one of the 
main contributing factors to the development of undernutrition during childhood 
cancer therapy (den Broeder et al. 1998). However, comparison of the energy intakes 
observed in this study to the published literature is problematic due to the different 
methodologies used to assess nutrient and energy intake, the different phases of the 
disease studied, and the different diagnosis included in the studies. Delbecque-
Boussard et al. (1997) observed a significantly lower energy intake at diagnosis in 
ALL patients. However this difference disappeared by day thirty-six. Similarly, the 
current study observed a reduced intake in the ALL group, not at diagnosis, but at 
three months. Moreover, the current study identified only a small percentage (8%) of 
patients failing to achieve their daily energy requirements at libitum at diagnosis 
compared to Smith et al. (1991), who observed that 27% of the total cohort treated 
for various types of cancer failed to achieve requirements. However, when stratified 
according to diagnostic group, 30% of the solid tumour patients in this study did not 
meet their requirements ad libitum. 
This discrepancy between the results may be justified by many factors such as the 
different sample sizes, the type of diagnosis included in the study, the different time 
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frame and the estimate energy requirements used to compare intakes against. For 
example, Smith et al (1991) had a greater proportion of patients with solid tumours 
(excluding benign brain tumours) than the current investigation (68% vs. 50%) and a 
bigger sample size, which may have affected the results. Moreover, the baseline 
measurement in the current study was carried out between one and two weeks from 
diagnosis, as advised by the haematology-oncology team. Consequently, the patients 
were already undergoing chemotherapy when measured at baseline. In contrast 
Smith et al (1991) assessed dietary intake retrospectively based on recall of food 
eaten immediately prior to diagnosis. Moreover, in Delbecque-Boussard et al. (1997) 
took measurements before any treatment was started. This suggests that the 
discrepancy in the baseline results could be explained by the fact that many patients 
in the current study were taking steroids at the time of assessment. Moreover, 
Delbecque-Boussard et al. (1997) stopped assessing intake after less than three 
months, and Smith et al (1991) assessed dietary intake before diagnosis only, so 
energy intake after three months of therapy is unknown and comparison to current 
results is impossible. 
Another important factor that needs to be considered when interpreting the daily 
energy intake data is the standard used for comparison. In this study, the energy 
requirements were determined using the Henry equation (2005) adjusted for physical 
activity, as explained in the section 4.2.9. Since physical activity is the most variable 
component of total energy expenditure, it has to be accounted for when assessing 
daily energy requirements. Specific physical activity could not be measured for this 
cohort. Therefore, based on the published evidence supporting a decreased level of 
physical activity during treatments for childhood cancer (Aznar et al. 2006; Jacob et 
al. 2007; Jansen et al. 2009; Sanford et al. 2008), the physical activity level for lesser 
physical activity levels was used for the calculation of the individual energy 
requirements. However, it is not clear whether this estimation of the level of physical 
activity accurately reflects this population. 
A variety of prediction equations are described in the literature to calculate BMR 
(Henry 2005; Schofield et al. 1985) and the studies available (Bond et al. 1992; 
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Carter et al. 1983b; Delbecque-Boussard et al. 1997; Smith et al. 1991) investigating 
daily energy intake used a variety of different equations, which may have caused 
some discrepancies between their results. Moreover, irrespective of which equation 
was used to assess daily energy requirement, all these equations are developed for 
healthy groups and their use in disease can cause substantial error (Elia 1992b; 
Henry 2005; SACN 2011). This is because the hypermetabolic effect of the disease 
and the hypometabolic effect of decreased body weight and lean body mass alter 
BMR, even when weight, gender and height are taken into consideration (Elia 
1992b), although the extent of this is unknown.  
Although some authors has observed an increased REE depending on tumour burden 
at diagnosis (den Broeder et al. 2001; Schmid et al. 2005; Stallings et al. 1989; 
Vaisman et al. 1993), the evidence to support a long term hyper-metabolism in 
children remains inconclusive (Green et al. 2008). In the clinical dietetic 
management of adult cancer patients, a stress factor is added to BMR to account for 
the metabolic demands of the cancer (Barak et al. 2002; Delarue et al. 1990). On the 
contrary, this stress factor is not added to pediatric cancer patients, probably due to 
the limited evidence on REE and the consequent lack of specific stress factors for 
use with paediatric cases. It is unknown whether the patients in this current study 
were hypermetabolic. Therefore it is unknown whether the predicted individual 
energy requirements calculated using the Henry (2005) equation for healthy children 
represent an acceptable estimate for the children studies in this research. Further 
work which examines the REE in childhood cancer patients is now essential and this 
should take into consideration the different protocols and treatment phases of 
childhood cancer. Only then clinically effective assessment of energy intake 
adequacy can be carried out. 
Adequacy of energy intake was based on <80% of the daily energy requirements 
which has been largely used by others (Carter et al. 1983a; Smith et al. 1991). 
However, its ability to detect energy intake adequacy in children with cancer has not 
been validated. Moreover, when assessing energy requirements in a disease state is 
essential not only to consider the requirements to maintain energy balance, but also 
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the energy required to allow changes in body composition. This is pivotal to allow 
repletion of endogenous stores in undernourished patients and depletion of excess 
FM in overnourished patients. 
An important finding of this study is that all the patients at each time point, 
regardless of their diagnostic group, were meeting their protein requirements. These 
results show that protein energy undernutrition in this cohort is uncommon. Similar 
findings have been reported elsewhere (Carter et al. 1983, Delbecque-Boussard et al. 
1997, Garcia et al. 1989). However, in this study and previous studies (Carter et al. 
1983, Delbecque-Boussard et al. 1997, Garcia et al. 1989) the protein intake was 
compared to the DRV for the healthy children. This criterion to assess adequacy may 
be questionable since the specific protein requirement for children treated for cancer 
is unknown. An example where protein requirements for a healthy child might not 
apply to this population group is in the temporary increase in energy and protein 
requirements following a period of infection and slow growth, to allow catch up 
growth (MacDonald 2007). Extra protein is required to allow replenishment of lean 
tissue as a consequence of starvation and a catabolic state. The amount of protein 
needed to allow catch up growth varies according to the rate at which catch up 
growth is achieved, and the weight of the child. It has been suggested that the protein 
requirements can be up to 70% greater than those based on actual weight and age 
(FAO 2010). 
Additionally, in this study the biological value of the protein consumed was not 
assessed. The dietary requirements used in this study (Department of Health 1991), 
are based on estimate of the amount of high-quality egg or milk protein required for 
nitrogen balance. However, considering the high amount of protein foods consumed 
and the type of food eaten, it is likely that diet provided high biological value 
protein. 
The recommendation for fat intake in healthy children in the UK is a gradual 
transition (commencing at two years) from the high fat diet of infancy (around 35%) 
to a modified diet by five years providing <35% energy from fat (Department of 
Health 1991; Department of Health Report on Health and Social Subjects 1994). The 
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current investigation may indicate that, although not significant many patients were 
consuming a high fat diet during the treatments especially at three months.  
The findings of this study are probably a reflection of the dietetic recommendation 
for an energy-dense diet during treatment for cancer (Alexander et al. 1997). The 
recommended high fat diet aims to prevent waste and restore endogenous energy 
stores in those patients experiencing decreased intake. However, the increased risk of 
late onset of obesity in ALL patients (Ventham and Reilly 1999), and the increase in 
FM percentage observed in this current study, casts doubt on this dietetic practice in 
ALL patients. Additionally, it highlights the importance of specific guidelines for 
childhood cancer patients who are obese at presentation or at high risk of treatment 
related obesity. Moreover, during childhood, eating behaviours are developed which 
set the foundations for future eating habits and weight status (Savage et al. 2007). 
Therefore, the encouragement of a high fat diet for a prolonged period of time, in 
patients that are already obese may have detrimental effects later in life. This may 
negatively influence food choice and eating behaviours as adults.  
This study showed that many patients only achieved their daily energy requirements 
through NS. The discrepancy between daily energy intake at libitum and the intakes 
with NS serves to highlight the importance of nutrition intervention to achieve daily 
energy requirements. This study showed that patients in this cohort may have 
suboptimal intake during treatment if not provided with NS. This can lead to 
undernutrition and, in turn can impair growth. However, a number of patients 
receiving NS in this cohort were not meeting their energy requirements even with 
NS. This discrepancy between intake with NS and the daily energy requirements 
highlights the difficulties of tolerating enteral feeding during cancer therapy for 
some patients (den Broeder et al. 1998). Although, chemotherapy treatments share 
the same side effects as nasogastric feeding, it is reasonable to assume that the low 
tolerance for some patients to ETF was a consequence of the side effects of 
chemotherapy treatments, such as nausea, diarrhoea and vomiting. While the current 
study did not aim to assess the impact of chemotherapy side effects, the dietetic 
notes and consultation with the oncology dietitian showed that the lowest tolerance 
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to ETF occurred during chemotherapy and improved after the completion of the 
chemotherapy course. Therefore, although anecdotal, these observations illustrate 
how energy intake in this patient group is affected by the treatments phase even 
when NS is delivered via ETF. 
In summary, children treated for cancer are likely to experience a reduced energy 
intake during the first three months of treatments, with the exception of ALL patients 
who have a high energy intake in the first month of treatment. This study has shown 
that energy provided by NS is essential for some patients to achieve their daily 
energy requirements, even though tolerance of the feeds can be problematic during 
the cycles of intense chemotherapy. Currently, the mechanisms involved in weight 
and FM gain observed in ALL patients are not fully understood. Further studies that 
focus on the nutritional management of this specific patient group are now pivotal. 
4.4.5 Biochemical profile  
Cancer and its treatment cause many metabolic disturbances which can lead to 
intricate metabolic abnormalities in the host. Many cancer treatments are mediated 
by a free radical dependent mechanism (Sangeetha et al. 1990) which is likely to 
affect micronutrient status. Moreover some prescription drugs may interfere with 
nutritional status by altering absorption, excretion and metabolism of nutrients 
(Force et al. 2003; Valuck and Ruscin 2004; Gibson 2005). Therefore, cancer and its 
therapy may cause alterations in mineral and vitamin status. The present study 
longitudinally examined the micronutrient status of children to detect clinical or 
subclinical deficiency states by blood assessment. The choice of micronutrients 
investigated in this study was based on the biochemical tests currently available at 
the RHSC. The plasma level of the micronutrients investigated should generally 
reflect the body content of the nutrient examined. However, plasma levels may be 
affected by biological factors such as inflammation, chemotherapy, and the disease, 
and thus may not accurately reflect nutritional status (Gibson 2005). Therefore, in 
this study the entire clinical profile of the patients was taken into consideration when 
interpreting the results.  
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The liver test function showed a damaging effect of treatment on the liver, whereas 
renal function was not affected at the time points when data were collected. A full 
discussion of the detrimental effect of chemotherapy on the liver and the kidneys 
goes beyond the purpose of this thesis. However, in order to interpret the results it is 
essential to take into consideration the functionality of these metabolic organs. 
In this study, albumin was borderline low in 20% of the total cohort at diagnosis. 
When albumin was analysed in relation to hsCRP, it was shown that it was 
associated with inflammation. Although albumin has been largely used as indicator 
of nutritional status in childhood cancer studies (Kibirige et al. 1987; Yu et al. 1994), 
its use to detect poor nutritional status is believed to be inappropriate (Donaldson et 
al. 1981; Forse and Shizgal 1980; Merritt et al. 1985; Santos et al. 2003). This is 
because albumin is an acute phase reactant, and hypoalbuminemia is caused by 
inflammation as a sparing mechanism to sustain the synthesis of inflammatory 
chemicals needed to maintain the inflammatory response (Donaldson et al. 1981; 
Forse and Shizgal 1980; Merritt et al. 1985; Santos et al. 2003). Therefore, it is likely 
that the low plasma albumin observed in this study is an indicator of inflammation 
rather than undernutrition. 
In the current study, vitamin B12 was found to be low in a small percentage of 
patients during the entire data collection period, with both solid and haematological 
cancers being equally affected. Quantitative comparison of the prevalence of vitamin 
B12 deficiency to the NDNS (Department of Health 2012) was not possible due to 
limited patient numbers in this study and the different age group covered by the 
NDNS (Department of Health 2012). Therefore, it is not possible to establish if the 
vitamin B12 deficiency observed in this study reflects the healthy population or if it is 
caused by metabolic abnormalities during cancer therapy. Moreover, the literature is 
lacking in studies of vitamin B12 status in children during cancer therapy.  
The commonest cause of vitamin B12 deficiency is the lack of intrinsic factor 
produced by the stomach, which causes impaired absorption (Department of Health 
1991). However, in this study the lack of intrinsic factor as a leading cause of 
vitamin B12 deficiency seems unlikely, considering that the deficiency resolved 
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without any intervention in all the patients. A possible explanation for the transient 
vitamin B12 deficiency observed in some patients in this study could be the use of 
proton pump inhibitors (PPI). These drugs are often prescribed during cancer therapy 
in patients taking steroids, and to treat excess gastric acid production as consequence 
of the chemotherapy treatments. The presence of gastric acid is needed for the 
association of vitamin B12, with intrinsic factor required for the absorption in the 
ileum. 
Many studies (Force et al. 2003; Valuck and Ruscin 2004) have identified an 
association between the use of PPI with low vitamin B12 and pernicious anaemia, 
with long term users being at higher risk. Although only a small percentage of 
patients in this cohort were found to be vitamin B12 deficient, monitoring of vitamin 
B12 status for those on long term PPI courses may be recommended. This is 
especially relevant considering the role of vitamin B12 in blood cell formation and 
maintenance of brain and nervous system function (Department of Health 1991). 
Moreover, pernicious anaemia is detected by measuring haemoglobin plasma 
concentration, which in this group is generally low due the chemotherapy. Therefore, 
blood monitoring of vitamin B12 is the best method to detect deficiency. For those 
patients who required supplementation, the only option for administration may be 
the parenteral route. This is because many of these patients are thrombocytopenic 
and intra muscular injections can cause significant muscle haematomas as a result. 
Overall, the current findings highlight the risk of vitamin B12 deficiency for those 
patients treated for long term with PPI. In response to this finding, children treated 
for cancer at the RHSC are now monitored for vitamin B12 status. 
Along with vitamin B12, folate has an essential role in cell division and growth. 
Plasma folate has been reported to be a good indication of folate status (Department 
of Health 1991) and this assessment technique has recently been introduced in the 
NDNS to assess folate status (Department of Health 2012). In the current study, 
folate deficiency was only found in one patient. Therefore, poor folate status in 
childhood cancer seems to be unlikely. However methotrexate is known to cause 
folate deficiency through inhibition of dihydrofolate reductase (Manna et al. 2005). 
  
193 
 
Consequently children treated with methotrexate may be at risk of poor folate status. 
However the literature lacks studies aiming to evaluate the folate status of children 
with cancer, and comparison to the literature was not possible. Moreover it may be 
possible that folic acid supplementation may interact with the chemotherapy. Only 
one study aimed to investigate this topic (Lennard et al. 1986) and it showed that 
folate supplementation may interfere with the treatments. However, the study is very 
dated and further work which examines folate status in children during cancer 
therapy and the role of supplementation is required. 
In this study, vitamin E status was assessed using serum α−tocopherol: cholesterol 
ratio. Alpha-tocopherol is the predominant form in human tissues, and levels of 
circulating α−tocopherol are correlated with circulating lipids (Horwitt et al. 1972). 
To account for the different plasma lipid levels, plasma tocopherols can be expressed 
as a ratio with plasma total cholesterol. This study showed that all the patients had a 
normal α−tocopherol: cholesterol ratio at any time point. These results are in contrast 
with Malvy et al. (1997) who concluded that children treated for cancer have low 
vitamin E status compared to their matched healthy counterparts. However, in their 
study, the plasma α−tocopherol was decreased in the cancer patients, whereas the 
α−tocopherol: cholesterol ratio did not differ from the controls. Therefore, it could 
be postulated that discrepancy in the results was caused by the different assessment 
method. It appears that when measured by the recommended parameter of 
α−tocopherol: cholesterol ratio (Horwitt et al. 1972), vitamin E status is not affected. 
However, vitamin E status in children with cancer has not been extensively assessed 
and the limited sample size in this study does not allow the drawing of any 
conclusions. Therefore, this topic requires further elucidation. 
4.4.6 Vitamin D, PTH and calcium axis 
This study aimed to compare vitamin D status, plasma calcium, plasma phosphate 
and parathyroid function in children treated for cancer. This showed a high 
prevalence of low serum 25(OH) D during the data collection period. It must be 
noted that when patients were diagnosed with poor vitamin D status, vitamin D 
supplementation was started. Considering the time for blood results to be analysed 
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and interpreted, and the time necessary to initiate the intervention, it is likely that the 
results from the six month measurements onwards have been affected by this 
intervention. 
In healthy populations, plasma 25(OH) D concentrations show a marked seasonal 
variation, being lowest during winter and highest during summer (Lund and 
Sørensen 1979). In the UK, the population relies on body stores and dietary vitamin 
D to maintain vitamin D status during winter months (SACN/RCPCH 2007). 
Interestingly, this study did not indicate any seasonal differences in plasma vitamin 
D. These results support the idea that children treated for cancer do not spend 
adequate time outdoor to allow vitamin D synthesis. Therefore, it highlights the 
inability of the child to replenish their vitamin D stores during the summer months 
and the importance of dietary sources to meet vitamin D requirements in this cohort. 
The median plasma level of vitamin D in this study cohort was generally lower that 
that reported by the NDNS (Department of Health 2012) for a comparable age group 
(11-18 years of age). The prevalence of vitamin D deficiency was found to be higher 
in the solid tumour group at diagnosis compared to the haematological group, with 
44% of the solid tumour patients being vitamin D deficient compared to the 29% of 
the haematological patients. However, at three months the haematological group 
(33%) had the highest prevalence of vitamin D deficiency compared the solid group 
(0%). Low plasma 25(OH) D was associated with low plasma calcium, and in some 
patients, with low plasma phosphate. The lack of association between calcium and 
vitamin D is due to the tight regulatory mechanisms that control calcium 
homeostasis, preventing plasma calcium increasing above a maximum concentration 
at higher plasma 25(OH) D. 
Statistical comparison against the NDNS prevalence of vitamin D deficiency 
(Department of Health 2012) was not performed because of the different age group 
covered by the survey. However, quantitative comparison, showed a clear increased 
prevalence of vitamin D deficiency in this cohort compared to the 19.3% reported by 
the NDNS. Indeed this inconsistency may be explained by the latitude differences 
between Scotland and the entire UK. However, this observation may also suggest a 
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particularly high risk for vitamin D deficiency in childhood cancer patients as 
previously reported (Helou et al. 2008; Sinha et al. 2010; Halton et al. 1996). 
However, comparison to the prevalence of vitamin D deficiency reported in the 
literature is difficult because of the different diagnostic groups covered in the 
literature. 
As discussed, it is plausible that childhood cancer patients do not spend much time 
outdoors, even before diagnosis, due to the disease and the side effects of treatments. 
Moreover it is unlikely that the diet adequately compensates for the luck of sun 
exposure, considering the limited sources of dietary vitamin D (SACN 2007) and the 
poor nutritional status during cancer therapy.  
The increased prevalence of poor vitamin D status observed in the haematological 
patients after treatment was started highlights the possible detrimental effects of 
steroid therapy on vitamin D status (Zhou et al. 2006). This would put this group of 
patients at even higher risk of vitamin D deficiency than their solid tumour 
counterparts. Moreover, Vitamin D in obese subjects is deposited in fat (Mawer et al. 
1972) and it has been recently suggested that vitamin D status negatively correlates 
with BMI in adults and adolescents. In this study, BMI and vitamin D status were 
observed to have an ‘∩’ shaped association with both low and high BMI being 
related to poor vitamin D status. Hence the trend towards obesity during cancer 
therapy observed in ALL patients may be an independent risk factor of vitamin D 
deficiency (Baradaran et al. 2012; Goshayeshi et al. 2012; Zwart et al. 2011). In 
contrast, the association with low BMI would suggest a general detrimental effect of 
poor nutritional status on vitamin D status. This is likely to be related to decreased 
nutrient intake, disease severity and the consequent lack of sunshine exposure. 
Vitamin D deficiency is associated with secondary hyperparathyroidism. A negative 
association between plasma PTH and plasma 25(OH) D has been extensively 
reported (Chapuy et al. 1997; Ooms et al. 1995). Similarly, some authors have 
reported hypoparathyroidism to be associated with low plasma 25(OH) D (Sahota et 
al. 2001). This finding suggests that in some patients, the normal compensatory 
mechanism to maintain calcium homeostasis did not occur. Low plasma vitamin D 
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causes reduced calcium absorption, which leads to reduced plasma calcium. This, in 
turn, causes the release of parathyroid hormone which restores 1, 25(OH) D levels 
and enhances the release for calcium from the bones. In the current study, it appeared 
that some patients did not have an adequate PTH response. This failure of the 
parathyroid gland to support the adequate PTH response has been observed 
elsewhere in adult female subjects (Sahota et al. 2001). The authors suggested that 
this is caused by decreased plasma magnesium (Sahota et al. 2001). However, in the 
current study, plasma magnesium was within normal levels hence, the causes for 
failure of the parathyroid to support the adequate PTH response in this study are 
unknown.  
These findings clearly suggest the need for screening and potential supplementation 
of vitamin D. Based on this study’s results, the Royal Hospital of Sick Children, in 
collaboration with the author, has developed a protocol for vitamin D screening and 
supplementation during cancer therapy. All patients admitted with a cancer diagnosis 
are now started on a calciferol supplementation regime at a dosage to treat 
insufficiency and their plasma 25(OH) D is measured. Once the results from the 
screening are ready, the calciferol dose is adjusted as shown in Table 4.14 and 
plasma 25(OH) D monitored. This strategy was based on the length of time required 
for the blood tests to be analysed and the need for a prompt intervention. 
 < 6 months of age > 6 months of age > 1 year of age 
Insufficient 200-400 IU/d 200-400 IU/d 400-800 IU/d 
Deficient  3000 IU/d for 8-
12 weeks 
6000 IU/d for 8-12 
weeks 
6000 IU/d for 8-12 
weeks 
Table 4.14 Treatment of vitamin D deficiency and insufficiency according to age 
(Pearce and Cheetham 2010) 
However, the efficacy of vitamin D supplementation to improve vitamin D status in 
children treated for cancer has not been proven yet. Therefore intervention studies 
should aim to elucidate this topic, especially in obese patients or those taking 
steroids. It had been observed that pharmacological doses of 6000 IU/d given for a 
prolonged period of time lead to increased plasma 25(OH) D accompanied with 
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hypercalcemia. Vitamin D toxicity occurs at plasma 25(OH) D > 200nmol/l (Gertner 
and Domenech 1977; Mawer et al. 1985; Rizzoli et al. 1994). Therefore considering 
the risk of toxicity, it is important to monitor plasma 25(OH) D during 
supplementation and to establish if the current recommendation for healthy children 
applies to this cohort. This is extremely important considering the unknown 
interaction of chemotherapy on nutrient metabolism. 
4.4.7 Serum vitamin A, supplementation and toxicity. 
The present study has shown that 25% of haematological patients had low plasma 
retinol at three months. Although the cohort was small, these results may suggest 
either an increased demand for the vitamin or a decreased dietary intake during 
cancer. However, from the limited data available in this study it is not clear if the 
increased risk observed in the haematological occurred by chance or if this particular 
patient group it is at higher risk. Other studies (Malvy et al. 1997) have reported low 
plasma retinol in childhood cancer patients affected by different diagnosis suggesting 
that vitamin A deficiency is common among all diagnosis.  
An interesting finding of this study is the excess plasma retinol observed in several 
patients during treatments, with two patients being above toxicity level. In this study 
blood was taken when it was convenient for the nursing staff and generally not in a 
fasting state. Therefore, it is likely that the observed plasma vitamin A above the 
normal range, but below toxicity, was caused by the postprandial transient increase 
in plasma vitamin A.  
During the data collection period, four patients were supplemented with a 
multivitamin solution for children (ABDEC, Parke-Davis/Pfizer) containing retinol 
as vitamin A palmitate 733 mg/ day for children and 362.5 mg/d for babies. The 
reasons for supplementation varied, from poor vitamin D status, to parental concern 
about vitamin intake. The two patients found to have toxicity level plasma retinol 
had normal or elevated plasma retinol at initiation, and after taking the supplements, 
reached toxicity level within three months. The reasons for plasma retinol toxicity at 
safe levels of vitamin A supplementation are unknown. It has been suggested that it 
may be caused by decreased hepatic uptake (Smith and Goodman 1976). These 
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results may imply that the liver damage caused by chemotherapy affects vitamin A 
metabolism in children during cancer therapy. Although the number of patients was 
very small, and conclusions can not been drawn based on only two patients, these 
results are important, and they call into question the safety of vitamin A 
supplementation in this cohort. Moreover they stress the importance of micronutrient 
status monitoring during cancer therapy. It has to be noted that in consideration of 
the current findings, vitamin D supplementation at the RHSC is now given as 
vitamin D alone and not as a multivitamin complex. 
4.4.8 C- reactive proteins, copper, zinc, selenium and ferritin 
Research in the area of trace elements and minerals status in children treated for 
cancer has previously focused on plasma zinc and copper concentrations (Carpentieri 
et al. 1986; Cavdar et al. 1980; Gupta et al. 1994; Malvy et al. 1997; Mocchegiani et 
al. 1994; Sgarbieri et al. 1999).  
Similar to the studies above, this study showed increased plasma copper and 
decreased plasma zinc. However, the current study is the only study to analyse 
copper and zinc in relation to inflammation. Although hsCRP values were missing 
for some patients, a link was observed between inflammation and abnormal level of 
copper and zinc. Zinc and copper are acute phase reactants, and the changes in 
plasma concentration are likely to be caused by inflammation rather than 
undernutrition (Galloway et al. 2000). This is further supported by the normalising 
effect of chemotherapy and end of treatments on zinc and copper plasma levels 
observed during the data collection. Moreover, in this study few patients were 
identified as selenium deficient by the blood test, and patients were reported to have 
extremely high level of ferritin, which was associated with inflammation. Similarly 
to copper and zinc, selenium and ferritin are acute phase reactants and their plasma 
levels during an acute phase do not assess selenium and iron status but inflammation. 
Therefore, plasma levels of these compounds should be use as indicators of poor 
nutritional status only when the patient does not have acute phase status. However, 
determination of poor nutritional status without biochemical indices but by physical 
examination can be challenging. This is because chemotherapy has a masking effect 
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on physical signs and symptoms of deficiency. For example alopecia is sign of biotin 
deficiency (Gibson 2005) but also a side effect of chemotherapy. Therefore, the 
assessment of micronutrient status in this cohort can be problematic. 
The findings in this current study highlight the detrimental effects of cancer and its 
treatments on micronutrient status, and the importance of monitoring during 
childhood cancer treatments.  
4.5 Conclusions 
This research aimed to identify the risk factors for both under and over- nutrition in 
childhood cancer. These findings underlined the common risks of undernutrition and 
obesity in this childhood cancer cohort, and also indicated apparent differences in 
nutritional risk according to diagnosis and treatment. It is now apparent that 
nutritional screening during cancer therapy is urgently needed.  
The initial aim was to define specific parameters such as age at diagnosis, cancer 
treatment, type of tumour and duration of illness (important in determining 
nutritional risk) using BMI centile as primary outcome. The particularly small 
number of newly diagnosed childhood cancer patients during the data collection 
period was a major limiting factor for the current study. This is a reflection of the 
low incidence of childhood cancer and the particular low incidence during the data 
collection period. The small sample size, and the many drop outs, has prevented 
statistical examination by unifactorial and multifactorial analysis for the 
identification of specific factors contributing to the development of under and 
overnutrition. Moreover, the small sample size, and the lack of statistical strength, 
may have led to type I and type II errors, leading concerns over the strength of the 
results. 
However, although this study had the limitation of a small cohort size, it had the 
strength of following a group of patients for a long period during cancer treatments 
using several nutritional parameters. Hence, it still has achieved the study aim and 
objectives, providing important observational information on nutritional status 
during cancer treatments.  
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In summary, this study has shown that solid cancer patients have an increased risk 
for nutritional deprivation, low endogenous energy stores and increased requirement 
for nutrition support. In contrast, the haematological group experiences excess 
weight gain, excess endogenous fat storage and increased energy intake in the first 
phase of their treatments. Moreover, this current study has highlighted the 
importance of nutrition support during cancer therapy to achieve energy 
requirements, and its effectiveness in counteracting further nutritional depletion. 
Finally, the findings in this current study have shown a detrimental effect of cancer 
and treatments on micronutrient status. This evidence supports the need for 
micronutrient monitoring in this patient group. Remarkably, the preliminary 
vitamin D and B12 findings have already led to the development of clinical guidelines 
for the routine monitoring of micronutrients at the RHSC, Edinburgh, further 
highlighting its importance. However, more research is needed to assess the safety of 
nutritional intervention in this patient group, as treatment may affect micronutrient 
metabolism.  
It is apparent that extended longitudinal monitoring of nutritional status in children 
with cancer is now essential. Therefore, more research is now needed to identify the 
specific risk factors for malnutrition in paediatric cancer, such as age at diagnosis, 
gender, type of tumour, stage of tumour, treatment modalities, and protocols and 
stage of treatments. This research is still on-going and hopefully, by the end of the 
data collection period (January 2014) it will have achieved a sample size adequate to 
allow stratification according to these variables and more powerful statistical 
analysis.  
It is anticipated that the findings from the full set of data will allow the development 
of a screening tool specifically designed for this cohort. This is intended to facilitate 
early and effective nutritional intervention to reduce the risk of nutritional problems 
in children with cancer throughout the course of the disease and its treatment. 
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5 CHAPTER FIVE 
SUMMARY AND CONCLUSION 
 
Despite considerable interest in the prevalence of malnutrition in childhood cancer 
patients and its impact on the outcome, little attention has been paid to their 
nutritional care. To date, there are no clinical guidelines for the nutritional 
management of this group of patients and the research is scarce and fragmented. 
Moreover, little is known about micronutrient status during childhood cancer 
therapy. Therefore, understanding the factors that contribute to the development of 
both undernutrition and obesity found in childhood cancer will prove central to the 
nutritional management and intervention of this patient group. 
The current series of investigations in children with cancer have shown that this 
patient group has a particularly high risk of undernutrition throughout treatment and 
even in the remission phase. In the prospective study undernutrition was not a 
common feature after six months of data collection; however, it is likely that this 
reflects the small sample size rather than a low risk for undernutrition. Moreover, 
this current study has shown that obesity is also a common feature of childhood 
cancer during both the treatment and remission phases.  
Stratification of childhood cancer patients by diagnostic group has highlighted 
differences in nutritional status, body composition, dietary intake and the need for 
NS. The prevalence of undernutrition has been observed to be higher than expected 
for the UK population at both diagnosis and during treatments for both solid and 
haematological groups. However, the two studies showed conflicting results for the 
prevalence of undernutrition at diagnosis for the haematological group. It could be 
postulated that this inconsistency originates from the small sample size of the 
prospective study. Moreover, it is likely that the retrospective study had included 
high nutritional risk haematological malignancies such as high risk ALL,I n contrast 
to this current study where all the ALL patients were low and standard risk ALL. 
Although undernutrition throughout the treatments and in the remission phase was 
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common in both solid tumour patients and haematological patients, obesity was 
higher than expected for the UK population in haematological patients only. It is 
apparent that undernutrition is a consequence of the metabolic disturbances caused 
by both cancer and treatments and it can reflect disease status. However, the causes 
for the onset of obesity in childhood cancer patients are still not fully understood. 
The current studies showed a high need for NS during childhood cancer treatments. 
The extent of use of NS in relation to cancer diagnosis and treatment modalities has 
showed that that a high proportion of children receiving some type of NS, required 
the most advanced NS treatment from the early stages of therapy. This indicates a 
large extent of nutritional depletion. Although almost half of the children received at 
least one type of NS, the data showed that within both solid tumours and 
haematological malignancies, there are specific types of cancer which are associated 
with a particularly high risk of undernutrition. In particular, CML, AML, malignant 
bone tumours, Neuroblastoma and CNS malignancies required advanced NS. 
Consideration of the extent of use of NS in relation to the treatment modalities 
indicated that the highest usage was among children receiving chemotherapy and 
radiotherapy (recurrence treatment). The lowest usage appeared to be amongst 
children receiving surgery only. These results suggest an increased risk of 
undernutrition in relation to some treatment modalities, in particular chemotherapy. 
However, it is not clear whether this is a reflection of the diagnosis itself, the 
treatment modality alone, the disease severity or, more likely, a combination of all 
factors. Moreover, chemotherapy comprises many different treatment protocols and 
therefore it was not possible to identify specific associations between aspects of the 
treatment and nutritional implications.  
In some patients with solid malignancies, endogenous energy reserves were 
considerably depleted at diagnosis when compared to the reference values, 
suggesting an increased reliance on the provision of energy from fat to maintain 
energy balance prior to diagnosis and during the first phase of treatment. In contrast, 
haematological patients experience excess fat deposition during the first months of 
treatment suggesting a prolonged positive energy balance. Many clinicians and 
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authors consider weight gain to be a side effect of steroid therapy, however whilst 
this contribute to the early weight gain in haematological patients, it cannot be the 
solely cause for the long term increased risk for obesity observed in this current 
study and reported in the literature. A well known risk factor for the late onset of 
obesity with modern treatments is the reduced physical activity; however it seems 
unlikely that the reduced physical activity alone can account for the increased risk of 
obesity in this cohort. It may be speculated that there is an adaptive response caused 
by excess FM loss during chemotherapy, followed by excess fat storage during on-
steroids periods, which may lead to fat overshooting and an early adiposity rebound. 
The understanding of the mechanisms causing excess body fat in this cohort is now 
pivotal to prevent this sequela. 
Energy intakes were found to be lower than recommendations in those with solid 
tumours during the first phases of treatments. This reduced intake may in part 
account for the depletion in the energy stores observed in the solid group. In some 
patients, NS was essential to achieve the recommended daily energy intake. These 
observations, in conjunction with the effectiveness of NS in preventing further 
nutrition deterioration and improve nutritional status, highlight the importance of 
nutritional monitoring and NS in this cohort. However, despite receiving NS, many 
patients were still unable to meet the prescribed targets due to poor tolerance of the 
feeds, as a consequence of treatment side effects. In light of these findings, novel 
strategies aiming to detect nutritional risk early are required to initiate NS as soon as 
possible to prevent excessive nutritional deterioration. 
In contrast, the haematological group was found to have an increased daily energy 
intake during the first phase of treatments, followed by a reduced daily energy 
intake. The observed increased energy intake is likely to have been a consequence of 
steroid therapy. The results of increased energy intake in conjunction with weight 
gain suggest a positive energy balance during the first phases of treatments, which is 
known to continue into remission. Although obesity is a well-known issue in ALL, 
there are no specific clinical guidelines to address this nutritional concern in this 
specific cohort. Nevertheless, the simple clinical guidelines for the management of 
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paediatric obesity were not adopted in this patient group during the study data 
collection. Interestingly, obese patients were advised to have an energy dense/high 
fat diet, which may be inappropriate. Additionally, the literature lacks intervention 
studies aiming to modify patients’ behaviour or treatment regimens in order to 
prevent the late onset of obesity. Therefore the appropriate clinical management of 
excess weight gain in ALL is yet to be determined. 
A particular strength of the present study design is that it permitted prospective 
examination of micronutrient status. It is apparent that cancer and its therapy cause 
metabolic abnormalities which may affect micronutrient status. This study has 
shown that children treated for childhood cancer are at high risk of vitamin D 
deficiency. Moreover, due to the impaired absorption caused by PPI, vitamin B12 
deficiency can also occur. Perhaps more importantly, despite being supplemented 
with safe doses of vitamin A, few patients quickly reached plasma toxicity level. In 
view of these findings new strategies that aim to assess micronutrient status from 
diagnosis onwards are required. Moreover, multivitamin supplementation, a common 
practise in children with cancer, should only be advocated when a specific 
micronutrient deficiency is identified. This should be done under close supervision 
by the medical and dietetic staff along with blood screening to assess micronutrient 
status and avoid toxicity. 
The main limitations of this present study are the lack of BMI data, which has 
prevented full assessment of the prevalence of malnutrition in the retrospective 
study, and the lack of power analysis caused by the limited sample size in the 
prospective study. The reasons for the limited sample size in the retrospective study 
are that childhood cancer incidence is very low, with about 55 patients referred to the 
RHSC Edinburgh per year. Moreover, during the data collection period the incidence 
of childhood cancer in South-East Scotland was even lower that the average 
incidence recorded (51 patients in 18 months) at the RHSC. All these factors have 
negatively affected the sample size and thus limited the statistical power of the 
prospective study.  
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These results highlight the complexity of clinical research and the need for very 
large numbers of participants to identify the overall risk factors for malnutrition. 
However, this type of research requires multicentre and even multi-country studies, 
which can be very lengthy and expensive. Therefore, robust data is required prior to 
the start of such studies to indicate the number of participants required to achieve 
clinically meaningful results and to identify the risks factors to be investigated. 
Therefore, although limited in the sample size, the observational information 
obtained in this current research is very valuable, especially in consideration that it 
sets the basis for a further 18 months of data collection. It is hoped that when the 
prospective study is completed, the 36 months of data collection will provide robust 
data which can then be validated in larger studies. 
These series of studies have highlighted the importance of nutritional screening 
during childhood cancer therapy. Indeed there is a need for a screening tool to 
identify children at high medium and low risk of malnutrition. However, considering 
the extent of nutritional issues that a child can experience during cancer therapy, it is 
uncertain whether only the high risk children should be having their nutritional status 
assessed by a dietitian or whether comprehensive monitoring of all of the children 
treated for cancer is necessary. Until a specific screening tool for this patient group is 
designed and validated, it would be recommended to assess growth by BMI centile 
and micronutrient status regularly throughout the treatments. Moreover, children 
with solid tumour should be monitored with arm anthropometry to avoid the 
masking effect of tumour mass on weight related measurements. This will ensure 
that patients requiring NS and supplementation are quickly identified and their 
progress during NS is monitored.  
The findings of this study have underlined areas of investigation for future work. 
Further studies on the nutritional risk of children with cancer are now required. Most 
importantly, these studies should have a sample size large enough to allow the 
identification of specific risk factors for both undernutrition and obesity in paediatric 
cancer such as age at diagnosis, gender, type of tumour, stage of tumour, treatment 
modalities, protocols and stage of treatments. If possible such investigations should 
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be prospective in nature and continue for up to five years. This is important because 
nutritional issues, especially obesity, may continue well into adulthood. Moreover, 
intervention studies are now required to evaluate the type of interventions needed to 
address the modifiable risk factors for obesity such as low physical activity and 
dietary intake. 
Finally, the interaction of cancer treatments, micronutrient status and 
supplementation must be investigated further, especially to assess the need for 
supplementation and its safety during cancer therapy. This is important as many 
patients may develop some micronutrient deficiency and they may need to be 
supplemented. 
In conclusion, this study has shown that children undergoing cancer treatments are at 
high risk of both undernutrition and obesity and it indicates apparent differences in 
nutritional risk according to diagnosis and treatment. Moreover it has highlighted the 
detrimental effect of cancer and its treatments on micronutrient status. Therefore, 
nutritional status monitoring during childhood cancer therapy is essential and the 
need for a screening tool specifically designed for this patient group is now pivotal.  
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Raquel Revuelta Iniesta 
PhD student 
Dietetics, Nutrition and Biological Sciences 
Queen Margaret University 
 
Sheila Adamson 
Collaborations Development Co-
ordinator 
Queen Margaret University, 
Edinburgh  
Queen Margaret University Drive 
Musselburgh 
East Lothian EH21 6UU 
 
Direct Dial 
Tel (0)131 474 0000 Fax (0)131 474 
0001 
Email: sadamson@qmu.ac.uk 
 
 
07 June 2012 
 
 
Dear Raquel 
 
Request for Ethical Approval for a Research Project – Assessment of 
reliability, validity and precision between intra and inter observer 
anthropometrical measurements performed in children and young adults. 
 
Thank you for your response to the letter I sent you following consideration of your 
application by the Research Ethics Panel. 
 
Professor Nigel Gleeson, Vice-Convener of the Panel, has reviewed your response 
to the points you were required to address, and has confirmed that he is happy to 
take Convener’s Action to grant full ethical approval for your research.  
 
A standard condition of this ethical approval is that you are required to notify the 
Panel, in advance, of any significant proposed deviation from the original protocol. 
Reports to the University are also required once the research is underway if there 
are any unexpected results or events that raise questions about the safety of the 
research. Please find the appropriate form for this enclosed. 
 
We would like to thank you for your co-operation and wish you well with your 
project. 
 
Yours sincerely, 
 
 
 
 
Sheila Adamson 
Collaborations Development Co-ordinator 
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From: Martin, Dawn  
Sent: 04 February 2010 09:36 
To: Paciarotti, Ilenia 
Cc: McKenzie, Jane 
Subject: Ethical Approval Application 
 
 
Dear Ilenia 
 
I am writing to let you know that the Research Ethics Committee considered your 
application for ethical approval for the following study at yesterday’s meeting: 
 
Nutritional Risk in Childhood Cancer 
 
The Committee noted that you have secured ethical approval from the NHS and that 
separate approval from QMU is not necessary at present. However, should you 
revise the project in such a way that you require full ethical approval from QMU at 
any point in the future, you are invited to submit an update of the form directly to 
me. 
 
Whilst members did not scrutinise the form with a view to rejecting or granting 
approval, some comments were provided, which I could forward to you if you would 
consider that helpful. You would not be required to respond or act on these, but the 
additional feedback may be of interest as the study progresses. If you would like 
these, please let me know and I will type then up in due course. 
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Regards 
 
Dawn 
 
 
Dawn Martin 
Assistant Registrar, Quality Enhancement 
Queen Margaret University  
Edinburgh 
EH21 6UU 
 
(0131) 474 0000 
dmartin1@qmu.ac.uk 
QMU Quality website:  
http://www.qmu.ac.uk/services/quality.htm 
 
Scottish Charity No. SC002750 
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CHILD INVITATION TO PARTICIPATE 
 
“Assessment of reliability, validity and precision of anthropometrical 
measurements performed in healthy children” 
 
 
Invitation to take part in the study 
- We would like to ask you for help with our study. 
- We want to make sure that you understand what is all about before you decide if you 
would like to take part 
- Please talk it over with your mum/dad and take time to decide 
 
What is the study about?           
 
 
 
 
 
 
 
 
                                                   
 
 Will taking part help me? 
 
Taking part 
will not hurt 
you 
Will it 
hurt me? 
We would like to measure your weight, height and the thickness of 
your arm to help us prepare for a larger project in which children with 
cancer are involved.  
I would recommend wearing short sleeves on the day to facilitate 
taking the measurements. 
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Do I have to take part? 
 
 
 
 
 
If you have questions you can speak with: 
Raquel Revuelta Iniesta              rrevueltainiesta@qmu.ac.uk  
Ilenia Paciarotti                    ipaciarotti@qmu.ac.uk   
Dr Jane McKenzie                 jmckenzie@qmu.ac.uk    
Independent advisor (Dr Iain Gow)    igow@qmu.ac.uk 
 
Only the researchers 
involved in the study 
as we will not tell 
anyone else about 
your measurements 
Will anybody 
know about 
my 
measurements
 
Taking part might not help you but you will help the 
researchers, Ilenia and Raquel, to improve their 
techniques.  
It will also help many children with cancer. 
 
No, this is up to you! 
If you don’t take part don’t worry, that is fine 
If you take part but change your mind later on. That is 
also fine. Just let us know 
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 INFORMATION SHEET FOR PARENTS 
 
 
 
“Assessment of reliability, validity and precision of anthropometrical 
measurements performed in healthy children” 
 
 
This study will be carried out by Ilenia Paciarotti and Raquel Revuelta Iniesta; we are both 
PhD students at Queen Margaret University under the supervision of Dr. Jane Mckenzie. The 
purpose of this project is to assess measurements of body composition in healthy children in 
preparation for an ongoing project at the Royal Hospital of Sick Children (RHSC), which 
aims to assess nutritional risk in children with cancer.  
 
We are looking for boys and girls aged between 2 and 18. 
 This study will involve: 
 Meeting with the children in a private location: QMU clinic room or other 
suitable place. 
 The following anthropometrical measurements will be taken on your child 
twice by each of the researchers: 
 Weight – measured clothed, without shoes, on standing scale 
 Height – measured clothed, without shoes, using a standing height 
measure 
 Middle upper arm circumference - this involves finding the middle 
point between the elbow and shoulder and measuring the 
circumference. Measurements are taken on the non-dominant arm 
 Triceps skinfold- this involves measuring the thickness of the skin on 
the triceps. For this measurement we use paediatric calipers which 
pinch the skin gently to measure the thickness 
 Wearing short sleeves will facilitate measurement of the arm. 
 Will it hurt my child? 
 Your child should not experience any pain, however the triceps skin fold is 
sometimes perceived as unpleasant by the children. 
 Benefits of taking part 
 This study will not benefit your child directly; however the information 
obtained will help the researchers to conduct the study performed at the RHSC  
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 Confidentiality and anonymity 
 All children who take part in the project will be given an identification number 
and all data will be anonymous. 
 Withdrawal 
 You or your child will be able to withdraw from the study at any time without 
providing any explanation. 
 
 Contact details 
 Researchers’ name: 
 Raquel Revuelta Iniesta   rrevueltainiesta@qmu.ac.uk  
 Ilenia Paciarotti         ipaciarotti@qmu.ac.uk  
 Supervisor: 
 Dr. Jane McKenzie      jmckenzie@qmu.ac.uk  
 Independent advisor: 
 If you wish to consult a person who is not involved in this research for 
independent advice, please contact: 
 Dr. Iain Gow          igow@qmu.ac.uk  
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CONSENT FORM 
 
“Assessment of reliability, validity and precision of anthropometrical 
measurements performed in healthy children” 
 
 
I confirm that I have read and understood the information sheet for the above study, that I 
have had the chance to ask questions, and that I have received satisfactory answers to the 
asked questions. 
 
 
I understand that my/my child’s participation is voluntary and that I am free to withdraw 
myself/my child at any time, without giving any reason 
 
 
I agree to have my child take part in the above study 
 
 
 
 
 
Name of parent/carer                 Date                Signature 
 
 
 
 
Name of child/adolescent             Date               Signature   
(If considered appropriate) 
 
 
 
 
Name of researcher                  Date                Signature  
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       Child Life and Health 
       Reproductive & Developmental Sciences 
Clinical Sciences and Community Health 
       20 Sylvan Place 
       EDINBURGH EH9 1UW 
       Telephone: 0131 536 0615 
        
 
 
20
th
 August 2010 
 
 
 PARENT INVITATION TO PARTICIPATE 
 
 
“Nutritional Risk in Childhood Cancer (prospective study)” 
 
This research project will be carried out by the Royal Hospital for Sick Children, Edinburgh, 
the University of Edinburgh and Queen Margaret University 
 
The study has the full support and permission of the paediatric haematology and oncology 
department in Sick Kid’s, the Hospital and both Universities. 
 
 
What is the study about? 
 
Underweight is a major concern in the treatment of children and young people with cancer. 
Loss of weight or failing to gain weight normally, may occur during the treatment of cancer. 
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Becoming overweight may be a long-term problem for the survivors of childhood cancer. 
Children and teenagers who are losing weight or failing to gain weight normally may need 
additional calories. We realise that these nutritional problems are a source of great stress for 
families, as we all wish to provide adequate nutrition to our children. Your child will not 
receive any extra tests, procedures or interviews, except we may do slightly more frequent 
measurements of height or weight, and some extra growth measurements at follow up. We 
will also check 72 hour food diaries, and wish to record your child’s activity levels every 6 
months using a special meter worn on a belt around the waist during waking hours. 
 
Why do we need to do the research? 
 
Health services for children and adolescents with cancer depend on the need for those 
services. Advances come by clinical research. If underweight and overweight really are very 
common then we would argue for greater provision of services (e.g. dietitians) in order to 
help children and families. By studying in detail, we will be able to design further appropriate 
studies for these problems, aiming to improve care. 
 
How will we do this? 
 
We will ask the parents of children who had cancer diagnosed from August 2010 on and are 
being followed up in SE Scotland if they are willing to take part in the research study.  
 
What is involved for my child? 
 
Your child will not receive any extra tests, procedures or interviews, except we will do 
slightly more frequent measurements of height or weight, and some extra growth 
measurements in the ward and at follow up. We will also check 72 hour food diaries, and 
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wish to record your child’s activity levels every 6 months using a special meter worn on a 
belt around the waist during waking hours. We wish to measure your child’s quality of life 
and stress levels (stress levels only if 8 years or older) by means of a questionnaire. 
 
What is involved for me? 
 
We wish to measure your thoughts on your child’s quality of life by means of the same 
quality of life (PedsQL) questionnaire. We also wish to measure the effects that your child 
having cancer has caused you, measuring your stress levels, emotional and physical health by 
means of a 2nd questionnaire (the SF36), this should take 5-10 minutes to fill in, although 
you may find filling in the forms time-consuming or tiresome. 
 
Lastly, to obtain more information about parent and carer issues with nutritional care, we will 
invite some parents to share their views with us by either having one to one interviews with a 
qualified research team member, or taking part in a focus group run by a qualified research 
team member. These interviews will be tape recorded and transcribed (the words typed) so 
that the researchers can look at what everyone said. You and your child will not be able to be 
identified from any information gained from these recordings. 
 
Where do I have to go? 
 
All the measures will be made at your child’s follow up visits or during admission to RHSC. 
 
If you or your child want to opt in to the study it is entirely up to you. Your child’s care will 
not be affected by whether or not you take part. If you/your child agree to take part but want 
to opt out later that is also fine and it will not affect your child’s care. 
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If you have any questions or would like a more detailed explanation of the study, please 
contact: 
 
 
Dr David Wilson (Sick Children’s Hospital Edinburgh) Tel: (0131-536-0615) 
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CHILD INVITATION TO PARTICIPATE 
 
“Nutritional Risk in Childhood Cancer (prospective study)” 
 
(To be read to children by their parents where necessary) 
 
 
 
Invitation to Take Part in the Study – What is it all about? 
 
We would like to ask you for help with our research project. 
 
We want you to understand all about it before you decide if you want to help or not. 
 
Please talk it over with your Mum/Dad and take time to decide what you want to do. 
 
 
What is the Study About? 
 
Getting underweight can happen if you get cancer and some kids and teenagers then get 
overweight later. We want to find out more about these problems. 
 
  
259 
 
 
What Will Happen if I Agree to Take Part? 
 
At follow up we will measure your height and weight as usual, and the thickness of your arm. 
We will also check some food diaries, and measure your activity levels every 6 months using 
a special meter worn on a belt around the waist during waking hours. We wish to measure 
what having cancer does to your life by means of some questions on a form called a 
questionnaire, and we will also ask your parents to fill in a similar form. 
 
We will not tell anyone else about your measurements or results 
 
Will it Hurt Me? 
 
Taking part will not hurt. 
 
Will Taking Part Help Me? 
 
Taking part might not help you but should help other children and teenagers in future 
 
 
Who Will Know I Have Taken Part? 
 
Only the researchers involved in the study. 
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Do I Have To Take Part? 
 
No – this is up to you. If you don’t take part don’t worry, that is fine. 
 
If you do take part and change your mind, don’t worry – that is also fine. Just let us know. 
 
 
Who do I Speak to if I Have Any Questions ? 
 
Dr David Wilson (Tel: 0131-536 0615) 
 
 
 
 
 
 
 
 
 
 
 
 
     Child Life and Health 
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       Reproductive & Developmental Sciences 
Clinical Sciences and Community Health 
       20 Sylvan Place 
       EDINBURGH EH9 1UW 
       Telephone: 0131 536 0801 
        
Study Number: 
Patient Identification Number for this trial: 
 
 
CONSENT FORM – child 8 to 12 years 
Title of Project: 
 
“Nutritional Risk in Childhood Cancer (prospective study)”. 
 
Name of Principal Researcher: Dr David C Wilson 
Please initial box 
 
I have read or my family have read out to me the study information sheet, 
 I have had the chance to ask questions and                             
I am happy with answers to the questions that I have asked. 
            
I understand that my taking part is up to me and that I am can   
stop at any time, and the doctors will go on treating me in the way      
 
they think is best for me.               
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3. I agree to take part in the above study.                     
 
 
________________________ ________________       ________________    
Name  Date Signature 
 
_________________________ ________________       ____________________ 
  
Name of Person providing information Date Signature 
(if different from researcher) 
 
_________________________ ________________      ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator) 
  
1 for child, 1 for researcher; 1 to be kept with hospital notes 
 
Date: 20
th
 August, 2010   Version number: Second 
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     Child Life and Health 
       Reproductive & Developmental Sciences 
Clinical Sciences and Community Health 
       20 Sylvan Place 
       EDINBURGH EH9 1UW 
       Telephone: 0131 536 0801 
        
Study Number: 
Patient Identification Number for this trial: 
 
 
CONSENT FORM – child less than 8 years 
Title of Project: 
 
“Nutritional Risk in Childhood Cancer (prospective study)”. 
 
Name of Principal Researcher: Dr David C Wilson 
 
         Please initial box 
 
I have read or my family have read out to me the study information sheet, 
 I have had the chance to ask questions and                             
I am happy with answers to the questions that I have asked. 
            
I know that I don’t have to help unless I want to. If I start, I can   
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stop at any time. The doctors will still try hard to make me better.          
 
3. I agree to take part in the above study.                     
 
 
________________________ ________________       ________________    
Name  Date Signature 
 
_________________________ ________________       ____________________ 
  
Name of Person providing information Date Signature 
(if different from researcher) 
 
_________________________ ________________      ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator) 
  
1 for child, 1 for researcher; 1 to be kept with hospital notes 
 
Date: 20
th
 August, 2010   Version number: Second 
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     Child Life and Health 
       Reproductive & Developmental Sciences 
Clinical Sciences and Community Health 
       20 Sylvan Place 
       EDINBURGH EH9 1UW 
       Telephone: 0131 536 0801 
        
Study Number: 
Patient Identification Number for this trial: 
 
 
CONSENT FORM 
Title of Project: 
 
“Nutritional Risk in Childhood Cancer (prospective study)”. 
 
Name of Principal Researcher: Dr David C Wilson 
Please initial box 
 
I confirm that I have read and understand the information sheet for the 
above study, that I have had the opportunity to ask questions, and that         
I have received satisfactory answers to the questions that I have asked. 
            
I understand that my child’s participation is voluntary and that I am free   
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to withdraw my child at any time, without giving any reason, without         
my infant’s medical care or legal rights being affected. 
3. I agree to have my infant take part in the above study.               
 
4. If asked I agree to take part in audio-taped interviews.                    
 
 
________________________ ________________       ________________    
Name of Parent/Carer Date Signature 
 
_________________________ ________________       ____________________ 
  
Name of Person providing information Date Signature 
(if different from researcher) 
 
_________________________ ________________      ____________________ 
Researcher Date Signature 
(Investigator or delegated medically qualified co-investigator) 
  
1 for parent/carer, 1 for researcher; 1 to be kept with hospital notes 
 
Date: 20
th
 August, 2010   Version number: Third 
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APPENDIX 6 
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Activity Diary 
Name: 
Date: 
Study code: 
 
Please wear the activity monitor for the next 7 days. You can choose to use the sticky pad or 
the belt to wear the activity monitor as shown to you by Ilenia the research nutritionist. The 
sticky pad should be placed over the monitor and secured on to the abdomen.The belt should 
be tied around /your child’s waist. The red monitor sits on the right hand side as shown by 
Ilenia. 
Put the activity monitor on first thing in the morning and record when you/ your child started 
to wear it under ‘Time ON’. 
Take the activity monitor off at bed time and record when you/ your child stopped wearing it 
under ‘Time OFF’ 
If you/ your child remove the activity monitor at any other time during the day please note 
these over the page. 
DAY 
 
TIME ON TIME OFF 
1 
 
  
2 
 
  
3 
 
  
4 
 
  
5 
 
  
6 
 
  
7 
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Please return activity monitor and this diary to Ilenia Paciarotti or Kerry White. 
 
Instructions for activity monitor 
You can choose to wear the activity monitor with an elastic belt or by placing a sticky pad 
over it to secure it in place. The activity monitor should be situated on the right hip under 
yours / your child’s waist with the black button at the top and Actigraph logo along the 
bottom. 
The activity monitor is set to record activity; you do not need to switch it on or off. Follow 
the instructions below for wearing the activity monitor: 
1. Place the elastic belt around yours/ your child’s waist if worn by belt, pull the elastic 
until the belt is secure and comfortable then tie and pull the belt buckle or place a new 
sticky pad “Tegaderm” over the activity monitor to secure it on the right hip under 
yours/ your child’s clothes. 
2. Make sure that the black button is at the top of the activity monitor and the Actigraph 
logo runs along the bottom. 
3. Record the time you/your child started to wear the activity monitor in the “Activity 
Diary” 
4. You/Your child should wear the activity monitor all day, but the activity monitor must 
be removed if you/your child is having a shower/ bath or going swimming and those 
activity should be noted on the “Activity Diary”. 
5. Remove the activity monitor at bed-time , if worn by sticky pad dispose the 
Tegaderm. 
6. Record the time your child stopped wearing the activity belt in the “Activity Diary”. 
7. Please return the activity monitor to Ilenia Paciarotti or Kerry White in the envelope 
provided either leaving it on the ward or posting it. 
 
Thank you! 
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List of Publications 
Abstracts 
I Paciarotti, J McKenzie, M Brougham, A Edgar, M Wilson, L Stewart, A Ling Koh, D C. 
Wilson. Children with cancer have high needs for nutrition support.2012. Clinical Nutrition,7 
(S1),pp. 79 
Poster presented at the ESPEN Congress 2012 
Ilenia Paciarotti, R. Revuelta Iniesta, J. McKenzie , M. Brougham , D.C.Wilson 
Outstanding Abstract. Low plasma vitamin D (25-hydroxycholecalciferol) in Scottish 
children and adolescents diagnosed with cancer. 2012. Clinical Nutrition,7 (S1),pp. 157 
Poster presented at the ESPEN Congress 2012 
R. Revuelta Iniesta, I Paciarotti , M. Brougham , J. McKenzie , D C. Wilson Systematic 
review of the prevalence of malnutrition in childhood cancer: effects of cancer and its 
treatments on nutritional status  
Poster submitted to  the ESPEN Congress 2013 
Articles  
I Paciarotti, J McKenzie, M Brougham, A Edgar, M Wilson, L Stewart, A Ling Koh, D C. 
Wilson. Children with cancer have high needs for nutrition support.2012. In submission 
Ilenia Paciarotti , R. Revuelta Iniesta , J. McKenzie , M. Brougham , D. C. Wilson 
Outstanding Abstract. Low plasma vitamin D (25-hydroxycholecalciferol) in Scottish 
children and adolescents diagnosed with cancer. In preparation 
R. Revuelta Iniesta, I Paciarotti , M. Brougham , J. McKenzie , D.C Wilson Systematic 
review of the prevalence of malnutrition in childhood cancer: effects of cancer and its 
treatments on nutritional status In preparation 
Ilenia Paciarotti , J. McKenzie , M. Brougham , D C. Wilson Short term effects of childhood 
cancer and its treatments on nutritional status and growth, a prospective study. In preparation 
 
 
 
